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A infecção pelo Vírus da Imunodeficiência Humana (VIH) caracteriza-se por 
perda progressiva de células T CD4+, conduzindo a Síndrome da Imunodeficiência 
Adquirida (SIDA). Actualmente, mais de 30 milhões de pessoas vivem com VIH. 
Portugal apresenta uma das incidências mais elevadas de infecção VIH-1 da Europa, e 
a prevalência mais alta de VIH-2, uma infecção essencialmente confinada à África 
Ocidental. 
A infecção pelo VIH-2 constitui uma forma naturalmente atenuada de doença, 
dada a perda lenta de células T CD4+, os níveis indetectáveis/baixos de vírus circulante 
e o impacto reduzido na mortalidade. Contudo, doentes VIH-2+ e VIH-1+ com igual 
número de células T CD4+ apresentam números semelhantes de células infectadas e 
níveis comparáveis de hiper-activação imunitária, indicando que também o VIH-2 está 
associado a estimulação imunitária persistente. 
Este trabalho baseou-se no pressuposto de que a investigação da infecção pelo 
VIH-2 revela estratégias usadas pelo sistema imunitário para enfrentar os desafios 
impostos pela infecção VIH crónica, elucidando a imunopatogénese associada ao 
VIH/SIDA. 
A progressão lenta da infecção pelo VIH-2 relacionou-se com dois factores. Em 
primeiro lugar, a regulação estrita de vias inibitórias de activação celular, com sobre-
expressão de moléculas inibitórias por células apresentadoras de antigénio e linfócitos 
T a constituir uma “assinatura” específica do VIH-2. Em segundo lugar, a preservação 
dos telómeros das células T CD4+ e da capacidade de resposta das células T CD4+ naïve 
à IL-7, contribuindo, provavelmente, para manter as células T CD4+. Contudo, a perda 
de células B de memória, mesmo em doentes avirémicos, indica que, ao longo da fase 
“assintomática/crónica” mais prolongada na doença VIH-2, ocorrem alterações 
irreversíveis e, possivelmente, exaustão do sistema imunitário. 
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Human Immunodeficiency Virus (HIV) infection is characterized by progressive 
CD4+ T-cell loss, ultimately leading to Acquired Immunodeficiency Syndrome (AIDS), 
and death. More than 30 million people live with HIV. In Western Europe, Portugal has 
one of the highest incidence rates of HIV-1 infection, and the highest prevalence of 
HIV-2 disease, which is otherwise mainly confined to West African countries. 
HIV-2 infection, a naturally-occurring form of attenuated HIV disease, features 
a very slow rate of CD4+ T-cell depletion, and undetectable to low levels of circulating 
virus, with limited impact in adult mortality. This is despite total numbers of infected 
cells being similar to those found in HIV-1 infection. Furthermore, HIV-2+ and HIV-1+ 
individuals with similar degrees of CD4+ T-cell depletion have comparable levels of 
hyper-immune activation, indicating that persistent immune stimulation also occurs in 
HIV-2 disease. 
This work aimed at investigating strategies mounted by the immune system in 
order to cope with challenges imposed by chronic HIV disease, using HIV-2 infection as 
an approach to study HIV/AIDS-related immunopathogenesis. 
We identified two main factors possibly contributing to the slow HIV-2 disease 
progression. Firstly, a tight regulation of T-cell activation-inhibition pathways, with 
over-expression of inhibitory molecules on antigen-presenting and T cells constituting 
a specific “HIV-2 signature”. Secondly, a preservation of CD4+ T-cell telomere length 
and sustained naïve CD4+ T-cell ability to respond to IL-7, which likely impact on the 
capacity to replenish the CD4+ T-cell compartment in HIV-2 infected individuals. 
Nevertheless, our finding of memory B-cell loss, even in aviremic HIV-2 disease, 
indicates that, over the prolonged “asymptomatic/chronic” phase of HIV-2 infection, 
irreversible damage and/or exhaustion of resources of the immune system ultimately 
occurs. 
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This study demonstrated that HIV-2 infection provides a unique natural model 
to identify rationales for novel therapeutic strategies complementary to antiretroviral 
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Chapter 1: Introduction 




The Human Immunodeficiency Virus (HIV) infection still represents one of the 
most important Global Health threats. 
This chapter is divided into three parts: the first overviews HIV and the natural 
course of HIV disease, as well as the mechanisms underlying progression to Acquired 
Immunodeficiency Syndrome (AIDS); the second addresses persistent immune 
activation as the main determinant of HIV/AIDS immunopathogenesis; and, finally, the 
third part focuses on CD4+ T-cell replenishment, a critical process to counteract CD4+ 
T-cell loss, the hallmark of HIV/AIDS. 
 
Part 1. The Human Immunodeficiency Virus and AIDS 
When, in the early 1980’s, severe cases of Pneumocystis carinii pneumonia were 
reported in previously healthy, young individuals, at three different hospitals in Los 
Angeles [1], the World in general, and the Scientific Community, in particular, were far 
from realizing that those were only the early days of a battle that would soon turn into 
the most challenging of wars.  
Today, 30 years after AIDS was first recognized, and its causative agent, HIV, 
identified, the epidemic has spread to all nations, although varying in prevalence, with 
Sub-Saharan countries bearing an inordinate share of the global HIV burden (Figure 1). 
The pandemic seems to have stabilized in recent years, but it is still far from 
eradication: by the end of 2009, 33.3 million adults and children were living with HIV 
and, in that year alone, 2.6 million were newly infected, whilst 1.8 million lost their 
lives due to AIDS-related illness [2].  
 
4 HIV-2 immunopathology: 
how the immune system deals with long-lasting infection 
 
Figure 1. Global prevalence of HIV by the end of 2009. UNAIDS report on the global AIDS epidemic, 
2010. 
 
1.1. Identification, taxonomic classification and origin of the virus 
The causative agent of AIDS was first isolated and identified in 1983, by Luc 
Montagnier and colleagues at the Institute Pasteur, France, who named it 
Lymphadenopathy-Associated Virus (LAV) [3]. At the same time, in the United Stated 
of America, Human T-Lymphotropic Virus (HTLV)-III was described by Robert Gallo as 
the virus causing AIDS disease [4]. The two original papers appeared back-to-back in 
Science and a legal dispute without precedent on who to give credit for the discovery 
was then initiated [5-7]. It was in this context that, in 1986, the International 
Committee on Taxonomy of Viruses, in order to standardize the nomenclature used in 
the increasing number of publications being added to the literature, whilst 
maintaining impartiality, ruled that both names should be dropped and replaced by a 
new one: Human Immunodeficiency Virus (HIV) [8]. 
Also in 1986, at the Institute Pasteur and in collaboration with Portuguese 
researchers, a second type of HIV was isolated from West-African patients [9], which 
was named HIV-2. 
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HIV belongs to the Retroviridae family, which includes all RNA reverse 
transcribing viruses, subfamily Orthoretrovirinae, genus Lentivirus [10]. Lentiviral 
(lente-, Latin for “slow”) infections are characterized by long latency periods. 
Both HIV-1 and HIV-2 are able to cause infection and disease in humans. 
However, while HIV-1 generated a worldwide disseminated pandemic, HIV-2 infection 
is much less prevalent and more geographically restricted, being primarily found in 
West African countries, India and, to a more limited extent, Portugal [11]. Of note, 
due to its historical and commercial links to West Africa, Portugal has been reported 
as the country in the European Union with the highest prevalence of HIV-2 infection 
[12-16] which, by the end of 2009, represented 3.2% of all reported AIDS cases since 
1983 [17]. 
HIV-1 is thought to have arisen from cross-species (or zoonotic) transmission of 
the Simian Immunodeficiency Virus (SIV) from chimpanzees (SIVcpz) to humans [18], 
while HIV-2 is believed to have had its origin on the virus from sooty mangabeys 
(SIVsm) [19]. These zoonotic transmission events are thought to have been multiple 








Figure 2. Multiple independent zoonotic transmissions of SIVcpz and SIVsm to humans. Black branches 
indicate evolution of SIV within natural hosts, black arrows indicate points of cross-species 
transmission, and red branches indicate subsequent evolution within human hosts. (A) SIVcpz and HIV-
1. Groups M, N and O are interspersed among SIVcpz strains from Pan troglodytes troglodytes (P.t.t.) 
and Pan troglodytes schweinfurthii (P.t.s.). Six of the nine group M subtypes are depicted, all deriving 
from a common ancestor indicated by a black asterisk. (B) SIVsm and HIV-2. Six of the eight HIV-2 
subtypes are represented, interspersed among SIVsm lineages. Adapted from Hahn et al, Science 2000. 
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As for HIV-1, at least three cross-species viral transmission events may have 
taken place from chimpanzees to humans [20, 21], giving rise to groups M 
(major/main) [22], O (outlier) [22, 23] and N (non-M, non-O) [24]; more recently, an 
additional one may have been responsible for generating the gorilla-derived group P 
[25]. Most HIV-1 infections are caused by group M viruses, which are divided into nine 
subtypes (A-D, F-H, J and K) [11]. 
Similarly, at least eight separate zoonotic transmission events [26] may have 
generated different HIV-2 subtypes (A-H) [27-30] in the human population. The 
majority of HIV-2 infections are caused by subtypes A or B, which have been referred 
to as the epidemic groups, while non-epidemic subtypes are known only as single-
person infections and do not appear to be transmissible among humans [26, 30, 31]. 
Determining the timing of the virus introduction in the human population has 
been a priority for HIV researchers. Estimates based on viral genome sequences 
predict that SIV has given rise to transmissible HIV lineages throughout the twentieth 
century, with HIV-1 groups M, O and N having been introduced in about 1908, 1920 
and 1963, respectively [26, 32, 33], and HIV-2 groups A and B appearing only in the 
early 1930s [26]. 
 
1.2. Structural biology and life cycle of the viral particle 
1.2.1. Morphology and constitution 
HIV virions are spherical in shape, with a diameter of, approximately, 1/10,000 
of a millimeter (Figure 3). The outer coat of the virus, known as the viral envelope, 
consists of a lipid bilayer which derives from the infected cell’s membrane during 
budding of new viral particles [34]. Embedded throughout the viral envelope are host 
cell’s proteins [35], together with clusters of viral glycoprotein (gp) heterodimers – 
often referred to as spikes – with the function of mediating virion’s attachment, 
docking and fusion with the host cell’s membrane, hence determining viral tropism 
[36]. Viral glycoprotein heterodimers consist of two portions, each one with a distinct 
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molecular weight and designated accordingly: an outer glycoprotein (surface, SU) – 
gp120 in HIV-1, gp105 in HIV-2 – and a transmembrane (TM) glycoprotein – gp41 in 
HIV-1, gp36 in HIV-2. Each viral spike comprises three surface molecules – the “head” 
– noncovalently attached to three transmembrane domains – the “stalk” [36, 37]. 
The envelope’s inner surface is lined with the matrix (MA) protein, a 
myristoylated protein of 17 kDa in HIV-1 (p17) and 16 kDa in HIV-2 (p16) [38], which is 







Figure 3. HIV virion. (A) Schematic representation of HIV’s structure, with the identification of viral 
proteins and genome. Adapted from www.niaid.nih.gov. (B) Transmission electron photograph of HIV. 
Cone shaped cores are sectioned in various orientations. Viral genomic RNA is located in the electron-
densewide end of core. Available at phil.cdc.gov (ID#948). 
 
Protected by the viral envelope, the capsid, also called viral core, is a cone-
shaped, highly organized multimeric structure [42], resulting from the assembly of 
multiple monomers of either a 24 or 26 kDa capsid protein (CA) in HIV-1 and HIV-2, 
respectively. The capsid contains the viral genome, which is associated with basic 
proteins of 7 and 6 kDa (nucleocapsid, NC, and p6, respectively), along with viral 
enzymes required for different replication events – reverse transcriptase (RT), 
integrase (IN) and protease (PR) –, some viral accessory and cellular proteins [42], and 
transfer RNAs (tRNAs), the latter of which serve as primers for reverse transcription 
[43]. The viral core’s main function is to organize and contain the viral genome for 
optimal delivery and efficient reverse transcription in target cells which, together, 
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contribute to effective replication in the new host cell, a process absolutely required 
for infection [42]. 
 
1.2.2. Genome 
HIV is a diploid virus, its genome consisting of two plus-stranded RNA copies. 
Each one of the RNA copies is about 9-10 kb long [44] and flanked by long terminal 
repeats (LTRs) that, although not encoding any proteins, are important for the 
regulation of viral transcription [34, 44]. Despite having similar genetic structures 
(Figure 4), HIV-1 and HIV-2 genome sequences may differ up to 60%, with HIV-2 
genome being far more homolog to that of SIVsm (up to 77% homology) [44-46]. 
 
Figure 4. Schematic representation of HIV-1 and HIV-2 genomes. Grey boxes represent structural genes; 
blue boxes indicate regulatory genes; and pink boxes refer to accessory genes. Adapted from Ayende et 
al, Retrovirology 2010. 
 
In addition to the genes common to all members of the Retroviridae family – 
gag (for “group-specific antigen”, coding for the structural components NC, MA, CA, 
and p6), pol (for “polymerase”, underlying the production of molecules with essential 
enzymatic functions: RT, PR, and IN) and env (for “envelope”, coding for the surface 
and transmembrane glycoproteins of the viral envelope) –, HIV also features genes 
encoding a number of regulatory and accessory proteins that regulate different steps 
of viral replication and may influence pathogenesis [47, 48].  
Viral proteins with regulatory functions (Tat – “transcriptional transactivator” – 
and Rev – “regulator of expression of viral proteins”) are involved in promoting and 
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regulating viral transcription, being essential for effective viral replication, and will be 
discussed subsequently. 
Accessory proteins are small molecules that play several roles during HIV’s life 
cycle, deriving their name from the observation that, although being of utmost 
importance in vivo, they are not essential for in vitro viral replication in certain cellular 
systems, such as immortalized T-cell lines. Accessory proteins include Vif (“viral 
infectivity factor”), Vpu (“viral protein U”, exclusive to HIV-1), Vpr (“viral protein R”), 
Vpx (“viral protein X”, exclusive to HIV-2) and Nef (“negative factor”), with evidence 
suggesting that vpx may have arisen by duplication of an ancestral vpr gene within the 
HIV-2 lineage [49]. Among the many functions attributed to accessory proteins, some 
are of particular interest, such as: promotion of provirus formation and enhancement 
of progeny virions release by negative interference with host restriction factors (Vif 
[50] and Vpu [51]); transport of the pre-integration complex (PIC) into the nucleus and 
activation of LTR transcription (Vpr [52]); antagonism of a host restriction factor which 
counteracts the synthesis of proviral DNA in myeloid cells (Vpx [47, 53, 54]); and 
avoidance of super-infection and immune surveillance through down-regulation of 
both specific cellular receptors needed for viral entry and major histocompatibility 
complex (MHC) molecules, respectively (Nef [55]). Overall, HIV accessory proteins 
mainly constitute a means to neutralize specific host factors that would, otherwise, 
compromise the efficiency of viral replication. 
 
1.2.3. Replication and assembly 
HIV’s life cycle may be divided into two distinct phases: an early phase referring 
to the initial steps of infection, from cell binding to the integration of proviral DNA 
into the host cell’s genome; and a late phase beginning with the expression of viral 
genes and continuing up to the release and maturation of new progeny virions. 
Figure 5 illustrates the different steps involved in this process, which is briefly 
addressed during the following sections. 
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Figure 5. Schematic representation of HIV’s life cycle. Adapted from www.niaid.nih.gov. 
 
“Finding the key under the mat”: the use of specific cell-surface 
(co)receptor(s) 
The CD4 glycoprotein constitutes the high-affinity receptor for HIV [56], being 
mainly expressed on CD4+ T cells, dendritic cells (DC) and monocytes/macrophages. 
Viral entry then typically depends on the sequential interaction of the viral envelope 
surface glycoproteins with this receptor and a seven-transmembrane-domain 
chemokine receptor [57] – the so-called coreceptor. 
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Although several chemokine receptors may function as HIV-1 coreceptors in 
vitro [58-60], multiple data suggest that only two of them, CCR5 and CXCR4, are of 
clinical relevance [61-64], with viral isolates being classified based on their ability to 
use CCR5 (non-syncytium inducing, NSI, R5 variants), CXCR4 (syncytium-inducing, SI, 
X4 variants), or both (R5X4 variants) as coreceptors for viral entry [57]. 
HIV-2 is able to bind a larger panel of cellular coreceptors [65-68], with some 
strains being capable of interacting with host cells even in the absence of CD4 [69]. 
Nevertheless, this HIV-2-associated increased promiscuity in terms of coreceptor 
usage has been shown not to be related with increased disease severity [70].  
HIV-1, HIV-2 and SIV are also able to bind the surface of dendritic cells through 
interactions of their envelope glycoproteins with the C-type mannose binding lectins 
DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing non-
integrin) and DC-SIGNR (DC-SIGN related) [71-73]. However, these molecules should 
not be considered (co)receptors, as they do not promote viral entry and productive 
infection; rather, they may allow HIV particles to use DC as a Trojan horses, and thus 
be of more relevance to viral dissemination [74, 75]. 
Coreceptor usage has implications for viral tropism and is determined by the 
viral envelope [76]. The mechanisms of viral attachment and fusion with the target 
cell have been extensively described for HIV-1, being likely similar for HIV-2, given the 
similarities in structure and functional domains of Env glycoproteins observed in both 
virions [77]. The initial binding of gp120 to cellular CD4 triggers a conformational 
change in the surface glycoprotein, leading to the exposure of the coreceptor binding 
site [61, 78]. The interaction of CD4-bound gp120 with the coreceptor induces further 
conformational changes, leading to the exposure of the N-terminus of gp41, which 
contains a fusion peptide that embeds into the host cell’s membrane [78]. The gp41 
ectodomain forms an extended coiled-coil conformation and a six-helix bundle 
structure, which promotes the juxtaposition of the viral and target cell membranes 
[78]. This results in a stable structure, facilitating the fusion between viral and cellular 
membranes and the release of the viral core into the host cell’s cytoplasm [58, 78]. 
12 HIV-2 immunopathology: 




“Unpacking to stay”: reverse-transcription and pre-integration complexes 
At this stage, the viral core undergoes destabilization and disassembly, also 
known as uncoating, leading to the generation of reverse transcription complexes 
(RTCs) and pre-integration complexes (PICs) [42]. RTCs are defined as HIV complexes 
that undergo reverse transcription (Figure 6), during which they convert their single-
stranded positive RNA viral genome into double-stranded complementary DNA 
(cDNA); RTC genomes are, thus, either RNA or RNA-DNA intermediates of reverse 
transcription [73, 79]. In contrast, PICs no longer contain any RNA, but only the 
double-stranded cDNA, along with, at least, four viral proteins (MA, RT, IN and Vpr), 







Figure 6. Schematic representation of the reverse transcription reaction, during which viral RNA is 
copied into a double-stranded cDNA molecule. The viral RT possesses three essential activities that are 
important for viral replication: RNA-dependent DNA polymerase (responsible for the process of reverse 
transcription), RNase H (mediating the cleavage of the genomic RNA in RNA/DNA hybrids during cDNA 
synthesis), and DNA-dependent DNA polymerase (for the synthesis of the second strand of the proviral 
DNA) [81]. (A) The process is mediated by the viral RT enzyme and a cellular tRNA3lys. The latter acts as 
primer and initiates negative strand cDNA synthesis, by binding to the primer binding site (PBS) region, 
located immediately 3' to the U5 region. During reverse transcription, the plus strand cDNA is 
synthesized discontinuously as two halves, the synthesis of one half being initiated from the 3’ 
polypurine tract sequence (PPT), and the other (B) starting from the central copy of PPT (cPPT). 
Consequently, the final product is a linear cDNA molecule bearing in its centre a stable plus strand 
overlap, referred to as the central DNA flap. Adapted from Arhel, Retrovirology 2010. 
 
The molecular mechanisms underlying HIV uncoating in the cytoplasm of 
infected cells remain to be elucidated. Although, in the beginning, the predominant 
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view was that the viral capsid was discarded immediately after fusion, close to the 
plasma membrane, in order to stimulate reverse transcription [79, 82-84], more 
recent data suggest that uncoating may, instead, be a gradual process [85]. This 
progressive uncoating would possibly take place in response to multiple cellular cues, 
such as interactions with cellular proteins or sub-cellular localization, or viral signals, 
such as the progress of reverse transcription. A yet third alternative suggests that viral 
capsids may remain intact until incoming complexes reach the nuclear membrane, 
with uncoating occurring at the nuclear pore upon completion of reverse transcription 
[42]. In any case, uncoating must be neither too early, nor too late, in order to 
productive infection to be ensured. 
Despite the intricacies of HIV-1 uncoating being far from resolved, a model for 
the early steps of HIV infection has been recently proposed [42]: first, viral entry into 
target cells delivers the intact capsid core into the cytoplasm. Exposure of the viral 
nucleoprotein complex to non-limiting deoxyribonucleotides then triggers reverse 
transcription [73, 79], a process that likely occurs in the intact capsid core, which is 
essential for maintaining a high concentration of enzyme around the nucleic acid (that 
would, otherwise, detach [86]), while being entirely permeable to the necessary 
deoxyribonucleotides. During reverse transcription, RTCs move rapidly toward the 
nuclear compartment, using microtubules and actin filaments to reach the nuclear 
pore [87, 88]. Since transport to nuclear pore is faster than reverse transcription, it is 
likely that most viral cDNA synthesis occurs within capsids docked at the nuclear pore. 
Ultimately, capsid-free, double-stranded cDNA-containing, PICs enter the nucleus [89], 
leading to the integration of the DNA intermediate into the host cell’s genome, where 
it is expressed under the control of host cell’s transcription factors [80].  
 
“Getting quietly settled”: the establishment of a viral reservoir 
Four different viral components have been identified that contribute to the 
nuclear import of HIV. The primary protein mediator of the PIC’s nuclear import is IN. 
IN contains a short nuclear localization signal (NLS), a feature also shared by MA, 
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which is important for targeting the PIC to the nucleus [73, 79, 80]. Although lacking 
an NLS, Vpr has been shown to interact directly with components of the nucleopore 
complexes (NPCs), possibly enhancing nuclear import efficiency [90, 91]; however, the 
presence of this particular viral protein may not be strictly necessary, as Vpr-deficient 
viruses have been reported to maintain their ability to efficiently infect cells and cause 
pathology [92]. In contrast, the Vpx protein, encoded by HIV-2 and SIV, has been 
shown to be both necessary and sufficient for PIC’s nuclear import [93]. Another 
component of the PIC that is important for nuclear entry is not a protein, but rather 
an unusual DNA structure; specifically, the DNA intermediate contains a discrete, 
centrally located region, where a third DNA strand forms a short overlap termed the 
central DNA flap [94]. This is formed during reverse transcription (Figure 6) and may 
enhance the nuclear entrance of PIC by recruiting cellular proteins that directly 
mediate its nuclear import. Alternatively, the DNA flap may be required for the PIC to 
achieve an appropriate conformation for import [88]. Of note, certain cellular proteins 
can also associate with the PIC during its journey to the nucleus, such as the high 
motility group protein HMG-I(Y), which has been proposed to be important for 
integration of the viral cDNA into the host cell’s genome [95] to form the so-called 
provirus. 
Proviral integration generally occurs in a non sequence-specific fashion, but may 
be influenced by the structure of the neighboring chromatin [96]. In agreement, HIV-1 
integration has been described to preferentially occur in highly transcribed genes 
(sites of transcriptionally active chromatin) [97, 98], hence favoring efficient HIV-1 
gene expression and maximizing virus propagation. 
Viral cDNA integration is mediated by the virally-encoded and imported IN 
enzyme, in two sequential and distinct phases [99]: first, IN excises the two terminal 
nucleotides from each 3’ terminus of the double-stranded viral cDNA (in a step called 
3’-processing); 3’-processed viral cDNA is then covalently linked to host DNA in a 
process called joining, or strand transfer. Finally, single-stranded DNA breaks, at the 
site of integration in the host genome, are repaired by host factors, establishing the 
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integrated, latent, provirus, which will then remain permanently associated with the 
host’s genetic material. 
 
“Taking advantage of the situation”: exploitation of the host cell’s 
transcriptional and translational machinery 
HIV proviral transcription is significantly influenced by the state of host cell 
activation and is regulated by sequences in the 5’-LTR of the viral genome, which are 
able to specifically bind numerous host cell transcription factors [100, 101]. In this 
way, HIV is able to harness the cellular transcriptional machinery in order to replicate, 
a feature resulting in the coordination of cellular activation and viral transcription. 
The HIV 5’-LTR comprises three functionally discrete regions [102]: (1) the 
transactivation response region, TAR (which binds the virus-encoded trans-activating 
protein, Tat, and is essential to achieve significant levels of viral transcription); (2) the 
core promoter region (that mediates a basal level of viral transcription in response to 
SP1 transcription factors and TATA-binding proteins); and (3) the modulatory 
enhancer region, which contains several elements binding cellular transcription 
factors, including nuclear factor kappa B (NF-κB). On exposure of the cell to several 
activation stimuli, such as tumor necrosis factor alpha (TNF-α) [103], cytoplasmic NF-
κB becomes physiologically active and translocates to the nucleus, where it mediates 
the activation of viral and cellular gene transcription by binding to the enhancer 
region [102]. Of note, while the HIV-1 5’-LTR presents a pair of NF-κB-binding DNA 
sequences in the enhancer region, HIV-2 has only one functional copy, and therefore 
responds more weakly to TNF-α stimulation [104, 105]. 
The basal transcriptional activity from the HIV LTR promoter is very low in most 
cell types, with very little messenger RNA (mRNA) being produced and translated into 
protein [106]; it can, however, increase significantly, leading to the production of large 
amounts of viral mRNA (and, consequently, protein) in activated cells. The switch from 
an inefficient to an efficient promoter is achieved, not only through the change in 
cellular factors, but also due to the action of Tat [107, 108]. 
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Tat binds to the TAR sequence on the nascent mRNA molecule, recruiting the 
cyclin T1/CDK9 complex to this location, which then phosphorylates RNA polymerase 
II [109]. This leads to a dramatic stimulation of transcription, allowing for the synthesis 
of full-length mRNA transcripts to occur. 
Transcription from the LTR generates a large number of viral mRNAs [110], 
which fall into three major classes [111]: 1) unspliced mRNAs (which function as the 
mRNAs for Gag and GagPol polyprotein precursors, and are packaged into progeny 
virions as genomic RNA); 2) incompletely spliced mRNAs (encoding the Env, Vif, Vpu, 
Vpr, and Vpx proteins); and 3) small, completely spliced mRNAs (which are translated 
into Tat, Rev and Nef) (Figure 7). Since most cellular mRNAs are fully spliced before 
their transport out of the nucleus, the need for unspliced and partially spliced RNAs to 
migrate to the cytoplasm poses a problem for HIV [111]. To circumvent this issue, the 
virus takes advantage of a system involving Rev and a specific RNA domain, the Rev-
responsive element (RRE), that is located in the env gene and is present in all 
unspliced and partially spliced mRNAs  [106, 112]. A Rev monomer initially binds to 
the RRE and, through protein-protein and RNA-protein interactions, multimerizes with 
other Rev molecules, eventually coating the RRE, and forming a complex that is 
capable of interacting with the cellular nuclear export machinery; as a consequence, 
the RRE-containing RNA is transported to the cytoplasm, after which Rev shuttles back 
to the nucleus, using its NLS [111, 112]. 
gag, pol and env are translated into Gag, Gag-Pol and Env polyprotein 
precursors [111]. Of note, while the genomic mRNA is translated by cytoplasmic 
ribosomes, env mRNA is translated on rough endoplasmic reticulum-associated 
ribosomes; then, the Env precursor enters the endoplasmic reticulum where it 
becomes glycosilated and is cleaved by cellular proteases into its SU and TM subunits 
[113]. The two glycoproteins remain associated and, through the Golgi, reach the 
plasma membrane, where they are either rapidly internalized (through recognition by 
the host cell machinery of an endocytosis motif) or incorporated into virus particles 
[114]. 
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Figure 7. Schematic representation of mRNA species generated during HIV-1 and HIV-2 proviral DNA 
transcription. Grey boxes represent structural genes; blue boxes indicate regulatory genes; and pink 
boxes refer to accessory genes. Adapted from Ayende et al, Retrovirology 2010 and Nielsen et al, 
Retrovirology 2005. 
 
“The multiplying menace”: viral progeny generation 
New virus assembly begins at the plasma membrane. The major player in virus 
assembly is the Gag precursor polyprotein, which contains determinants that target it 
to the plasma membrane, bind the membrane itself, promote Gag-Gag interactions, 
encapsidate the viral RNA genome, associate with the viral Env glycoproteins, and 
stimulate budding from the host cell [111, 113, 115], with the consequent acquisition 
of the viral envelope. 
During or shortly after virus release from the plasma membrane, the viral PR 
cleaves the Gag and Gag-Pol polyprotein precursors, generating the mature gag- and 
pol-encoded proteins, a process that leads to a series of structural rearrangements, 
ultimately resulting in virion maturation [111]. Importantly, this PR-mediated virion 
maturation has been described as essential for the production of competent viral 
progeny [116].  
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Of note, in the process of virus assembly, some host factors are also packaged in 
the new viral particles, including apolipoprotein B mRNA-editing, enzyme-catalytic, 
polypeptide-like (APOBEC) 3G and cyclophilin A [42, 111], the latter appearing to be 
HIV-1-specific [117, 118] and serving as a chaperone to prevent unfavorable CA 
aggregation [119]. 
 
“The virus with multiple faces”: quasispecies and circulating recombinant 
forms 
During HIV’s life cycle, significant genetic variability is introduced. Both 
recombination and point mutations contribute to this variation, with base-
substitutions being inserted mainly by error-prone DNA synthesis [120], or by the 
activity of cellular proteins, such as APOBEC3 cytidine deaminases [121, 122]. Of note, 
HIV recombination does not involve nucleic acid breakage and rejoining but, instead, 
results from RT template-switching between the two viral RNA molecules during 
provirus synthesis [123, 124] and lack of proofreading function [124]. As a result, in a 
given host, HIV exists as an array of quasispecies, in which nearly every virus in a 
generation differs from every other one. 
Many of these viral genome recombination events result in the intertwining of 
genetic segments derived from different established subtypes (see Chapter 1.1.). 
Because some of these recombinants are able to spread among individuals, they have 
been called circulating recombinant forms (CRFs) [123]. There are currently 54 HIV-1 
and one HIV-2 CRFs [125].  
 
1.3. Natural history of HIV infection   
Most HIV infections occur by sexual transmission, following exposure to cell-free 
or cell-associated virus in semen, vaginal secretions or mucosal surfaces [126]. Other 
routes of infection include transmission via intra-venous drug use, exposure to blood 
and blood products by transfusions, and exposure of fetus or infant to HIV from an 
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infected mother [126] (in utero, during delivery, or after birth, through breastfeeding). 
Of note, HIV-2 has lower progeny virus production and low viral load in body fluids 
than HIV-1, features that may account for the lower transmission rate observed for 
this infection [12]. For instance, sexual and mother-to-child transmissions of HIV-2 are 
around 5- to 9-fold and 10- to 20-fold reduced in relation to HIV-1, respectively [127]. 
 
“Playing hide-and-seek”: acute/primary infection 
Following transmission of HIV-1, there is a period of, approximately, ten days, 
known as the eclipse phase, before viral RNA becomes detectable in the plasma [128] 
(Figure 8). Evidence suggest that infection is initiated by a single virus, the so called 
“founder virus”, indicating that a selection bottleneck may exist, leading to the 







Figure 8. Kinetics of immunologic and virologic events observed during HIV acute/primary and early 
asymptomatic chronic phases. Approximate timings for positivity to HIV screening tests are shown. 
ELISA: enzyme-linked immunosorbent assay; PCR: polymerase chain reaction. Moir et al, Annual Review 
of Pathology 2011. 
 
When the virus and/or virus-infected cells reach the draining lymph nodes, they 
encounter activated CD4+CCR5+ T cells, which constitute the ideal targets for further 
infection, due to the close association between cell activation and viral replication 
[102]. This process is enhanced by both DC and B cells that bind and carry the virus to 
activated T cells (via DC-SIGN [132] and CD21 [133], respectively). The virus then 
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replicates rapidly in the absence of an efficient immune response, spreading 
throughout the body to other lymphoid tissues, particularly the gut-associated 
lymphoid tissue (GALT), where activated CD4+CCR5+ memory T cells are present in 
high numbers [134]. This leads both to an exponential increase of plasma viremia, 
reaching a peak three to four weeks post-virus exposure, and to massive CD4+ T-cell 
depletion in the gut [128, 135], which may be in turn related to the marked decrease 
observed in circulating CD4+ T lymphocytes. Rapid viral replication and peak viremia 
may be associated, in HIV-1-infected individuals, with an acute clinical syndrome, 
defined as flu-like clinical manifestations [126]. No cases of acute HIV syndrome have 
been reported for HIV-2 infection. 
Viral reservoirs are progressively established and may be divided into two main 
categories [126]: 1) cellular reservoirs consisting of mainly CD4+ T cells  (that are highly 
susceptible to viral replication upon activation, but also carry the virus in a latent 
proviral form), as well as monocytes and dendritic cells [136-139]; and 2) virus 
entrapped by follicular dendritic cells (FDC) in germinal centres within lymphoid 
tissues, mostly in immune complexes [140, 141]. 
After the point of peak viremia, viral load starts to progressively decrease, 
reaching a more stable level, known as the viral set point [126, 128, 142], process that 
occurs simultaneously with CD4+ T-cell rebound. Virus diversification occurs during 
this decline in viral load, with multiple escape mutants being selected under the 
pressure of adaptive immune responses – both early HIV-specific CD8+ T-cell 
responses, first detected just before peak viremia and possibly contributing to the 
decline in plasma viral load, and neutralizing antibodies [126, 128]. This viral set point, 
maintained by a balance between virus replication and the immune responses, is 
typically significantly higher for HIV-1 than for HIV-2-infected individuals [143].  
 
“Forgotten but not gone”: asymptomatic chronic infection 
Following the primary phase of HIV infection, an asymptomatic period takes 
place, during which progressive CD4+ T-cell depletion, ongoing viral replication and 
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overall immunological dysregulation still occur, albeit no or few clinical manifestations 




Figure 9. Natural history of HIV infection. (A) Clinical, immunological and virological evolution of HIV 
infection. Adapted from Fauci et al, Annals of Internal Medicine 1996. (B) Kinetics of CCR5- and CXCR4-
using viral strains during the course of HIV infection. Regoes&Bonhoeffer, Trends in Microbiology 2006. 
The length of asymptomatic chronic infection varies from patient to patient, and 
depends on a fine balance between viral replication and the ability to maintain 
immune resources. Typically, the rates of CD4+ T-cell depletion are much more 
pronounced in HIV-1- than HIV-2-infected individuals, with plasma viral load remaining 
one to two log10 higher in the former, translating into a longer asymptomatic phase in 
HIV-2 infection [146]. 
Importantly, CD4+ T-cell depletion during chronic HIV infection has been shown 
to be intricately related to hyper immune activation [144], which, as shall be discussed 
in detail later, constitutes a hallmark of HIV disease, playing an important role in the 
associated immunopathogenesis [102]. 
 
“The darkest hour”: late infection and AIDS 
As a consequence of the continuous viral replication and eventual collapse of 
the host’s immune system, the final stage of HIV infection, AIDS, is set, ultimately 
leading to death (Figure 9A). The clinical state of AIDS may be defined, either by the 
occurrence of particular opportunistic infections [147], or on the basis of CD4+ T-cell 
counts, with levels below 200 CD4+ T cells/µl of blood being currently used as a 
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general AIDS-defining criteria implemented by the USA Centres for Disease Control 
and Prevention (CDC) [148]. 
 
“Changing keys”: coreceptor switching and HIV disease progression 
While CCR5-using viral strains seem to be the most commonly used for the initial 
establishment of HIV infection, predominating during the long asymptomatic phase, 
disease progression is often associated with the emergence of syncytium-inducing, 
CXCR4-using viral variants [61, 78, 149] (Figure 9B). Although the mechanisms driving 
coreceptor switching are still a matter of debate, this process appears to be important 
for HIV-1 pathogenesis, as individuals in whom CXCR4-using variants emerge 
(approximately 40-50% of all infected patients) display a more rapid decline in CD4+ T 
cells and a significantly faster progression to AIDS and death than individuals in which 
viral variants only use CCR5 [58, 149]. This may be related with the expression of 
CXCR4 on a broader range of cells, including naïve CD4+ T cells and thymic precursors, 
in comparison with the more restricted expression of CCR5 on activated memory CD4+ 
T lymphocytes [61, 78]. 
Of note, previous data from our Laboratory have shown that the frequency of 
CCR5+ cells within total memory CD4+ T cells tended to be higher in HIV-2- than in HIV-
1-infected individuals with the same degree of CD4+ T-cell depletion, suggesting that 
the slower HIV-2 disease progression is not related with lack of CCR5 availability [150]. 
 
“Fighting fire with fire”: host hindrance to HIV infection 
HIV/AIDS pathogenesis involves complex interactions mediated by both viral and 
host-derived factors, depending on host genomics and immunological responses. 
Genetic determinants of host susceptibility to viral infection and replication include 
genes coding for chemokine receptors, as well as the so-called “host restriction 
factors”: components of the innate immune responses that interfere with different 
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stages of the virus life cycle, being either constitutively expressed, or induced by 
interferon (IFN)-α production in response to viral infection.  
Perhaps the most important example of chemokine receptor-mediated host 
resistance to infection is the naturally-occurring 32 base-pair deletion in the CCR5 
gene (CCR5Δ32) resulting in a truncated protein product [151]. In the homozygous 
state, this deletion provides near complete protection from HIV infection [151, 152]; 
while in the heterozygous form it may confer a delay of up to 2-4 years in disease 
progression [153]. The CCR5Δ32 deletion is found at a frequency of 10-16% in 
Northern Europe, decreasing in a Southeast cline toward Mediterranean, and 
gradually disappearing in the African and Asian populations [154]. 
There are three main classes of restriction factors that are effective against HIV: 
tripartite motif (TRIM) proteins, cytidine deaminases, such as APOBECs, and tetherin. 
TRIM5α is an interferon-induced [155, 156] antiviral factor that protects humans 
and other primates against a broad range of retroviruses, in a species-specific manner, 
by targeting the capsid molecules of the incoming virus in the cytoplasm and 
disrupting its replication [154]. The mechanism by which TRIM5α renders the virus 
uninfectious remains unclear, but it may be that, by coating the viral core with 
multivalent complexes, TRIM5α trimers are able to interfere with the uncoating 
process [157-159]. 
APOBECs are cytidine deaminases that induce G-to-A hypermutation in newly 
synthesized retroviral cDNA, resulting in instability of the nascent viral retrotranscripts 
or lethal mutations [160-162]. Although APOBEC3G was the first to be identified as an 
important antiretroviral factor [163], displaying the most potent anti-HIV-1 activity 
[164], other family members, such as APOBEC3F, 3H and 3B have also been shown to 
inhibit HIV-1 replication [165]. In non-activated CD4+ T cells, APOBEC3G remains as an 
enzymatically active low-molecular mass form that hinders the accumulation of 
reverse transcripts upon viral cellular entry; after T-cell activation, the low-molecular 
mass complexes assemble into high molecular mass complexes without cytidine 
deaminase activity. This suggests that active APOBEC3G would represent a restriction 
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factor for the progress of infection in resting CD4+ T cells, whereas in activated 
lymphocytes, inactive APOBEC3G would allow efficient retrotranscription of viral RNA 
[166, 167]. Of note, APOBEC3G is counteracted by the viral protein Vif [162], which 
neutralizes its action by three major mechanisms [165]: mediating its targeting for 
degradation, impairing the translation of its mRNA and preventing its incorporation 
into viral particles. 
Tetherin (or CD317, or Bone Marrow Stromal Cell Antigen 2, BST-2) is a heavily 
glycosylated integral membrane protein that is usually only expressed efficiently on 
plasmacytoid dendritic cells (pDC), some cancer cells, terminally differentiated B cells 
and bone marrow stromal cells; however, its expression is strongly induced by type I 
IFNs [168]. With an unusual structure [169], it acts like a cross linker between the 
virions and the cellular membrane. This physical bond keeps the new viral particles 
attached to the plasma membrane, or to each other, impeding their release [170, 
171]. The tetherin-mediated restriction of HIV-1 particle is only completely successful 
in the absence of Vpu, which is able to counteract its effects, either by targeting it to 
degradation [165], or by binding and redirecting it to perinuclear compartments [51, 
172]. Of note, in HIV-2, where there is no Vpu, tetherin-mediated restriction is 
counteracted by Env [173-177]. 
A particular case of host resistance to productive viral infection is that observed 
in cells from the myeloid-lineage, including monocytes, dendritic cells and 
macrophages. Although these cells play an important role in initial HIV infection and 
viral dissemination, they seem to be restrictive to post-entry HIV-1 infection in vitro 
[136, 138, 178]. Nevertheless, the Vpx protein from SIVsm and HIV-2 lineages has 
been shown to be able to efficiently enhance HIV-1 infection in human DC and 
macrophages, promoting the accumulation of full-length viral cDNA [47, 179]. 
Recently, it has been shown that Vpx counteracts the effect of a particular host 
restriction factor – SAM domain HD domain-containing protein 1, SAMHD1 [180] – by 
mediating its degradation [53]. SAMHD1 was shown to be critical for HIV-1 replication 
restriction in non-permissive cells, including monocytes, monocyte-derived DC and 
macrophages [181], with SAMHD1-defficient monocytes being susceptible to HIV-1 
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infection [182]. Although many aspects of the biological function of SAMHD1 are still 
unknown, it has recently been proposed that SAMHD1 restricts HIV-1 replication by 
inhibiting reverse transcription and viral cDNA synthesis [183, 184]. SAMHD1-
mediated HIV-1 restriction in myeloid-lineage cells, besides protecting them from 
efficient HIV-1 infection, has been suggested to impair their ability to present HIV 
antigens, thereby limiting the triggering of anti-HIV-1 specific T-cell responses [181]. 
Conversely, SIVsm and HIV-2 encode Vpx to overcome SAMHD1-mediated restriction, 
which probably induces antiviral immunity, thus limiting viral infection in natural hosts 
[181]. Accordingly, the interactions between SAMHD1 and Vpx may contribute to the 
differing consequences of HIV-1 and HIV-2 infections in humans. 
 
1.4. Models of HIV/AIDS pathogenesis 
1.4.1. Non-pathogenic vs. pathogenic SIV infection 
SIV-infected non-human primates (NHPs), such as sooty mangabeys (SM), 
African green monkeys (AGM), mandrills (MND), and chimpanzees (CPZ), typically 
represent natural hosts of the virus, with no progression to disease being observed 
[185]. Less frequently, however, infection of NHP with SIV strains from other species 
results in pathology [21]. This is the case of the infection of Asian rhesus macaques 
(RM) with SIVSM, which has been widely used as the model most closely resembling 
HIV-induced disease in humans [186-188]. Both non-pathogenic and pathogenic SIV 
infections have been extensively explored to investigate HIV/AIDS pathogenesis. 
Most infected natural hosts are able to live a normal life, both in the wild and in 
captivity [189]. Only two cases of AIDS have been reported in animals that had been 
infected for very long periods of time [190, 191]. The exact mechanisms that make SIV 
infection generally non-pathogenic in natural NHP hosts remain elusive. Although 
these animals present levels of circulating virus that are remarkably similar to those 
found during pathogenic SIV/HIV infections, they tend to maintain preserved 
peripheral CD4+ T-cell counts and reduced levels of generalized immune activation 
[192, 193] (Figure 10) which, as shall be discussed in detail later, is one of the 
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hallmarks of SIV/HIV disease [192, 194]. Interestingly, rare cases of CD4+ T-cell 
depletion in the presence of low levels of immune activation have been reported in 
SIV natural hosts, with no progression to AIDS being observed [195], suggesting a 
protective role for reduced immune activation in non-pathogenic SIV disease, in 
particular, and HIV/AIDS pathogenesis, in general. 
 
Figure 10. Non-pathogenic SIV vs. pathogenic SIV/HIV infections. Graphs illustrate the dynamics of viral 
load, CD4
+
 T cells in peripheral blood (PB) and gut-associated lymphoid tissue (GALT), and immune 
activation during the course of (A) non-pathogenic SIV infection in natural hosts and (B) pathogenic 
SIV/HIV infections. SM: sooty mangabeys; AGM: African green monkeys. Adapted from Paiardini et al, 
Annual Reviews of Medicine 2009. 
 
Of note, even though GALT CD4+ T-cell depletion is a common feature of both 
pathogenic and non-pathogenic acute infection, its extent seems to be less dramatic 
in natural hosts than in progressive SIV/HIV diseases [192, 193]. Indeed, whereas 
depletion of mucosal CD4+ T cells increases with HIV/SIV disease progression [135], in 
natural hosts the levels of mucosal CD4+ T lymphocytes remain stable (SM), or even 
increase (AGM) during the chronic phase of infection [196]. The preservation of 
mucosal immunity in SIV-infected SM and AGM is in agreement with the observation 
that these animals do not show microbial translocation from the intestinal lumen to 
the systemic circulation, in contrast to what has been reported for pathogenic HIV/SIV 
infections [197-199]. 
Another key feature of natural SIV hosts is their paucity of CCR5 expression on 
CD4+ T cells from blood, lymph nodes, and mucosal tissues [200], a phenotype that 
may be the result of a convergent evolutionary co-adaptation between primate 
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lentiviruses and their natural hosts, contributing to their non-pathogenic infection 
[192, 200]. 
 
1.4.2. Clinical models of HIV-1 infection 
A minority of all HIV-1-infected patients manifest a non-progressive disease, and 
thus are of particular interest to investigate the mechanisms underlying natural 
control of HIV/AIDS immunopathology. These so-called “long-term non-progressors” 
(LTNP) were first described in the 1990s, and are characterized by their ability to 
naturally preserve CD4+ T-cell counts above 500/µl of blood for, at least, ten years 
after infection [201-203].  
Individuals who are able to maintain circulating viral load below the detection 
limits (less than 1% of all HIV-1-infected individuals) were subsequently identified, 
being referred to as “elite controllers” [204, 205]. A large proportion of “elite 
controllers” is thought to also meet the criteria for LTNP, though a slow progressive 
CD4+ T-cell decline has been reported [206]. 
Both host and viral factors seem to be involved in this natural ability to control 
HIV-1 infection, in particular: the high prevalence of AIDS-protective HLA-B*27 and 
HLA-B*57 alleles [205, 207-209]; and the occurrence of nef-deleted HIV-1 mutants 
[210]. 
 
1.4.3. HIV-2 infection 
The clinical spectrum of HIV-2 infection is similar to that observed for HIV-1 
[211]. However, HIV-2 is generally less pathogenic, with most patients presenting a 
much slower disease progression, characterized by a clinically latent period of twenty 
or more years, that results in a mortality rate estimated to be two-thirds lower than 
the one observed for HIV-1 [212-214]. HIV-2 infection therefore constitutes a 
naturally-occurring attenuated form of HIV disease, providing an important 
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opportunity to study immune control and pathogenesis of HIV/AIDS that has been yet 
underestimated. 
The mechanisms underlying the better disease prognosis associated with HIV-2 
infection remain unclear. HIV-2-infected patients present a much slower rate of CD4+ 
T-cell decline than their HIV-1+ counterparts [146] and low to undetectable circulating 
viral load [143]. Nevertheless, levels of proviral DNA have been reported to be similar 
in both infections [215, 216], with ongoing viral replication being observed even in 
aviremic HIV-2-infected individuals [216]. These findings suggest that, in the context 
of HIV-2 disease, productive viral infection and replication do occur but, nonetheless, 
fail to be translated into circulating virus. Of note, when HIV-1- and HIV-2-infected 
patients are matched for the degree of CD4+ T-cell depletion, their levels of immune 
activation are similar [217], stressing the importance of this particular factor for 
HIV/AIDS immunopathology and associated disease progression. 
 
1.5. Strategies for HIV control 
1.5.1. Antiretroviral therapy (ART) 
The advent of antiretroviral therapy has brought about a substantial decrease in 
the death rate associated with HIV-1 infection, changing it from a rapidly lethal 
disease into a chronic manageable condition, compatible with a very long survival of 
infected individuals [218].  
Since the USA Food and Drug Administration (FDA) approval of 3’-azido-2’,3’-
dideoxythymidine (AZT), the first anti-HIV drug, in 1987, a variety of new therapies 
have arisen. There are now over 30 antiretroviral products, formulated either singly or 
in combination, to treat HIV-1-infected individuals [219]. These are subdivided into 
different classes of drugs based on the particular phases of the viral life-cycle they 
have been designed to target: fusion inhibitors, entry inhibitors (CCR5 antagonists), RT 
inhibitors (either nucleoside analogs, NRTI, or non-nucleoside analogs, NNRTI), 
integrase strand transfer inhibitors and protease inhibitors [218].  
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Despite the enormous success of antiretroviral drugs in hampering viral 
replication and reducing circulating viral load, disease progression and transmission, 
the cure of HIV/AIDS disease and the control of HIV reservoirs have not been 
achieved. In fact, once initiated, ART has to be maintained for life, with the inherent 
side-effects and economic burden [220]. The longer the period on ART, the higher the 
risk for emergence of drug-resistance and viral genetic diversity which, ultimately, 
lead to ART failure [221]. Thus, the definition of the best moment to start ART is 
critical, being the subject of an intense ongoing debate [221-223]. 
Regarding HIV-2 infection, ART regimens are associated with a much more 
reduced clinical success [146, 216, 224, 225]. Many factors are likely to contribute, 
including the fact that all antiretroviral drugs have been specifically designed to 
control HIV-1 replication.  Apart from having an innate resistance to NNRTI [226, 227], 
HIV-2 may have decreased susceptibility to fusion inhibitors [223]. Of note, there are 
no randomized clinical trials for the treatment of HIV-2 infection, which complicates 
clinical decisions during the follow-up of HIV-2-infected individuals [223]. 
 
1.5.2. Cytokine-based complementary therapeutic interventions 
ART alone is not sufficient to recover CD4+ T-cell counts in about 20% of HIV-1-
infected patients despite the efficient suppression of plasma viral load [228]. These 
so-called immunologic discordants highlighted the need for other strategies to be 
developed and used in conjunction to ART, in order to achieve full immunological 
reconstitution under treatment. 
Due to their ability to induce both proliferation and survival, cytokines of the 
common γ-chain cytokine family – such as interleukins-2 (IL-2), -7 (IL-7), -15 (IL-15) and 
-21 (IL-21) – have emerged as possible central regulators of peripheral CD4+ T-cell 
homeostasis during HIV infection [229]. Studies are ongoing to define the applicability 
of therapies based on the use of these cytokines as a complement to ART [230-237]. 
Whilst IL-2 appears to have a negligible impact on CD4+ T-cell recovery in HIV-1-
infected individuals on ART [238], the effects of IL-15 administration, besides 
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promoting extensive memory T-cell expansion in NHP [239], remain largely unknown 
[240, 241]. On the other hand, IL-7-based immunotherapy has recently been shown to 
enhance T-cell recovery and thymic output in HIV-1-infected patients on ART [242], 
rendering this particular cytokine an attractive therapeutic adjuvant in HIV disease. 
Of note, as HIV is known to be able to persist in viral reservoirs that are not 
eliminated by ART [243], the use of proliferation-inducing common γ-chain cytokines, 
in particular IL-7, is thought to be of relevance to help “purge” the pool of latently 
infected cells, consequently contributing to viral eradication [233, 244, 245]. 
 
1.5.3. Preventive strategies 
Besides treating HIV/AIDS disease, reducing the incidence of new infections 
currently remains one of the greatest Public Health challenges. No single prevention 
strategy is currently totally effective and applicable to all populations [246]. 
Male condoms still appear to constitute the most highly effective form of HIV 
prevention [247]. Other interventions, including the treatment of sexually transmitted 
infections (STI) [248], male circumcision [249, 250], and the use of non-antiretroviral 
microbicide vaginal gels [251], have been shown to be clinically successful in reducing 
HIV acquisition. 
Recently, ART-based pre-exposure prophylaxis (PrEP) has also been proposed as 
a preventive strategy [252-254]. Preventive strategies relying on ART administration 
have been extensively used to avoid infection as post-exposure prophylaxis (PEP) after 
contact with HIV-infected blood or fluids [255, 256]. Although an intense public 
debate is still ongoing about the applicability of PrEP, the FDA has very recently 
approved its use for prevention in populations at high risk of sexually acquired HIV 
infection [257]. 
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Part 2. Hyper immune activation as the main cause of CD4+ T-
cell depletion in HIV infection 
Factors other than the direct killing of CD4+ T cells by the virus have been 
suggested to be involved in HIV/AIDS immunopathology, in particular the persistently 
increased immune activation. In fact, during chronic HIV infection, the frequency of 
infected CD4+ T lymphocytes has been shown to be too low to solely account for the 
observed CD4+ T-cell loss [135, 258].  
The idea that chronic immune activation could play a major role in AIDS 
pathogenesis was first proposed in the late 1980s/early 1990s [259-261]. Shortly after, 
data from several groups started to progressively accumulate, suggesting that levels of 
immune activation, particularly at the CD8+ T-cell level [262], constituted a better 
correlate of disease progression than actual viral load, both in HIV-1 [217, 262-265], 
and HIV-2 [217] infections. Additionally, studies of SIV infection of natural hosts 
showed that, despite the high levels of circulating virus, there was no progression to 
AIDS in the absence of increased levels of immune activation [195, 266-268]. Taken 
together, these findings supported a new paradigm in HIV/AIDS immunopathogenesis, 
indicating hyper immune activation as a fundamental driving force of HIV-associated 
immune dysfunction. 
Immune activation in the context of HIV infection is a broad term encompassing 
several features associated with cell activation, proliferation, differentiation and 
death, as well as the secretion of soluble molecules, and their subsequent effects 
[269]. HIV-infected individuals present elevated markers of immune activation, and 
associated disturbances, on CD4+ and CD8+ T cells [217, 270], as well as on B cells [271, 
272], monocytes [273] and dendritic cells [274-276]. High levels of pro-inflammatory 
cytokines, such as TNF-α and IL-6, and chemokines, like macrophage inflammatory 
protein-1β (MIP-1β) and monocyte chemoattractant protein-1 (MCP-1), have also 
been described during HIV infection [277-280]. 
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“Dr. Jeckyll, Mr. Hide”: the pros and cons of heightened immune activation 
Immune activation in response to HIV infection is essential to mount host 
immune responses, which are of utmost importance for viral suppression, both during 
the primary phase and the asymptomatic period of infection [126]. Paradoxically, this 
may also provide an immunological environment that actually drives viral replication 
[102]. Additionally, increased immune activation is associated with major lymphocyte 
disturbances, including increased activation-induced cell death (AICD), alterations in 
cell trafficking, and progressive disruption of microenvironments required for 
hematopoiesis and lymphocyte homeostasis [102, 135, 281-283]. 
Hence, persistent immune activation, not only derives from, but also compels 
HIV/AIDS disease progression.   
 
2.1. Underlying mechanisms 
The mechanisms underlying persistent immune activation during HIV infection 
are not fully clarified, but are likely to be multiple and include factors other than the 
direct impact of viral replication. 
 
“Adding fuel to the fire”: direct effects of the virus and associated host 
immune responses 
HIV is able to directly activate cells of the innate immune system, particularly 
plasmacytoid dendritic cells (pDC), through direct binding to Toll-like receptors (TLR) 
[284, 285]. The upregulation of costimulatory and maturation marker expression on 
pDC, which constitute the first line of immune defense against viral infection, leads to 
1) the production of type I interferons with both immune-stimulating and anti-viral 
activity [286]; 2) the bystander maturation of myeloid DC (mDC) [287] with the 
resulting enhancement of antigen-presenting functions, and 3) the overall stimulation 
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of T and B lymphocytes [288, 289], resulting in the activation of adaptive HIV-specific 
immune responses (both cellular and humoral). 
During primary HIV-1 infection, robust specific T-cell responses are induced, in 
particular cytotoxic CD8+ T cells, which play a key role in viremia decline and viral set 
point establishment [290]. These HIV-specific T-cell responses persist at high levels 
during chronic infection, being continuously boosted by the antigen (ag) produced 
during HIV replication [291, 292]. Nevertheless, HIV-specific CD4+ T cells are present at 
a lower magnitude, possibly due to their preferential loss due to HIV infection [135]. 
Of note, in contrast to HIV-1 disease, HIV-2 infection seems to feature a better 
maintenance of HIV-specific CD4+ T-cell responses, both in frequency and in quality 
[293-297], and an overall preservation of polyfunctional HIV-specific T-cell responses 
[298]. These features may contribute to the better HIV-2 disease prognosis [146]. 
The antibody response to HIV following infection is largely ineffectual, with early 
responses being mostly directed against non-neutralizing epitopes of the viral 
envelope [299, 300] and later responses being unable to keep up with the rapidly 
diversifying virus [301, 302]. Of note, several studies have suggested a better ability of 
HIV-2-, in comparison with HIV-1-infected individuals, to generate and preserve 
significant levels of circulating HIV neutralizing antibodies during the chronic phase of 
the disease [303-307]. These findings have been suggested to be related to particular 
conformations of the HIV-2 envelope proteins that may favour the triggering of potent 
neutralizing antibody responses [308]. 
Although virus-specific adaptive immune responses can be beneficial, 
contributing to the suppression of viral replication, they may also promote the 
inflammatory state associated with HIV infection [145].  
Additionally, HIV proteins may play a direct role by inducing the activation of 
lymphocytes and monocytes/macrophages, as well as the production of pro-
inflammatory cytokines and chemokines [269, 309], thereby promoting viral 
replication. In particular, gp120 may be able to activate immune cells, or enhance 
their responsiveness to activation, even in the absence of direct infection, through the 
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binding of CD4 or coreceptors, resulting in the induction of intracellular signaling 
pathways [310-314]. Another viral protein, Nef, is also able to induce lymphocyte 
activation, either directly [315-317] or through its action in infected macrophages 
[318-320]. 
 
“Several means justify one end”: indirect effects of viral replication 
Other factors besides the direct effects of HIV replication have been suggested 
to contribute to persistent immune activation, as listed below. 
 Unrelated infections: overall immune disturbances observed during HIV disease 
may result in suboptimal immune control of additional pathogens, including, but not 
limited to, those causing opportunistic infections during the later disease stages. Thus, 
reactivation of latent forms of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) 
[321, 322], for example, ultimately lead to additional antigenic stimulation, and may 
further contribute to augment the level of immune system activation. 
 Microbial translocation: the massive HIV-associated depletion of CD4+ T cells 
from the GALT [323] contributes to disrupt the integrity of the gut’s mucosa, resulting 
in microbial translocation from the gut to the blood [324, 325]. HIV-1 infection has 
been associated with a significant increase in plasma lipopolysaccharide (LPS) levels, 
an indicator of microbial translocation that directly correlates with measures of 
immune activation [197]. Microbial translocation has been reported to primarily result 
in a profound activation of the innate immune responses [273, 326], as bacterial 
products such as LPS, flagellin and CpG constitute TLR ligands that directly stimulate 
peripheral monocytes/macrophages and DC to produce pro-inflammatory cytokines, 
whilst also interfering with adaptive immune responses [327]. Overall, sustained 
microbial translocation has been suggested to contribute to generalized activation and 
differentiation of lymphocytes and monocytes, being associated with: 1) markers of 
disease progression and severity in HIV-1 and HIV-2 infections [328]; and both 2) poor 
CD4+ T-cell recovery [329, 330] and 3) residual viral replication [331] in the context of 
antiretroviral therapy. Recently, microbial translocation has also been suggested to 
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predict disease progression of untreated HIV-infected patients with high CD4+ T-cell 
counts [332]. However, although this process seems to play an important role in HIV 
pathogenesis in the developed world, it is unclear whether it contributes to HIV 
disease in African cohorts. Of note, while, in some African studies, no associations 
have been reported between circulating LPS and progression to AIDS [333, 334], in 
others, microbial translocation has been described as a major driving force of chronic 
inflammation in HIV disease [335, 336]. 
Heightened cytokine production: the increased production of pro-inflammatory 
cytokines, primarily induced at the level of innate immune responses to viral 
replication, may mediate non-antigen specific “bystander” activation of T and B 
lymphocytes. This “bystander” activation also involves the up-regulation of apoptosis-
related molecules (such as the Fas molecule, CD95) on the surface of lymphocytes, 
rendering them more prone to AICD and significantly contributing to immune 
disturbances during HIV/AIDS progression [337-339]. Importantly, in addition to 
enhancing T-cell activation, some pro-inflammatory cytokines, such as IL-1β, IFN-α and 
TNF-α, may also decrease trans-epithelial resistance in mucosal tissues [340], thus 
promoting microbial translocation and contributing to further immune activation. 
CD4+ regulatory T-cell (Treg) loss/dysfunction: an additional factor with the 
potential to affect hyper immune activation associated with chronic HIV disease is the 
reported depletion and/or functional impairment of CD4+ Treg cells observed in some 
studies [341, 342]. Although the results regarding the Treg compartment in HIV 
infection are conflicting [343, 344], as discussed in more detail later, an impairment of 
the known ability of Treg to suppress immune activation either through direct cell-to-
cell contact, production of anti-inflammatory cytokines or inhibition of DC activity, 
would be very relevant in HIV/AIDS pathogenesis. 
 
2.2. Consequences 
The state of HIV-associated chronic immune activation and inflammation has 
wide-ranging deleterious effects on the immune system. 
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A direct consequence of T-cell activation is the enhancement of integrated virus 
transcription, with subsequent production of new virions with the ability to infect new 
target cells [345]. A vicious cycle is then established, in which HIV replication 
promotes immune activation and immune activation potentiates viral replication and 
the inherent consequences of viral mutation and evolution. 
Chronic T-cell activation results in persistent turnover and promotes the 
differentiation of naïve into memory-effector cells. This contributes to the depletion 
of naïve T-cell subsets and skewed T-cell differentiation, leading to an over-
accumulation of T cells at intermediate/end stages of differentiation during the course 
of HIV disease [346-349]. Importantly, although a large number of T cells end up dying 
upon activation, the dynamics of activation, expansion and apoptosis seem to differ 
for CD4+ and CD8+ lymphocytes [350-352]: while CD8+ T cells experience extensive 
expansion upon activation and can establish a stable pool of resting memory cells, the 
capacity of CD4+ T cells to expand and survive seems to be lower, such that the vast 
majority of activated CD4+ T cells undergo apoptosis rapidly. Hence, the ultimate 
consequence of immune activation is a marked depletion of CD4+ T cells, which 
constitutes the hallmark of HIV disease progression. 
Polyclonal B-cell activation and hypergammaglobulinemia are also hallmarks of 
HIV infection [353]. HIV-1-related chronic immune activation has been shown to 
profoundly affect B cells, being associated with progressive impairments of specific 
humoral responses, loss of memory B cells, massive B-cell apoptosis and loss of 
germinal centres in lymphoid tissue [339, 353-359]. Of note, TGF-β has been reported 
to mediate collagen deposition and tissue fibrosis [360, 361], leading to structural 
effacement of lymph node architecture during HIV-1 and pathogenic SIV disease, 
thereby possibly contributing to B-cell disturbances, and impaired reconstitution of 
the B cell compartments upon ART [353, 362]. 
Importantly, the innate immune system is also significantly dysregulated by 
persistent immune activation [128, 285]. Disturbances regarding cell numbers, 
activation, function and survival of pDC, mDC and monocyte subsets have been 
extensively reported during the course of HIV disease [275, 363-371]. Defects in the 
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innate immune system are likely to be of major importance in the pathogenesis of HIV 
disease, not only by facilitating viral replication and contributing to defective adaptive 
responses, but also through the promotion of inflammation [285]. 
 
2.3. Counteractive responses 
The immune system has developed specific regulatory mechanisms to prevent 
the deleterious effects of immune activation-driven pathology resulting from 
unchecked immune responses. One of these mechanisms is the up-regulation of 
inhibitory or immune checkpoint molecules, such as Programmed-Death 1 (PD-1) and 
T-cell Immunoglobulin and Mucin domain-containing molecule 3 (TIM-3), which 
dampen T-cell responses by different processes; another consists of the generation of 
cell populations with immunosuppressive capacity. 
 
2.3.1. Inhibitory pathways – PD-1 and its ligands 
Although having been initially described as a molecule preferentially expressed 
on dying cells [372], PD-1 (also known as CD279) was one of the first inhibitory 
receptors identified, with its important inhibitory function being revealed by the 
autoimmune-prone phenotype of pdcd1-/- mice [373, 374]. 
A member of the CD28 family [375], PD-1 is a 288 amino acid (aa) type I 
transmembrane protein composed of one immunoglobulin (Ig) super-family domain, a 
20 aa stalk, a transmembrane domain, and an intracellular domain of 95 aa residues 
containing both an immunoreceptor tyrosine-based inhibitory motif (ITIM), and an 
immunoreceptor tyrosine-based switch motif (ITSM) [376, 377]. PD-1 is expressed on 
both lymphocytes and cells of the myeloid lineage [375, 376]. Of note, although not 
expressed on resting T cells, PD-1 may be induced upon activation, either by direct 
TCR engagement [376, 378, 379], or by the effect of commom γc cytokines, such as IL-
2, IL-7, IL-15 and IL-21 [380]. 
38 HIV-2 immunopathology: 
how the immune system deals with long-lasting infection 
 
There are two identified PD-1 ligands, PD-L1 (B7-H1; CD274) [381] and PD-L2 
(B7-DC; CD273) [382], both consisting of type I transmembrane glycoproteins with 
short cytoplasmic tails containing no known motifs for signal transduction [376, 383]. 
PD-L1 is constitutively expressed on activated T cells and antigen-presenting cells, APC 
[384], as well as on B cells [385] and natural killer, NK, cells [386]; whereas PD-L2 is 
mainly restricted to DC and monocytes [384] and, more recently, also described on 
activated T cells [387, 388]. Both PD-1 ligands’ expression has been shown to be 
induced by IFN-γ [384] and commom γc cytokines [380]. Importantly, as PD-1 and its 
ligands are expressed on the same cell types, bidirectional signaling may occur. 
 
“Keeping cells on a diet”: inhibitory signaling through the PD-1 receptor 
Inhibitory receptor signaling typically attenuates immune responses, as widely 
described in T cells [376]. Whilst TCR engagement enables T cells to switch from 
quiescent into actively expanding cells, co-stimulation is thought to be required for 
the glucose uptake necessary for cell division and effector differentiation [377, 389]. 
Co-stimulation, by activating phosphatidylinositol-3-kinase (PI3K), and its downstream 
target Akt (protein kinase B), leads to increased expression of glucose transporters on 
the plasma membrane and general up-regulation of glycolytic enzyme activity [390]. 
PD-1 engagement leads to PI3K activation blockade, thereby impairing T-cell 
activation by denying the cell the resources required for cell division, effector function 
and differentiation [391] (Figure 11). Moreover, PD-1 ligation and subsequent 
interference with early activation events inhibits 1) the induction of the cell survival 
factor Bcl-xL [392]; 2) IL-2 production [393, 394]; 3) and the expression of transcription 
factors associated with effector cell function [376]. Of note, PD-1 ligation inhibits 
antigen receptor signaling only in cis and not in trans [395], indicating that PD-1 
ligation must occur close to the site of antigen receptor engagement, an idea 
supported by the redistribution of PD-1 from uniform cell surface expression to the 
synapse during T-cell–APC interactions [396].  
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Figure 11. The inhibitory effects of PD-1 
signaling in T cells. PD-1 engagement on the 
cell surface leads to phosphorylation of PD-1 
cytoplasmic tyrosine residues, promoting 
the binding of phosphatases. This, in turn, 
interferes with phosphorylation of the PI3K 
pathway, affecting downstream signaling 
through Akt. PD-1 engagement ultimately 
decreases the induction of cytokines and cell 
survival molecules, also causing disturbances 
in glucose metabolism. Adapted from Riley, 
Immunological Reviews 2009. 
 
 PD-1 signaling typically has greater effect on cytokine production than on 
cellular proliferation, with significant effects on IFN-γ, TNF-α and IL-2 production 
[376]. Importantly, PD-1-mediated inhibitory signals depend on the strength of TCR 
stimulation, with greater inhibition being achieved at low levels of TCR signaling. This 
inhibition can be overcome by co-stimulation through CD28 [381] and/or IL-2 [393]. 
Of note, while many studies have shown that PD-Ls engagement can drive the 
inhibition of T-cell proliferation and cytokine production, others have found PD-Ls to 
enhance T-cell activation [397-400]. The reasons for these contradictory results are 
not yet clear and remain controversial, with some data suggesting that PD-L1 can 
increase T-cell proliferation by inhibiting IFN-γ-induced nitric oxide production by 
macrophages, a factor that can inhibit T-cell proliferation [401]. In addition, apart 
from influencing immune responses by binding to PD-1, PD-L1 has been shown to be 
able to interact specifically with B7-1 (CD80) to inhibit T-cell responses [402], further 
suggesting that bidirectional signaling may occur. 
 
“Exhaustion vs. collateral damage control”: the PD-1/PD-L1 pathway in 
HIV infection 
PD-1 and its ligands play important roles in controlling immune responses 
against pathogens that cause acute and chronic infections – such as HIV –, being of 
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potential relevance for mediating the delicate balance between effective immune 
responses and immune-mediated tissue damage. 
In the context of chronic HIV-1 infection, PD-1 up-regulation was first described 
as a marker of cellular exhaustion on HIV-1-specific CD4+ and CD8+ T cells [403-405].  
Exhausted T cells are usually defined as no longer able to proliferate and exert 
effector functions, such as cytotoxicity and cytokine secretion in response to antigen 
stimulation [406]. Exhaustion has been suggested to be a progressive and hierarchical 
process, with proliferation and CTL function being lost first, followed by the loss of IL-
2, TNF-α and IFN-γ production capacity [407].  
Of note, HIV-1-specific T-cell “exhaustion”, defined on the basis of PD-1 
expression, has been shown to be partially reversible upon blockade of the PD-1/PD-
L1 pathway [394, 403-405]. Moreover, not all exhausted T cells have been described 
as expressing PD-1 [404] and not all PD-1+ cells have been shown to feature functional 
impairment [405, 408], suggesting an additional role of other inhibitory molecules for 
the true definition of T-cell exhaustion in the context of HIV infection (as will be 
discussed later).  
Importantly, the frequency of PD-1+ HIV-1-specific T cells has been extensively 
shown to directly correlate with markers of disease progression and severity [404, 
409-411], decreasing in the context of ART-mediated immune activation reduction 
[412, 413] and viral load suppression [403, 404, 414]. This reinforces a possible major 
role of the PD-1/PD-L1 pathway during HIV pathogenesis. 
A growing body of evidence now suggests that increased PD-1 levels may, 
instead of reflecting immune exhaustion, serve as a mechanism to control tissue 
damage [415, 416] driven by chronic immune activation [417] and/or persistent 
antigenemia associated with ongoing viral replication, even at low levels [292, 418]. In 
agreement with this view, PD-1 expression has been documented to depend on both 
T-cell activation and differentiation status, with central and effector memory 
populations, which include the majority of HIV-1-infected cells [419], and not the 
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terminally differentiated ones, expressing the highest levels of the inhibitory molecule 
[408, 420, 421],  
 
“It takes (at least) two to tango”: cooperation of PD-1 and TIM-3 during 
chronic HIV infection 
TIM-3 expression has recently been reported to identify a highly dysfunctional, 
non-proliferating, no cytokine-producing, population of activated T cells, with highly 
elevated frequencies in progressive HIV-1 disease [422]. 
TIM-3 is an Ig super-family member that differs from other inhibitory molecules 
in that its activation-mediated up-regulation occurs specifically on T cells that have 
differentiated to produce IFN-γ (CD4+ T helper 1 and CD8+ T cytotoxic 1 cells). Hence, it 
typically limits Th1 responses [423, 424]. Of note, recent studies suggest that TIM-3 
may also act as a human monocyte inhibitor, with its blockade being associated with 
increased pro-inflammatory cytokine production upon TLR stimulation [425, 426].  
The mechanisms underlying TIM-3 regulation are still poorly understood, with 
evidence suggesting its induction to be dependent on Th1-cell activation [423, 424], 
and the transcription factor Tbet [427], whilst also being potentially involved in the 
differentiation of Th1 vs. Th17 cells [428]. Engagement of TIM-3 by its only identified 
ligand (galectin-9, Gal-9, a lectin highly expressed by leukocytes, fibroblasts and 
endothelial cells in inflamed tissues [429, 430]), typically results in the apoptosis of 
TIM-3+ cells [423]. How this engagement process leads to the inability of T cells to 
enter cell cycle and secrete cytokines remains unknown, as well as the mechanisms 
underlying the persistence of the TIM-3+ population [428, 431-434]. 
 TIM-3 has been observed to be co-expressed with PD-1 in the context of both 
chronic viral infection, including HIV disease [435], and cancer [436]. This co-
expression was restricted to a small percentage of T cells featuring the most 
exhausted phenotype, whilst T cells expressing PD1 alone still retained some function 
[422, 435-438]. Hence, co-blockade of the PD-1 and TIM-3 signaling pathways has 
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been shown to be more effective in restoring exhausted T-cell function than targeting 
either pathway alone [436, 439]. These findings further support the idea that PD-1 
expression, by itself, may not always be associated with cellular exhaustion, being 
insufficient to fully characterize it in the absence of additional inhibitory molecules 
with potentially synergistic effects. 
 
2.3.2. CD4+ regulatory T cells 
CD4+ regulatory T cells (Tregs) may also act as modulators of immune activation. 
Tregs actively suppress effector T cells and inhibit immune-mediated tissue 
damage, being typically characterized by the expression of the Treg-restricted 
transcription factor forkhead box protein 3 (FoxP3) [440], high level IL-2 receptor (IL-
2R) α chain, CD25, expression, and suppressor functions [441]. Tregs are known to 
express the above described inhibitory molecules PD-1, PD-L1 and TIM-3 [442, 443]. 
FoxP3+ Tregs may be divided into two subsets: naturally occurring (nTregs) and 
induced Tregs (iTregs), with the first being generated in the thymus [444, 445], and 
the latter developing in the periphery from FoxP3 naïve CD4+ T cells through a 
process that, in vitro, has been described to depend on IL-2 and TGF-β [446]. Although 
initial Treg activation requires antigen-specific TCR stimulation, once activated they do 
not require further TCR ligation, thus being able to inhibit T-cell responses in an 
antigen-nonspecific manner [447, 448]. 
 
“Teaching cellular yoga lessons”: Treg-mediated immune suppression 
FoxP3 negatively regulates IL-2 transcription and up-regulates CD25 expression, 
rendering exogenous IL-2 essential for Treg survival [449, 450]. The constitutively high 
expression of CD25 allows efficient absorption of IL-2 by Tregs, and the concomitant 
depletion of IL-2 from the local milieu and thus any nearby conventional T cells. Some 
studies have suggested that IL-2 consumption by Tregs may result in cytokine 
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deprivation-induced apoptosis of effector T cells [451]; alternatively, Tregs may inhibit 
IL-2 mRNA production in Foxp3 effector T cells [452]. Another factor that has been 
described to be important for Treg function is the anti-inflammatory cytokine IL-10. IL-
10-producing FoxP3+ T cells were found to be abundant in the intestinal lamina 
propria and thought to play a critical role in mucosal tolerance. Additional 
mechanisms used by Tregs to influence immune responses include, but may not be 
restricted to [453]: 1) direct interactions with DC (with Tregs down-regulating co-
stimulatory molecules such as CD80 and CD86, and thereby “educating” DC to become 
less efficient); and 2) lysis of effector T cells, APC, or NK cells, with some data 
indicating that Tregs may use granzyme A and perforin to kill target cells [454]. 
 
“The Godfather”: PD-1/PD-L1 effects on Treg induction and function 
Tregs and the PD-1/PD-L1 pathway are both critical in inhibiting immune 
activation, with elimination of either one leading to uncontrolled T-cell responses. Of 
note, the PD-1/PD-L1 pathway has been reported to be involved in the ability of Treg 
to suppress immune responses [455, 456], with resting Tregs possibly retaining PD-1 
in intracellular compartments and translocating it to the cell surface upon TCR 
activation [457]. Furthermore, PD-L1 engagement has been shown to: enhance and 
sustain FoxP3 expression, and thus suppressive function of established iTregs [458];  
increase the de novo generation of FoxP3+ iTregs from naïve CD4+ T cells; and convert 
Th1 cells into Treg [459]. Interestingly, in the context of chronic infection, Treg 
proliferation and function seem to be inhibited by PD-1 signaling [460]. 
 
“A double-edged sword”: the role of Tregs in HIV infection 
Several groups have analyzed frequencies and function of Tregs in HIV-1-
infected patients. Nevertheless, the results are still somewhat controversial, with 
some authors supporting the idea that Tregs may contribute to HIV-1 pathogenesis by 
suppressing HIV-specific immune responses [344, 461-463], whilst others suggest that 
44 HIV-2 immunopathology: 
how the immune system deals with long-lasting infection 
 
these cells may have a protective role in HIV pathogenesis by limiting immune 
activation [342, 343, 464, 465]. 
In the context of HIV-2 infection, an expansion of Tregs has been reported, that 
was observed to be more directly linked to CD4+ T-cell depletion than to circulating 
viral load, supporting an apparently better preservation of circulating naïve and 
memory Tregs as compared with other CD4+ T-cell populations in HIV/AIDS [466].  
 
2.3.3. Additional immunosuppressive mechanisms 
Additional mechanisms able to inhibit immune activation have been described, 
involving the production of inhibitory factors, such as indoleamine 2,3-dyoxigenase 
(IDO) and IL-10. 
IDO is an intracellular enzyme that catalyzes the degradation of the essential 
amino acid tryptophan (Trp), and is produced at high levels by pDC, exerting a 
powerful suppressive effect on T-cell proliferation and activity [467]. IDO has a 
tolerizing function in physiological settings, whilst during chronic pathologic disorders 
it has been suggested to play a role in impairing efficient immune responses, hence 
favoring the persistence of infection [274]. In addition, IDO activity seems to be closely 
linked with Treg function: Tregs induce IDO expression by pDC, and IDO-expressing 
pDC promote Treg differentiation from naïve CD4+ T cells [468, 469]. Of note, as HIV is 
a potent activator of pDC, high levels of IDO expression are induced during acute HIV 
infection, which are then maintained during the chronic phase, concomitant with an 
impaired adaptive anti-HIV-specific response [470-472]. 
Production of the anti-inflammatory cytokine IL-10 by APC has been shown to 
lead to T-cell response impairment in the context of chronic viral infection, with 
blockade of the interaction between IL-10 and its receptor resulting in restoration of 
T-cell function and viral clearance [473, 474]. In HIV-1, IL-10 levels have been reported 
to be elevated and associated with markers of disease progression [475]. Of note, it 
has recently been proposed that high amounts of microbial products (likely associated 
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with microbial translocation) and inflammatory cytokines in the plasma of HIV-1 
infected individuals may direct PD-1 up-regulation by monocytes, leading to IL-10 
production and reversible CD4+ T-cell dysfunction [476]. 
 
“Trying to keep chaos under control”: immunosuppressive effects of viral 
proteins 
Paradoxically, some viral proteins have also been described as helping to 
contribute to the attenuation of T-cell responses, particularly in the context of HIV-2 
infection. This may translate into an adaptive advantage for the virus, as it could allow 
a longer period of virus production to occur, by increasing the life span of infected 
cells, through immune activation reduction and apoptosis suppression. 
HIV-2 Nef has been shown to down-modulate TCR-CD3 in infected T cells, 
thereby limiting their responsiveness to activation mediated by this complex [315]. Of 
note, this capacity has been proposed to have been lost during viral evolution in the 
SIV lineage that gave rise to HIV-1, likely resulting in its increased pathogenicity in 
humans [315]. Nevertheless, HIV-1 Nef has been shown to induce PD-1 expression 
during in vitro infection [477], demonstrating an important role of Nef in the 
regulation of inhibitory molecules.  
 Finally, viral envelope glycoproteins have been described to have immune-
suppressive properties [478-482], with the HIV-2 envelope glycoprotein gp105 
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Part 3. Ability to replenish CD4+ T cells in HIV infection 
The immune system has the ability to reconstitute itself following profound 
depletion, through both thymic-dependent and -independent mechanisms. During HIV 
infection, there is a need to reconstitute an extremely depleted memory CD4+ T-cell 
pool. This process depends, not only on the homeostatic proliferation of memory 
CD4+ T lymphocytes, but also on the reconstitution of the memory CD4+ T-cell pool 
with cells differentiating from the naïve compartment. Importantly, HIV-induced 
immunopathology directly limits the above renewal processes by impairing thymic 
function and disrupting lymph node architecture [484]. 
Notably, CD4+ T-cell regenerative pathways seem to be significantly different 
from those underlying CD8+ T-cell restoration. Indeed, whereas reconstitution of CD8+ 
T-cell numbers, after T-cell depletion, has been shown to be rapid and mainly rely on 
peripheral expansion, recovery of CD4+ T cells appears to be both more limited and 
slower, being critically dependent on the naïve CD4+ T-cell pool and, therefore, 
constrained by the age-related decline in thymopoiesis [485, 486]. Furthermore, while 
a significant proportion of activated expanded CD8+ T cells may later rejoin the resting 
memory CD8+ T-cell pool, the fate of activated CD4+ T cells seems to be different, with 
fewer being able to survive [352, 487, 488]. Finally, maintenance and homeostatic 
expansion of naïve CD4+, but not CD8+, T cells seems to be critically dependent on the 
presence of a preserved microenvironment of the secondary lymphoid tissue [489].  
 
3.1. De novo CD4+ T-cell production 
The thymus is an encapsulated organ, comprised of thymic stroma and 
hematopoietic cells, and consisting of several lobules with distinct cortical and 
medullary areas [490]. Cortical and medullary thymic epithelial cells (cTEC and mTEC) 
constitute the main components of the thymic microenvironment, with each subset 
playing a distinct role in thymocyte development [490]. 
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T cells are produced in the thymus from pluripotent CD34+ hematopoietic stem 
cells (HSC), derived from the foetal liver (initially) and bone marrow [491, 492].  
Double-negative (DN) CD4CD8 T-cell precursors give rise to double-positive (DP) 
CD4+CD8+ thymocytes, which then undergo selection, lineage commitment, and 
differentiation into naïve CD4+ and CD8+ single-positive (SP) T cells [493] (Figure 12). 
These latter steps are primarily determined by TCR signaling, and are dependent upon 
the interaction of CD4 and CD8 with major histocompatibility complex (MHC) class II 
and I molecules, respectively, expressed on thymic stromal cells [494]. 
Figure 12. Simplified model of T-cell development. After entering the thymus, CD4CD8CD34
+
 
hematopoietic stem cells (thymic immigrants) undergo TCR gene rearrangements, by the end of which 
they acquire a fully functional TCR-CD3 complex. During this process, CD4 and CD8 molecules are also 
sequentially and progressively up-regulated, first generating an intermediate population comprising 
immature CD4
+











 thymocytes then go through a process of positive and negative selection, giving 




 single-positive T cells that finally exit the thymus. CXCR4 and CCR5 
molecule expression is also modulated during thymopoiesis, as indicated, with CXCR4 being found 
throughout all thymocyte subsets, and CCR5 being mainly restricted, although at low levels, to mature 
thymic emigrants. Adapted from Fang et al, AIDS 2008. 
 
IL-7 has been identified as essential for human T-cell development, being highly 
produced by thymic epithelial cells [495-498]. The IL-7 receptor (IL-7R) is a 
heterodimer consisting of the IL-7Rα chain (CD127) and the common γ chain (γc, 
CD132), the latter subunit being expressed at all stages of thymocyte maturation, at 
varying levels [499]. Importantly, studies with exogenous IL-7 have shown it to be able 
to promote survival, proliferation and differentiation of developing thymocytes, 
depending on their maturation state [499-501]. 
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Of note, although thymic function has been shown to decline with age, a 
substantial output of naïve CD4+ and CD8+ T cells appears to be maintained into late 
adulthood [502, 503], providing a T-cell pool with a broad TCR repertoire, potentially 
more able to respond to neo-antigens [504, 505]. 
 
“Burning down the nursery”: thymic infection by HIV 
Surface expression of the HIV coreceptors CXCR4 and CCR5 is also modulated 
during thymocyte development. Whilst CXCR4 is expressed throughout all thymocyte 
developmental stages (peaking at the immature CD3CD4+CD8 single positive phase 
and being slightly up-regulated upon leaving the thymus – Figure 12), CCR5 expression 
is mostly restricted to a small proportion of thymocytes, being mainly observed on the 
surface of mature CD4+ and CD8+ single positive cells (and, in contrast to CXCR4, 
undergoing a mild down-regulation just prior exiting the thymus) [506]. Thus, both 
CCR5- and CXCR4-using HIV-1 strains have been reported to infect the thymus, being 
able to enter and complete reverse transcription in most thymocyte subsets [507]. 
Due to CXCR4’s broad expression pattern, CXCR4-using viruses are able to establish 
productive infection in immature, as well as mature thymocytes, contributing to a 
rapid depletion of CD4+ cells located within the cortex (more immature thymocytes) 
and medulla (mostly SP thymocytes) of the infected thymus [506]. Of note, as a 
consequence of the infection of immature thymocytes and subsequent thymocyte 
differentiation, HIV-1-infected CD8+ single positive T cells are also found in the thymic 
tissue [508, 509], and in the peripheral CD8+ T-cell population [510]. 
Importantly, thymocyte infection by HIV-1 has been recently reported to alter IL-
7 responsiveness of thymocytes, independently of CD127 expression, thereby further 
contributing to the disruption of thymopoiesis [511] and the associated thymic 
involution [512-514] observed during HIV disease. 
Of note, altered thymopoiesis during HIV-1 infection may be related, not only to 
thymic infection by the virus, but also to a compromised ingress of competent 
hematopoietic precursors into the thymus [515]. In fact, HIV-1 has been shown to 
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directly or indirectly affect HSC maturation in the bone marrow and, therefore, the 
production of several hematopoietic lineages [516-518]. In agreement, HIV-1-infected 
individuals often present abnormal bone marrow architecture and cellularity [519]. 
 
“After the damage is done…”: thymic output assessment 
Changes in thymic function may be evaluated by several methods [281], 
including thymus size and metabolic labeling assays and, more recently, quantification 
of T-cell receptor excision circles (TREC). 
TREC are episomal DNA circles generated during intrathymic rearrangement of 
T-cell receptor α, β and δ loci that are not replicated upon cell division, existing at high 
levels in recent thymic emigrants (RTE) [502, 520]. Different types of TREC can be 
quantified in peripheral blood, namely: 1) DβJβ (β) TREC, which are created early in 
thymocyte maturation, during the first step of TCRβ locus organization; and 2) signal-
joint (sj) TREC, that constitute the major byproducts of the TCRδ locus excision, and 
are generated at a later stage, after extensive intrathymic proliferation [502, 520]. 
The interpretation of data utilizing only sjTREC quantification has been proven to 
be difficult, with reduced sjTREC levels in the periphery having been suggested to 
simply reflect their dilution resulting from increased proliferation of the naïve T-cell 
pool [521]. Hence, the levels of sjTREC alone may not accurately mirror thymic output, 
since they may reflect, in part, cellular peripheral proliferative history. Conversely, the 
sj/β TREC ratio, which becomes fixed once sjTREC are generated, is not influenced by 
peripheral proliferation, and thus constitutes an indirect estimation of intrathymic 
proliferation and consequently a primary determinant of thymic output [520]. 
Of note, whilst the sj/β TREC ratio in peripheral T cells in HIV-1 infection has 
been shown to be significantly reduced [520], its maintenance in HIV-2 infected 
patients has been reported, suggesting a preservation of efficient thymopoiesis, even 
in older individuals [522]. This, in turn, may contribute to the better preservation of 
peripheral CD4+ T cells and the associated slower disease course. 
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Several attempts have been made to phenotypically identify RTE within 
peripheral T cells. Thus, the use of specific surface markers has been suggested in 
order to differentiate the TREChigh RTE-containing naïve T-cell populations from those 
consisting of TREClow cells that have undergone peripheral expansion. The first such 
marker to be identified was CD31 (platelet endothelial cell adhesion molecule-1, or 
PECAM-1) [523]. Peripheral naïve CD4+ T cells expressing this molecule are highly 
enriched in TREC, containing the true RTE population. On the other hand, CD31 naïve 
CD4+ T cells feature low to undetectable TREC levels [523]. More recently, protein 
tyrosine kinase 7 (PTK7) has been described as a marker of RTE [524], with PTK7+ naïve 
CD4+ T cells being uniformly CD31+, containing higher levels of sjTREC, in comparison 
with their PTK7 counterparts (both CD31+ and CD31), and rapidly decreasing after 
complete thymectomy. 
Importantly, whilst memory CD4+ T cells represent the primary target for 
infection by HIV in peripheral blood, naïve CD4+ T cells also appear to significantly 
contribute to the infected T-cell population, with both RTE and non-RTE naïve CD4+ T 
cells (defined based on the levels of CD31 expression) having been recently reported 
to be infected by HIV-1 in vivo [525]. Of note, no correlations were observed between 
the levels of RTE infection and intra-thymic precursor T-cell proliferation, suggesting 
that HIV-1 infection of immature thymocytes at early developmental stages makes a 
limited contribution to the circulating pool of infected naïve CD4+ T cells [525]. 
 
“Under the influence”: the impact of thymic function impairment on 
immune reconstitution during ART 
Thymopoiesis is likely to contribute to CD4+ T-cell reconstitution upon ART in 
HIV-1 infected patients [526-529]. In agreement, the baseline level of thymic function 
at the time of ART initiation has been positively correlated with evidence for thymic-
dependent reconstitution capacity following ART [530, 531]. 
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Of note, an important role for decreased thymic function in immune 
reconstitution has been suggested in HIV-1+ ART-discordant individuals [529, 532], an 
observation supported by evidence indicating that the incidence of immunologic 
discordance increases with age [529, 533]. As previously mentioned, whilst most HIV-
1+ individuals achieve measurable thymic-dependent T-cell replenishment in response 
to ART [526-528], around 20% feature only limited CD4+ T-cell recovery despite being 
able to achieve complete viral suppression [534].  
 
3.2. Homeostasis of the peripheral CD4+ T-cell pool – the 
fundamental role of IL-7 
Following thymic export, RTE are incorporated into the peripheral naïve T-cell 
pool, thereby contributing to its preservation and maintenance of a diverse T-cell 
repertoire [535-537]. The mechanisms underlying this incorporation remain 
controversial [537-540], with some authors suggesting RTE to be preferentially 
incorporated only in the context of a depleted T-cell compartment [541]. Of note, 
subsequent cycling of RTE, ultimately leading to efficient post-thymic T-cell 
differentiation, has been shown to be highly correlated with IL-7 responsiveness [542-
544]. 
 
“A helping hand”: the IL-7/IL-7R axis in peripheral T-cell homeostasis 
Besides playing an important role during thymopoiesis, IL-7 has also been 
described as a critical modulator of survival and homeostatic proliferation of both 
naïve and memory T cells [545]. 
In the periphery, IL-7 is mainly produced in the T-cell areas of secondary 
lymphoid organs (SLO) by fibroblastic reticular cells (FRC) [546]. IL-7 is constitutively 
produced, with T-cell responses to IL-7 being tightly regulated through the modulation 
of the IL-7Rα chain (CD127) [545]. 
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CD127 is expressed on naïve T cells (Figure 13) [547] and its expression is 
down-regulated upon strong TCR activation, being lost on effector memory T cells and 
senescent memory populations, but re-expressed on the resting memory T-cell pool 
[547]. Furthermore, T cells have been shown to down-regulate CD127 after contact 
with IL-7 and, reciprocally, to up-regulate CD127 in the absence of the cytokine, a 
process involving new protein synthesis [548]. Such feedback control of CD127 
expression directly contributes to the size of the peripheral T-cell pool: whilst most 
resting cells express CD127, which allows them to receive basal IL-7 signals for survival 
and proliferation, activation or IL-7 signaling leads to CD127 down-regulation, thereby 
preventing excessive expansion. Furthermore, IL-7-mediated CD127 down-regulation 
on mature T cells may serve to maximize the number of T cells that can respond to the 
limiting amounts of IL-7 available when normal T-cell numbers are present. 
 
Figure 13. IL-7 receptor subunit expression during T-cell development. CD132 (γc receptor) expression 
is relatively constant, with the regulation of CD127 (IL-7Rα) expression largely dictating the availability 
of the IL-7 receptor. Adapted from Capitini et al, Journal of Internal Medicine 2009.  
 
IL-7 signaling mediates T-cell survival and maintenance in several ways: via up-
regulation of anti-apoptotic factors, such as Bcl-2 and Mcl-1 [549], which mediate the 
inhibition of pro-apoptotic molecules, such as Bax or Bim [550, 551]; maintaining 
longer telomeres by inducing telomerase activity [552]; and promoting cell 
proliferation, growth and metabolic activity by direct interaction with the PI3K 
pathway [553, 554]. 
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“Getting a life after the thymus”: naïve CD4+ T cells and IL-7 
Once RTE are integrated into the naïve peripheral pool of a T-cell-replete host, 
they usually enter a resting state with no, or very slow, proliferation, being able to 
remain at interphase for many weeks or months [555]. Naïve cells require low-affinity 
self-peptide:MHC signals, as well as IL-7, for survival and persistence in vivo, signals 
most likely available within the lymphoid tissue [496, 556]. Importantly, increasing 
evidence suggest that the maintenance of naïve T-cell quiescence is actively 
maintained through the interplay of various negative regulatory mechanisms aimed at 
preventing cell activation and cycling [557]. The repression of NF-κB seems to be 
particularly important in this context, involving continuous synthesis of the NF-κB 
inhibitor IκB, mediated by members of the forkhead transcription factor family, whose 
expression is high in naïve T cells [558, 559]. Recently, Foxp1 has been shown to be 
critical for maintaining naïve T-cell quiescence, via the negative regulation of CD127 
expression and signaling [560]. Furthermore, Tsc1-mediated suppression of mTOR, a 
central regulator of glycolysis and cellular metabolism, has also been shown to be 
crucial in actively sustaining the quiescence of naïve T cells [561]. Of note, unique 
patterns of chromatin condensation may also play a part in the preservation of the 
quiescent state, limiting the access of factors that are essential for peripheral T-cell 
proliferation to DNA, a feature that is only overcome upon TCR activation [562]. 
 Despite the pronounced reduction in thymic function observed during ageing, 
a significant proportion of naïve CD4+ T cells are maintained in the elderly [563, 564]. 
This has been suggested to be related with homeostatic peripheral proliferation [538, 
565], a process whereby naïve CD4+ T cells expand post-thymically, whilst retaining 
their naïve phenotype and functional characteristics. Hence, the appropriate 
homeostatic cues are likely to induce an attenuation of the negative regulatory 
pathways that maintain naïve T cells in a non-proliferative state, without resulting in 
“full” activation and consequent high level proliferation/differentiation. 
This scenario implies the existence of, at least, two distinct subsets of human 
naïve peripheral CD4+ T cells differing in their proliferative history [565]: one subset 
highly enriched in RTE, and a second subset comprising naïve CD4+ T cells that have 
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undergone low-affinity self-peptide:MHC-dependent peripheral proliferation. As the 
high TREC level content of CD31+ naïve CD4+ T cells has been observed to be only 
slightly reduced in comparison with that of thymocytes, this subset is thought to be 
the one containing RTE [523]. On the other hand, the significantly reduced TREC 
content observed in CD31 naïve CD4+ T cells, strongly suggests their more extensive 
peripheral proliferation [565]. In agreement, in healthy adults, CD31+ naïve CD4+ T 
cells have been shown to display a polyclonal TCR repertoire, whereas CD31 naïve 
CD4+ T cells are characterized by a more restricted TCR repertoire [566]. Moreover, 
the progressive age-associated decline in naïve CD4+ T cells has been reported to be 
mainly due to a reduction in the CD31+ naïve subset, whilst the CD31 subset persists, 
further supporting the involvement of thymic output in the maintenance of CD31+ 






Figure 14. Post-thymic proliferation of human naïve CD4
+
 T cells. After leaving the thymus, RTE are 











 T-cell subset. Upon cognate interaction with foreign antigens, both naïve subsets can then 
differentiate into memory/effector CD4
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 T-cell preservation mainly relies on low-affinity self-
peptide:MHC-TCR signaling. 
 
Importantly, IL-7 has been recently described to preferentially expand the 
CD31+ subset of adult naïve CD4+ T cells, without loss of CD31 expression, in a TCR-
independent way, whilst promoting the preservation of CD31 on non-proliferating 
cells [568]. This indicates that, in adulthood, IL-7 may play a preferential role in the 
maintenance of CD31+ naïve CD4+ T cells, a population that is known to include RTE 
and, in this way, contribute to  the preservation of TCR repertoire diversity within the 
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naïve CD4+ T-cell pool (Figure 14). Furthermore, apart from having been shown to be 
sufficient to induce widespread cycling of naïve T-cell populations, IL-7 also appears to 
contribute to the trafficking of RTE to lymph nodes [569], where they have optimal 
access to IL-7. Besides inducing TCR-independent homeostatic proliferation of CD31+ 
naïve CD4+ T cells [568], IL-7 may also favour low-affinity self-peptide:MHC-mediated 
cell cycling [545]. 
 
“Life goes on”: memory CD4+ T cells and IL-7 
Activation by foreign antigens induces CD4+ naïve T cells to undergo massive 
expansion for several days, with the concomitant acquisition of the appropriate 
effector functions [570]. Most effector cells die shortly afterwards, but a small fraction 
of them survive almost indefinitely as memory CD4+ T cells [571]. 
Although regulation of the overall pool size, under T-cell-replete conditions, 
applies to both naïve and memory CD4+ T cells, distinct mechanisms appear to control 
homeostasis of the two cell types. Hence, in contrast to what has been suggested for 
naïve CD4+ T cells, maintenance of memory CD4+ T cells seems largely independent of 
MHC-mediated signaling [496], and it appears to mainly rely on a combination of IL-7 
and IL-15, both for survival and intermittent homeostatic proliferation [572-574]. 
Foreign antigens have been suggested to play an indirect role, for example, through 
activation of the innate immune system, thereby leading to production of the key 
homeostatic cytokines required by memory CD4+ T cells [571]. 
 
“The circle of life”: apoptotic cell death and IL-7 
As T-cell homeostasis implies the maintenance of a constant number of cells, it 
is essential that thymic output and peripheral T-cell expansion are balanced by 
lymphocyte death. Hence, under such conditions where cytokines promote the 
proliferation of specific T-cell subsets, others must die. 
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In this respect, IL-7 has been shown to induce Fas (CD95) expression on naïve 
CD4+ T cells, rendering them highly susceptible to Fas-induced cell death, a process 
enhanced by the presence of IL-2 [575]. Of note, this susceptibility to apoptosis was 
not correlated with proliferation per se but, rather, with the maturation state of the 
cell, with RTE dying at the highest levels [575]. As RTE are, as previously mentioned, 
included in the CD4+ naïve T-cell subset that is preferentially expanded by IL-7, 
increased susceptibility to Fas-induced cell death appears to constitute an important 
mechanism for the control of IL-7-mediated naïve CD4+ T-cell proliferation [576]. 
 
“Trying to avert a major crisis”: IL-7 signaling-mediated homeostasis in the 
context of HIV-related lymphopenia 
Under normal circumstances, physiological use of IL-7 leads to stable levels of 
the cytokine. However, in lymphopenic states such as chronic HIV infection, circulating 
IL-7 levels rise, mainly due to a diminished consumption associated with reduced cell 
targets [577]. Accordingly, circulating IL-7 levels have been reported to be increased 
during HIV-associated lymphopenia, in direct association with CD4+ T-cell depletion 
[578, 579] and reduced CD127 expression on T cells [580-582]. Importantly, in 
comparison with HIV-1-infected counterparts, HIV-2-infected patients have been 
shown to feature a delayed increase in IL-7 levels during disease progression, as well 
as a better preservation of CD127 expression, particularly in the naïve CD4+ T-cell 
pool, suggesting a maximization of available resources in the context of this disease 
[583]. 
When in excess, IL-7 may be able to induce extensive naïve CD4+ T-cell 
expansion to self-antigens by amplifying the weak TCR signaling resulting from contact 
with self-peptide:MHC ligands, a feature that may promote autoimmunity [565, 584]. 
Additionally, IL-7 has been shown to induce naïve CD4+ T-cell TCR signaling-
independent proliferation [568]. Moreover, a component of the homeostatic response 
may also rely on induction by foreign antigens, particularly in the context of chronic 
HIV infection. Hence, the resulting overall enhancement in cellular proliferation may 
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also render T-cell-depleted patients at a greater risk of lymphoproliferative disorders 
or lymphoma [585]. 
 
“Pulling the plug”: disruption of secondary lymphoid tissues during HIV 
infection 
As ongoing viral replication occurs and chronic immune activation increases, 
pathological changes are induced in lymph node architecture in HIV-1-infected 
individuals [135]. Indeed, as disease progresses, lymph node structure effacement 
occurs and CD4+ T-cell population becomes depleted [586, 587]. Importantly, 
preservation of this niche is essential to ensure proper function of the homeostatic 
mechanisms maintaining the naïve CD4+ T-cell pool, as well as the productive 
interactions between T cells and APC that are involved in generating and maintaining 
memory CD4+ T cells. Thus, over time, damage by the virus to the supply routes and 
anatomical niches that maintain the resting CD4+ T-cell compartments act together 
with the homeostatic strains imposed by chronic immune activation to further 
exacerbate the progressive loss in CD4+ T-cell numbers. 
Recently, a model has been proposed in which collagen deposition and loss of 
the FRC network impede access to, and destroy the source of, IL-7 during HIV-1 
infection [283, 361]. As previously mentioned, naïve T cells depend on IL-7, produced 
by the FRC network, for survival. As HIV-1 infection progresses, chronic immune 
activation elicits a TGF-β-mediated Treg counter-response, and consequently, 
increased collagen production and deposition [360]. This sets in motion cooperative 
and cumulative mechanisms that contribute to progressive T-cell depletion [283, 361]: 
collagen deposition disrupts T-cell access to IL-7 provided on the FRC network, leading 
to increased apoptosis of T cells, particularly naïve CD4+ T cells; whilst, in turn, the 
decreased availability of T-cell-derived lymphotoxin-β (LT-β), on which FRC cells 
depend, further contributes to FRC network impairment. As a consequence, naïve 
CD4+ T cells are diminished in proportion to lymphoid tissue structure destruction, 
from early stages of HIV-1 infection. Because of the progressive and cumulative nature 
58 HIV-2 immunopathology: 
how the immune system deals with long-lasting infection 
 
of this pathological process, apoptosis of naïve CD4+ T cells continues at elevated 
levels after ART initiation, with damage to lymphoid tissue architecture being 
predictive of the degree of immune reconstitution achieved upon antiretroviral 
treatment [283, 588]. 
 
3.3. Immune senescence 
A general deterioration of the immune system occurs over time, possibly as a 
consequence of lifelong exposure to pathogens, leading to immune senescence. This 
may be, in part, responsible for the increased incidence and/or rapid progression of 
many infectious diseases that are observed during ageing [589].  
One of the characteristic features of immune senescence is the erosion of the 
T-cell compartment due to the combination of age-associated thymic involution and 
replicative senescence, a phenomenon describing the irreversible state of growth 
arrest that occurs following multiple rounds of cell division [590]. This so-called  
“Hayflick limit” [591] has been described extensively for both CD4+ and CD8+ T 
lymphocytes [592], with memory T cells presenting a significantly reduced replicative 
potential as compared to naïve T cells from the same individual [593, 594]. 
 
“Holding back the years”: telomeres and telomerase 
Telomere length constitutes a commonly used marker of replicative history. 
Localized at the end of linear chromosomes, telomeres consist of short, tandem 5’-
TTAGGG-3’ repeats, associated with specific proteins [595]. Telomere functions 
include the stabilization and protection of chromosomal ends from events such as 
degradation, illegitimate recombination and fusion with other telomeres or DNA ends; 
determination of chromosomal localization within the nucleus; and overall regulation 
of cellular replicative capacity [596]. In the absence of telomerase (see below), 
telomeres shorten by, approximately, 100 base-pairs per cell population doubling, 
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resulting in chromosome instability and, eventually, growth arrest and/or apoptosis 
[597]. A size of 5-7 kb is considered indicative of replicative senescence [597]. Hence, 
telomere length, not only provides a tool for the analysis of the replicative history, but 
is also predictive of the remaining proliferative potential of the cells. 
Telomerase is a ribonucleoprotein enzyme that synthesizes telomeric repeats 
using its own telomere sequence-specific RNA template, and thus helps prevent 
excessive telomere erosion during successive cell divisions [596]. Telomerase consists 
of two core components: a catalytic subunit (telomerase reverse transcriptase, TERT) 
and a telomerase RNA component (TERC) [598]. Although TERC is ubiquitously 
expressed, the expression of TERT is tightly regulated and is considered a limiting 
factor for telomerase function [599]. Most normal somatic cells do not express 
telomerase, which is only active in germ cells, during embryogenesis, in adult stem 
cells and in activated immune cells [600]. In T cells, although little or no telomerase 
activity is detected in the resting state, high levels are induced upon stimulation via 
TCR cross-linking or cytokines, including IL-7 [552, 601-603]. Of note, while telomerase 
activity may compensate for telomere loss, its induction in activated T cells is only 
transient [604], and lost upon repeated stimulation [605, 606]. This ultimately leads to 
telomere erosion and replicative senescence, with the concomitant and progressive 
accumulation of terminally differentiated T cells with short telomeres. 
Importantly, although loss of cell proliferation is a characteristic feature of 
replicative senescence, T cells in this state are still able to maintain some normal 
functions [592]. Hence, while senescent CD8+ T lymphocytes have been shown to 
retain normal antigen-specific cytotoxicity, senescent CD4+ T cells are able to secrete 
some cytokines after TCR stimulation, in an antigen-specific fashion [607]. 
Furthermore, evidence has also arisen for the acquisition of additional functions, 
including MHC-unrestricted cytotoxicity (natural killing) and suppressive effects on 
other T cells [608]. Thus, replicative senescence does not constitute a general 
breakdown of normal function but, rather, may comprise selected genetic and 
phenotypic alterations, resulting not only in loss, but also in gain of some functions 
[592]. 
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“Getting prematurely old”: replicative senescence and HIV/AIDS 
Several immunological alterations that characterize HIV infection, which is 
associated with increased cell proliferation, are remarkably similar to those naturally 
accumulated over time in HIV-uninfected elderly individuals [609, 610]. In agreement, 
telomere length of total peripheral blood mononuclear cells (PBMC) from HIV-1-
infected individuals has been observed to shorten at an increased rate in comparison 
with age-matched seronegative controls [611]. Furthermore, this accelerated 
telomere reduction was found to correlate with HIV/AIDS disease progression, 
supporting an association between an increased ageing of the peripheral immune 
system and T-cell loss, that ultimately leads to AIDS [611]. 
Importantly, although telomere shortening during HIV-1 disease has been 
consistently observed within the CD8+ T-cell subset [612-614], data on CD4+ T cells 
remain controversial, with increased, decreased and stable telomere length having 
been reported for this particular subset [615-617]. These findings support different 
telomere length dynamics in the two T-cell subsets [618], with CD4+ T-cell telomere 
shortening possibly occurring only at later disease stages [615, 619]. 
There are several possible explanations for the differences observed in 
telomere length between CD4+ and CD8+ T cells during the course of HIV-1 disease 
[620]. HIV-infected CD4+ T cells may undergo only few divisions before dying, thereby 
limiting the time frame during which telomere shortening can occur. Moreover, when 
activated CD4+ T cells are replaced by thymus-derived naïve cells, the longer 
telomeres of the naïve population may obscure any shortening that might have 
occurred in the memory CD4+ T-cell subset. Another possible explanation concerns the 
potential involvement of telomerase in the different telomere length dynamics of 
CD4+ and CD8+ T cells. In vitro experiments have failed to show any differences in 
baseline or inducible telomerase activity between CD4+ and CD8+ T cells in HIV-
infected individuals [614, 617, 621]. These data, obtained from HIV-infected 
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individuals in the chronic phase of the disease, do not preclude, however, a possible in 
vivo involvement of telomerase at an earlier point in the disease process. 
 
The advances in the understanding of HIV/AIDS immunopathogenesis made 
over the last 30 years have been extremely important. Nevertheless, further 
elucidation of the mechanisms underlying chronic immune activation and impairment 
of CD4+ T-cell replenishment during HIV infection is essential to achieve a “functional 
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This work investigated the responses mounted by the immune system in order 
to cope with the challenges imposed by chronic HIV disease, using HIV-2 infection as a 
strategy to study HIV/AIDS-related immunopathogenesis. As a naturally-occurring 
form of attenuated HIV disease, HIV-2 infection provides an important model that can 
facilitate the identification of factors related to a more efficient immune response, 
and better disease prognosis, potentially providing a rationale for novel therapeutic 
interventions. 
 
Although a hyper-activated immune system has long been recognized as a 
hallmark of HIV infection, closely linked to the continuous CD4+ T-cell depletion that 
characterizes HIV/AIDS, the mechanisms underlying progressive immune activation 
remain poorly understood. 
Of note, in spite of the approximate two-log difference in plasma viral load, 
HIV-1- and HIV-2-infected individuals with the same degree of CD4+ T-cell depletion 
feature comparable levels of immune activation. Nevertheless, rates of disease 
progression are clearly distinct, with HIV-2 infection having a limited impact on the 
mortality of infected adults. 
 
Innate immunity plays an important role in acute HIV infection, helping limit 
viral replication, whilst promoting the development of adaptive immune responses. 
During the course of chronic HIV disease, innate immune cells may act as modulators 
of overall immune activation. Thus, we hypothesized that the distinct course of HIV-1 
and HIV-2 infections may be related to the quality of the induced innate immune 
responses. Furthermore, it is likely that differences in the ability to replenish the CD4+ 
T-cell compartment also contribute to the distinct rate of disease progression that is 
observed in the two infections. 
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Therefore, this work aimed to address the following specific questions in 
HIV/AIDS pathogenesis: 
 
Specific Aim 1. Is the relatively “benign” course of HIV-2 infection associated 
with distinct monocyte and mDC imbalances? Do these relate to a putative increase in 
the translocation of microbial products, such as LPS, as described for HIV-1 infection?  
These results are described in Chapter 3.1. 
 
Specific Aim 2. Progressive CD4+ T-cell depletion is linked to immune activation 
in both HIV-2 and HIV-1 infections. Nevertheless, the rate of decline is much slower in 
HIV-2 disease. Is this associated with an up-regulation of inhibitory molecules that 
may limit HIV-associated immune activation and immunopathology?  
Results regarding the PD-1/PD-L1 pathway in monocytes and mDC are 
described in Chapter 3.1., whereas those related to T cells are in Chapter 3.2. 
 
Specific Aim 3. Replenishment of the CD4+ T-cell pool is critically dependent on 
the homeostasis of the naïve compartment. We addressed two main questions in this 
context: 
a) Does the homeostatic response of naïve CD4+ T cells during 
prolonged HIV-2 disease impact on telomere length? (Chapter 3.3.) 
b) Is the response of naïve CD4+ T cells to IL-7 stimulation preserved in 
HIV-2-infected individuals? (Chapter 3.4.) 
 
Specific Aim 4. HIV-1-associated immunodeficiency also features significant 
disturbances of the B-cell compartment. Is the better outcome of HIV-2 infection 
linked to a preservation of memory B cells?  
Results concerning this subject are described in Chapter 3.5. 
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3.1.  Activation of blood monocytes and myeloid dendritic cells 
is a hallmark of HIV-2 infection 
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HIV-2 represents a naturally-occurring form of attenuated HIV/AIDS, associated 
with low to undetectable plasma viral load throughout the course of disease, and a 
much slower rate of CD4+ T-cell decline than HIV-1 infection. In spite of the high 
degree of structural homology between the two viruses, HIV-2 uniquely expresses 
Vpx, which was recently shown to overcome host restriction of HIV-1 replication in 
monocyte and myeloid dendritic cells (mDC). We investigated here, for the first time, 
monocyte and circulating mDC imbalances in HIV-2+ patients.   
We found a significant expansion of CD14brightCD16+ monocytes, accompanied 
by up-regulation of HLA-DR expression and increased serum levels of soluble CD14 in 
HIV-2+ patients. In contrast to untreated HIV-1+ individuals, these alterations also 
occurred in early stage HIV-2 infection, before significant CD4+ T-cell loss, and 
appeared to be unrelated to an increase in plasma LPS levels. Importantly, monocytes 
from HIV-2+ patients featured a marked up-regulation of the inhibitory molecules PD-
L1/PD-1, which may contribute to the lack of significant increase of serum levels of 
pro-inflammatory cytokines and chemokines, typically produced by activated 
monocytes. Moreover, monocyte disturbances did not seem to translate into major 
mDC alterations in early stage HIV-2 infection. Nevertheless, HIV-2 disease 
progression, like untreated HIV-1 infection, led to mDC loss and acquisition of a more 
differentiated mDC phenotype.  
In conclusion, our data provide evidence of a heightened state of monocyte 
activation during HIV-2 infection, which is accompanied by marked up-regulation of 
the inhibitory molecules PD-L1/PD-1, possibly contributing to the relatively “benign” 
course of HIV-2 disease. These results challenge the current paradigm regarding the 
role of monocytes in HIV/AIDS, and in inflammatory processes in general, and offer 
the chance to identify novel therapeutic targets. 
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HIV infection leads to a state of heightened immune activation that is 
considered a main determinant of the progressive immunodeficiency [1].  
Monocytes/macrophages and myeloid dendritic cells (mDC) are key producers 
of pro-inflammatory cytokines and chemokines, thereby directing activation and 
differentiation of adaptive immune responses, and recruiting T cells to sites of viral 
replication [2]. Recent data have highlighted the high degree of monocyte subset 
heterogeneity, each subset having particular phenotypic and functional properties, 
possibly generating distinct tissue macrophages [3-6]. In this respect, HIV-1 infection 
has been consistently associated with an expansion of CD16+ monocytes, expressing 
variable levels of CD14 [7-10], which have been reported to be highly susceptible to 
infection and preferentially harbour the virus for long-term [11, 12]. Additionally, 
recent studies have confirmed that monocytes are able to differentiate into mDC at 
inflammatory sites [13], in agreement with previous in vitro data [14, 15]. These 
professional antigen-presenting cells (APC) have been shown to be depleted and 
functionally impaired in HIV-1 infection, particularly in its advanced stages and in 
individuals with high viremia [16, 17]. The mechanisms underlying monocyte and mDC 
disturbances during HIV-1 infection are not fully identified and are likely to be 
multifactorial [18].  
These cells are particularly sensitive to stimulation by bacterial products 
through Toll-like receptor (TLR)-engagement [19, 20]. Chronically infected HIV-1+ 
individuals and simian immunodeficiency virus (SIV)+ rhesus macaques were reported 
to feature increased levels of circulating bacterial products, particularly 
lipopolysaccharide (LPS) [21, 22], a component of Gram-negative bacteria cell-walls 
that binds TLR4 [23]. This has been suggested to be related to a high level of gut 
microbial translocation resulting from the disruption of mucosal immunity associated 
with HIV-1 and SIV infections [24]. Although this has been highlighted  as a main 
determinant of  the hyper-immune activation that characterizes HIV disease [21], the 
relevance of microbial translocation in HIV/AIDS remains controversial, as some 
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African cohort studies featured no associations between circulating LPS and HIV 
disease progression [25, 26]. 
Both monocytes and mDC are targets for HIV infection as they express CD4, in 
addition to the two main HIV coreceptors, CCR5 and CXCR4 [27]. Nevertheless, these 
cells are unable to support productive HIV-1 infection, either in vivo or in vitro [28, 
29]. Several mechanisms are likely to underlie the myeloid cell restriction of HIV-1 
replication [30]. In this regard, intracellular host restriction factors have been 
intensively investigated [31, 32], particularly apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide like (APOBEC) [33] and SAM domain HD domain-containing 
protein 1 (SAMHD1) [34, 35]. Of note, Vpx, a viral protein uniquely encoded by HIV-2 
and a group of SIV strains [36], is able to overcome SAMHD1-mediated lentiviral 
blockade by inducing its proteasomal degradation [35, 37]. 
HIV-2 infection is a naturally-occurring form of attenuated HIV disease, 
characterized by a slow rate of CD4+ T-cell decline, undetectable to low levels of 
circulating virus and limited impact on the mortality of infected individuals [38]. This is 
despite similar levels of proviral DNA in HIV-2+ and HIV-1+ individuals, indicating a 
comparable number of infected cells and an equal ability of the two viruses to 
disseminate and establish viral reservoirs [39, 40]. The much lower levels of plasma 
viral load in HIV-2 than in HIV-1 infection is thought to account for the lower rates of 
horizontal and vertical transmission and the confinement of HIV-2 infection to West 
Africa, and related countries such as Portugal [41].  
The reasons for the apparently better prognosis associated with HIV-2 
infection remain elusive [42]. We have shown that chronic immune activation is a 
major driving force for CD4+ T-cell depletion, in HIV-2 infection [43], as reported for 
HIV-1 [1]. Nevertheless, it is important to emphasize that the rate of progression of 
immune activation and the linked CD4+ T-cell decline is much slower in HIV-2 than in 
HIV-1 disease [44].  
There are very few data regarding mDC and monocytes in the context of HIV-2 
infection. Duvall et al reported that mDC were less susceptible in vitro to HIV-2 than to 
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HIV-1 infection [45]. Moreover, although HIV-1 envelope proteins per se have been 
shown to induce mDC disturbances [46], we showed that the HIV-2 envelope protein 
did not alter the capacity of monocytes to differentiate into DC and the subsequent 
DC maturation [47]. This is despite our previous data showing that the HIV-2 envelope 
protein is able to induce TNF- production by monocytes [48, 49] and to suppress T-
cell proliferation through a monocyte-mediated mechanism [49]. 
Here, we provide the first comprehensive study of monocytes and mDC in 
untreated HIV-2+ and HIV-1+ individuals. Our data provide evidence of a heightened 
state of monocyte activation throughout the course of HIV-2 infection, which is 
accompanied by an up-regulation of the inhibitory molecules PD-L1/PD-1, possibly 




The clinical and epidemiological characterization of the studied cohorts is 
shown in Table 1. All HIV-2+ (n=29) and HIV-1+ (n=22) individuals were antiretroviral 
therapy naïve, and had no ongoing opportunistic infections or tumours. The HIV 
cohorts were selected from patients under follow-up at the Hospital de Santa Maria, 
Lisbon, Portugal, in order to include individuals with comparable degrees of CD4+ T-
cell depletion (Table 1), although HIV-2+ were expected to be infected for significantly 
longer than HIV-1+ individuals [44]. In line with the comparable degree of CD4+ T-cell 
depletion, both cohorts exhibited a similar up-regulation of activation markers within 
CD4+ and CD8+ T cells, as previously reported [43]. Importantly, 21 out of the 29 HIV-2-
infected patients had undetectable viremia, and the highest level documented (26,263 
RNA copies/ml) was significantly lower than the levels observed in HIV-1+ individuals 
(Table 1), as expected. Nevertheless, comparable levels of proviral DNA in PBMC were 
found (Table 1), in agreement with previous reports [39, 40]. Of note, the HIV-1 cohort 
included 4 individuals with undetectable viremia, formally defined as elite controllers, 
which usually represent less than 0.01% of the HIV-1+ individuals [50]. All individuals 
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gave written informed consent for blood sample collection and processing. The study 
was approved by the Ethical Board of the Faculty of Medicine, University of Lisbon. 
 
Table 1. Clinical and epidemiological dataa. 
 Seronegative HIV-1 HIV-2 
Numbers 
(male/female) 
17 (6/11) 22 (17/5) 29 (9/20) 
Age (years) 43±2 (27-57) 39±2 (23-61)# 48±3 (19-78) 
Ethnicity 
(caucasian/other) 
15/2 16/6 15/14 
% CD4+ T cells 44.9±2.0 (34.4-61.1) 22.8±3.3 (1.3-47.2)*** 28.3±2.6 (7.1-54.1)*** 


































NA 172±55 (5-975) 176±66 (5-1033) 
a





4 of 22 HIV-1+ patients and 21 out of 29 HIV-2+ patients had undetectable viremia. In these cases, 
the cut-off value of the test (40 and 200 RNA copies/ml for HIV-1 and HIV-2, respectively) was used 
to calculate the mean. 
#







comparing infected cohorts with seronegative individuals. 
 
Cell isolation and cell culture 
PBMC were isolated from heparinised blood, immediately after venopuncture, 
by Ficoll-Hypaque density gradient centrifugation (Sigma, St. Louis, MO, USA). 
Monocytes were purified using magnetic beads (StemCell Technologies, France), with 
<2% T-cell contamination, as assessed by flow cytometry. In vitro responses to LPS 
were evaluated in total PBMC cultures, set at 2x106 cells/ml in 24-well plates, in 
RPMI1640 (Gibco-Invitrogen, Paisley, U.K.) supplemented with 10% human AB serum 
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(Sigma-Aldrich, St Louis, MO, USA), 100 U/ml penicillin/100 g/ml streptomycin 
(Gibco-Invitrogen) and 2 mM glutamine (Gibco-Invitrogen) in either the absence or 
presence of LPS (100 ng/ml; Sigma-Aldrich). After 22 hours of culture at 37 ºC and 5% 
CO2, supernatant was harvested and stored at -80 ºC until subsequent 
cytokine/chemokine quantitation.  
 
Flow cytometry 
PBMC were surface stained as previously described [51] with the following 
anti-human mAbs (clone specified in brackets): FITC-conjugated HLA-DR (L243, BD 
Biosciences), CD16 (NKP15, BD Biosciences), CD20 (2H7, eBioscience), CD3 (CLB-T3/2) 
and CD14 (CLB-mon/1), both from Sanquin; PE-conjugated CD38  (HIT2, eBioscience), 
CD80 (L307.4, BD Biosciences), CD40 (5C3) and PD-L2 (MIH18), both from eBioscience; 
PerCP-conjugated CD4 (SK3, BD Biosciences), HLA-DR (L243, BD Biosciences); PE-Cy7-
conjugated CD123 (6H6 , eBioscience) and CD14 (61D3, eBioscience); APC-conjugated 
CD8 (RPA-T8, eBioscience), CD11c (B-ly6) and CD86 (FUN-1) from BD Biosciences and 
PD-L1 (MIH1, eBioscience). At least 400,000 events were acquired in a large gate 
including lymphocytes (lymphogate) and monocytes (monogate), defined according to 
forward/side scatter characteristics. Within this gate, mDC were defined as lineage 
negative (lin; including FITC-conjugated mAbs against CD16, CD14, CD3, and CD20), 
HLA-DR+CD123-CD11c+. Gated mDC were further analysed for the expression of PD-L1, 
PD-L2 and the co-stimulatory molecules CD40, CD80 and CD86. Monocytes were 
analysed within a monogate and further gated using CD14 and CD16 expression into 
four distinct subsets: CD14dimCD16, CD14brightCD16, CD14brightCD16+ and 
CD14dimCD16+. HLA-DR and PD-L1 expression was assessed using mean fluorescence 
intensity (MFI) within each subset. Lymphocytes were analysed within a lymphogate. 
Cells were acquired using a CANTO flow cytometer (BD Biosciences) and analysis was 
performed with FlowJo software (version 8.5.3, Tree Star, Inc., Ashland, OR). Absolute 
cell numbers in the blood were calculated by multiplying their representation by the 
absolute lymphocyte and/or monocyte counts obtained at the clinical laboratory. 
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 Cytokines, chemokines, sCD14, and LBP and plasma LPS quantification 
Human Cytokine LINCOplex (Millipore Corporation, Billerica, MA, USA) and the 
Luminex LX100 (Luminex Corporation, Austin, TX, USA) were used to quantify the 
following cytokines and chemokines according to manufacturer’s instructions: IL-10, 
IL-12 p40, MIP-1β and TNF-α in culture supernatants collected as described above; 
and  IL-10, IL-6, TNF-α, MCP-1 and MIP-1β levels in serum, obtained on centrifugation 
of freshly drawn blood and stored at -80ºC until use. ELISA tests were used to quantify 
serum levels of sCD14 (R&D systems, Minneapolis, MN, USA) and LBP (Hycult 
Biotechnologies, Uden, The Netherlands).  Plasma LPS levels were quantified using the 
Limulus Amebocyte Assay (Cambrex, Walkersville, MD, USA) according to the 
manufacturer’s instructions. Plasma samples were diluted and pre-treated as 
previously described [21].  All samples were assayed in duplicate. 
 
Plasma viral load and proviral DNA assessment 
HIV-1 viremia was quantified by RT-PCR (detection threshold of 40 HIV-1 RNA 
copies/ml, Roche, Basel, Switzerland). HIV-2 viremia was assessed using an RT-PCR-
based assay [52] with a detection limit of 200 HIV-2 RNA copies/ml. The cut-off values 
of the tests were considered for statistical analysis in cases where detection was 
below these levels. 
HIV-1 and HIV-2 total viral DNA (integrated and nonintegrated viral DNA 
species) were quantified using real-time PCR assays that amplify highly conserved 
regions in HIV-1 and HIV-2 gag with a detection range of 7 orders of magnitude and a 
sensitivity of 5 copies, as we have previously described [40]. 
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Statistical analysis was conducted with Mann-Whitney tests and Spearman’s 
correlations using GraphPad Prism version 5.00 for Windows (GraphPad Software, San 
Diego, California, USA). 
Results were expressed as median and range, or mean±SEM, as indicated, and 
P values <0.05 were considered significant. 
 
Results 
HIV-2 infection is associated with marked monocyte activation and PD-L1 up-
regulation 
Monocyte imbalances were investigated in untreated HIV-2+ individuals (Table 
1), who had low to undetectable plasma viral load, as expected [40], and were likely to 
have been infected for a long period given the very slow rate of CD4+ T-cell decline 
that characterizes HIV-2 infection [44].  
Numbers of circulating monocytes were similar in the untreated HIV-2 and HIV-
1 cohorts, as compared to age-matched seronegative subjects (485±177, 485±133, 
and 496±251 cells/µl for HIV-2, HIV-1 and seronegative cohorts, respectively).  
Monocytes were sub-divided into four subsets, defined according to the levels 
of CD14 and CD16 expression [6], as illustrated in Figure 1A: CD14brightCD16, 
CD14brightCD16+, CD14dimCD16+ and CD14dimCD16.  
We found that the HIV-2 cohort featured a significant expansion of 
CD14brightCD16+ monocytes as compared to seronegatives (Figure 1A), that directly 
correlated with T-cell activation (Supplemental Figure 1A). This subset expressed the 
highest levels of HLA-DR, suggesting an activated phenotype [7] (Figure 1B). Notably, 
in comparison with seronegatives, the HIV-2 cohort showed a significant up-regulation 
of HLA-DR within whole monocytes and within each subset, with the exception of 
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CD14dimCD16 cells. The same effect was observed in the CD14dimCD16+ subset of the 
HIV-2 cohort in comparison with HIV-1+ individuals (Figure 1B).  
Additionally, HIV-2 infection was associated with an increase of the 
CD14dimCD16 subset (Figure 1A), that lacked any apparent relationship with CD4+ T-
cell depletion or T-cell activation (Supplemental Figure 1B). The origin of the 
CD14dimCD16 subset remains a subject of intense debate [53-56]. Although it may 
represent over-activated monocytes [57], possibly shedding CD14 at an increased rate 
[58], the levels of HLA-DR expression were not significantly higher in this population in 
the HIV cohorts than in seronegatives (Figure 1B). Conversely, a significant up-
regulation of the inhibitory molecule PD-L1 within CD14dimCD16- monocytes was 
observed in both infections, being significantly more marked in the HIV-2 cohort 
(Figure 1C). 
PD-L1 expression was markedly up-regulated in HIV-2+ individuals, and this 
increase within the CD14brightCD16+ and CD14dimCD16 subsets was statistically 
significant in comparison with HIV-1+ patients (Figure 1C). We also analyzed PD-1 
expression levels (MFI) on total monocytes and found a significant increase in HIV-2+ 
patients (2098±216), both in comparison with HIV-1+ (1493±92, p=0.0272) and 
seronegative individuals (1405±167 and p=0.0174). In contrast, there were no 
significant differences between PD-1 levels in the HIV-1 and seronegative cohorts 
(p=0.4162). The levels of PD-1 and PD-L1 expression on monocytes were positively 
correlated in all three cohorts (HIV-2: r=0.6251, p=0.0004; HIV-1: r=0.5247, p=0.0122; 
seronegatives: r=0.7147, p=0.0019), suggesting that their expression may be co-
coordinately regulated [59].   
Finally, serum levels of soluble CD14 (sCD14), a classical marker of monocyte 
activation [58], were significantly higher in the HIV-2 cohort in comparison with 
seronegatives, reaching levels similar to those found in HIV-1+ individuals (Figure 1D). 
Overall, our data provide evidence of a heightened state of monocyte 
activation during HIV-2 infection, which was accompanied by an up-regulation of the 
inhibitory molecules PD-L1/PD-1. 
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Figure 1. Monocyte imbalances in HIV-2-infected patients. (A) Representative flow cytometry analysis 
of monocyte subpopulations, the dot-plot refers to an HIV-2+ individual with 523 CD4
+
 T cells/µl and 
undetectable levels of viremia. A gate including only monocytes (monogate) was defined by forward 
and side scatter characteristics. Cells were further gated according to the expression of CD14 and CD16. 

















Frequencies of the different subsets within the monogate are shown. The right-
hand graph shows the relative proportion of each monocyte subset within total monocytes (CD14
+
 
cells) in HIV-1+ and HIV-2+ and seronegative (Seroneg) individuals. Expression of (B) HLA-DR and (C) PD-
L1 in terms of Mean Fluorescence Intensity (MFI) on total monocytes (left-hand graph) and on 
monocyte subsets (right-hand graphs) in the three cohorts. (D) Serum sCD14 levels in subgroups of HIV-
1+, HIV-2+ and seronegative individuals representative of the cohorts as a whole in terms of both CD4
+
 
T-cell counts and viremia (where applicable). Bars represent mean±SEM. Numbers under the bars 
represent the number of individuals analyzed. p values <0.05 were considered significant and are 
shown for all statistical differences observed. 
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Monocyte activation occurs in the absence of detectable viremia in HIV-2 
infection 
Next we assessed the relationship between the observed monocyte alterations 
and plasma viral load, since HIV-2 is associated with low to undetectable viremia 
irrespective of disease stage [43]. The expansion of CD14brightCD16+ monocytes was 
significantly higher in viremic patients despite the low levels of plasma HIV-2 load 
(200-26,263 RNA copies/ml), as shown in Figure 2A. Accordingly, the expansion of 
CD14brightCD16+ monocytes was directly correlated with viremia in HIV-2 infection 
(r=0.3987, p=0.0356) as well as in HIV-1 infection (r=0.6117, p=0.0025). Moreover, in 
contrast to HIV-1 infection, it was also positively correlated with the proviral DNA 
quantified in total PBMC in HIV-2+ individuals (HIV2: r=0.5931, p=0.0018, n= 25; HIV1: 
r=0.1140, p=0.6338, n= 21).  
Nevertheless, aviremic HIV-2+ patients featured significantly increased 
expression of HLA-DR on the CD14brightCD16+ subset (Figure 2B), and of PD-L1 on both 
CD14brightCD16+ (Figure 2C) and CD14dimCD16 subsets (Supplemental Figure 2), as well 
as increased sCD14 levels (Figure 2D), as compared to seronegatives, showing that 
monocyte activation occurred during HIV-2 infection, even in the absence of 
detectable circulating virus.  
In contrast to HIV-2+ patients, who were largely aviremic irrespective of 
disease stage, only four HIV-1+ patients were able to control viral replication in the 
absence of antiretroviral therapy [50]. These four “elite controllers” had undetectable 
viremia for 2 to 10 years, and relatively well-preserved CD4+ T-cell counts 
(814242cells/l; range 344-1425). Notably, these four individuals lacked significant 
monocyte imbalances, except for a significant overrepresentation of the 
CD14dimCD16 subset, which was also observed in aviremic HIV-2+ patients (Figure S2).  
In conclusion, monocyte activation in HIV-2+ patients was largely unrelated to 
viremia, though circulating virus had a major impact on monocyte subset imbalances. 
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Figure 2. Impact of HIV-2 plasma viral load on monocyte imbalances. HIV-2 and HIV-1 cohorts were 





 cells within total monocytes (A); Mean Fluorescence Intensity (MFI) of HLA-DR (B) 




subset; and serum levels of sCD14 (D). Bars represent 
mean±SEM. Numbers under the bars represent the number of individuals analyzed. p values <0.05 
were considered significant and are shown for all statistical differences observed. Seroneg: 
seronegative controls. 
 
Monocyte activation occurs in early stages of HIV-2 infection 
Importantly, as illustrated in Figure 3, the majority of monocyte disturbances in 
HIV-2 infection occurred before significant loss of CD4+ T cells and up-regulation of T-
cell activation markers [43]. Early stage HIV-2+ patients (>350 CD4+ T cells/µl) showed 
a significant expansion of the CD14brightCD16+ subset (Figure 3A), accompanied by an 
over-expression of HLA-DR (Figure 3B) and a marked increase in the expression of PD-
L1 (Figure 3C) in comparison with seronegative individuals. These alterations were not 
significant in their HIV-1+ counterparts, despite their higher viremia, and the 
comparable increases in sCD14 levels found in both infections (Figure 3D).  
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Figure 3. Monocyte imbalances in early stage HIV-2 disease. Comparison of HIV-2+ and HIV-1+ patients 
with >350 CD4
+ 
T cells/µl and seronegative (Seroneg) controls in terms of: (A) relative proportion of 
monocyte subsets defined according to the levels of expression of CD14 and CD16 within total 
monocytes (CD14
+
 cells); (B) Mean Fluorescence Intensity (MFI) of HLA-DR within the different 
monocyte subsets; (C) Mean Fluorescence Intensity (MFI) of PD-L1 within the different monocyte 
subsets; and (D) serum levels of sCD14. Bars represent mean±SEM. Numbers under the bars represent 
the number of individuals analyzed. p values <0.05 were considered significant and are shown for all 
statistical differences observed. 
 
Thus, monocyte disturbances were much more marked in early stage HIV-2 
than HIV-1 infection. Given the recent studies suggesting a better ability of HIV-2 to 
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infect myeloid cells [34-36], we recruited additional HIV-2-infected patients, with early 
stage disease (>350 CD4+ T cells/µl) and undetectable viremia, who showed a profile 
of monocyte disturbances similar to those above described, and sort-purified their 
monocytes to quantify the levels of proviral DNA. Importantly, proviral DNA levels 
were below the test cut-off (5 copies/106 cells) in all eight studied individuals, 
suggesting that the monocyte alterations were unrelated to a significant reservoir of 
infected monocytes in the blood. 
Overall, monocyte activation and up-regulation of inhibitory molecules were 
features of HIV-2 infection from the early stage of disease.  
 
Evidence against a major role of plasma LPS levels in HIV-2 infection 
Circulating LPS, and other bacterial products arising from increased microbial 
translocation in the gut during HIV infection, have been suggested to play a key role in 
driving the generalized state of immune activation that characterizes HIV/AIDS 
pathogenesis and, particularly, monocyte activation [21, 22]. We quantified plasma 
LPS levels, and in agreement, analysis of the 3 combined cohorts revealed significant 
associations of plasma LPS levels with the degree of CD4+ T-cell depletion (r=-0.3033, 
p=0.0244, n=55), the expression of HLA-DR on CD4+ T cells (r=0.3056, p=0.0233, n=55), 
and the percentage of CD38+HLA-DR+ cells within CD8+ T cells (r=0.3110, p=0.0208, 
n=55), as well as with sCD14 (r=0.3457, p=0.0488, n=33).  
However, we found no statistically significant differences in plasma LPS levels 
between HIV-2+ and seronegative individuals (Figure 4A). Moreover, no statistical 
significant differences were found between plasma LPS levels in HIV-2+ patients with 
detectable and undetectable viremia (Figure 4A). 
Conversely, HIV-1+ patients at a more advanced disease stage (<350 CD4+ T 
cells/μl) featured significantly higher LPS levels than seronegatives (Figure 4A), though 
no significant correlations were found between plasma LPS levels and CD4+ T-cell 
depletion or immune activation (p>0.05). Moreover, a significant association was 
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found in the HIV-1 cohort between higher plasma LPS levels and the relative loss of 
the CD14brightCD16 population in favour of the other monocyte subsets, as shown in 
Figure 4B. No such association was seen in the HIV-2 cohort (Figure 4B). Additionally, 
plasma LPS levels positively correlated with the expression of HLA-DR on 
CD14brightCD16 cells of HIV-1+ patients (r=0.4936, p=0.0230, n=21), which contrasts 
with the significant negative correlation found in the HIV-2 cohort (r=-0.5491, 
p=0.0183, n=18).  
These results support a contribution of LPS in driving monocyte differentiation 
and activation in vivo during HIV-1 infection, but not in HIV-2 infection. Of note, no 
relationships were found between plasma LPS levels and PD-L1 expression (p>0.05). 
We also quantified serum LPS-binding protein (LBP) that is known to be 
produced by gastrointestinal and hepatic epithelial cells upon LPS stimulation, and 
thought to be relevant for its interaction with CD14 [23]. No statistically significant 
differences were observed in LBP levels between HIV-2 and both HIV-1 and 
seronegative cohorts (Figure 4C), and there were no correlations between LBP levels 
and any of the aforementioned parameters (p>0.05).  
Monocytes are known to become refractory upon repeated LPS stimulation 
[60]. Therefore, we compared the ex vivo ability of PBMC from HIV-2+ and HIV-1+ 
individuals to respond to LPS. A similar increase in IL-10, IL-12 p40, TNF-α and MIP-1β 
production was observed upon LPS stimulation in the three cohorts (Figure 4D). 
Moreover, there were no associations between cytokine production and markers of 
disease progression, except for the IL-10 stimulation index that was directly correlated 
with CD4+ T-cell count (HIV-2: r=0.5286, p=0.0138, n=21; HIV-1: r=0.5250, p=0.0445, 
n=15). Of note, no relationship was found between the ability to produce cytokines 
upon LPS stimulation in vitro and plasma LPS (p>0.05). 
In summary, plasma LPS did not appear to make a significant contribution to 
the monocyte imbalances we documented in HIV-2 infected patients.  
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Figure 4. Plasma LPS during HIV-2 infection. (A) Plasma levels of LPS in HIV-1, HIV-2 and seronegative 
(Seroneg) cohorts (left). Each symbol represents one individual and bars represent mean. The infected 
cohorts were further stratified according to CD4
+
 T-cell counts (>350 and <350 cells/µl; centre) and 
levels of viremia (undetectable versus detectable, right). Bars represent mean±SEM, with numbers 
under the bars representing the number of individuals analyzed. p values <0.05 were considered 
significant and are shown for all statistical differences observed. (B) Correlations between the levels of 











) within total monocytes (CD14
+
 cells). Values of p<0.05 were 
considered significant and are shown in bold. (C) Serum levels of LBP in the three cohorts. Each symbol 
represents one individual and bars represent mean. (D) Graphs show levels of IL-10, IL-12p40, TNF-α 
and MIP-1β in supernatants of freshly isolated PBMC cultured with LPS (closed circles) or medium alone 
(open circles) for 22 hours. Each symbol represents one individual and bars represent mean. 
 
No major disturbances in serum cytokine and chemokine levels in early stage 
HIV-2 disease 
We next assessed the serum levels of a panel of cytokines and chemokines 
known to be produced following monocyte stimulation: TNF-α, MIP-1β, MCP-1, IL-6, 
and IL-10.   
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Table 2. Correlations between serum cytokine and chemokine levels with markers of 
disease progression, as well as with mDC and monocyte imbalances. 
 
TNF-α MIP-1β MCP-1 IL-6 IL-10 
% CD4
+
 T cells -0.4026;0.011 0.4404;0.0057 0.0814;0.6224 0.3884;0.0145 0.1029;0.5330 
% HLA-DR
+ 





(CD8) 0.5628;0.0002 -0.5205;0.0008 -0.0648;0.6952 -0.4206;0.0077 0.0495;0.7648 





(Mo) 0.4267;0.0067 -0.3856;0.0168 0.0978;0.5538 -0.3037;0.0602 0.2396;0.1418 
HLA-DR MFI (Mo) 0.2320;0.1553 -0.3876;0.0162 -0.1557;0.3440 -0.3523;0.0278 -0.0574;0.7286 
PD-L1 MFI (Mo) 0.1848;0.2600 -0.1493;0.3710 -0.0184;0.9114 -0.1831;0.2645 -0.2238;0.1709 
Serum sCD14 (pg/ml) 0.4194;0.0079 -0.0080;0.9619 0.2582;0.1125 0.0535;0.7465 0.2896;0.0737 
% mDC -0.5219;0.0007 0.1827;0.2723 -0.0612;0.7114 0.2369;0.1464 -0.4764;0.0022 
% CD80
+  
(mDC) 0.5350;0.0004 -0.2403;0.1462 0.0683;0.6794 -0.2616;0.1076 0.2569;0.1143 
% CD86
+ 
(mDC) 0.3636;0.0229 -0.2106;0.2043 -0.1063;0.5196 -0.3120;0.0531 0.2029;0.2154 
% PD-L1
+ 
(mDC) -0.0217;0.8959 -0.3292;0.0436 -0.1572;0.3392 -0.370;0.0183 -0.0377;0.8199 
Analysis was performed with the whole cohorts combined (n=39; 15 HIV-2-infected patients, 15 HIV-1-
infected patients and 9 seronegatives). Only infected cohorts (n=30) were considered for correlations with 
viremia. Mo: monocytes. 
Spearman’s correlation coefficient was used to assess the correlation between two variables. R;p values 
are shown. p values < 0.05 are highlighted in bold. 
 
As shown in Table 2, serum TNF-α levels were directly correlated with CD4+ T-
cell depletion, viremia, and T-cell activation, as well as with the percentage of 
CD14brightCD16+ monocytes and sCD14 levels in the combined cohort (n=39; 9 
seronegatives; 15 HIV-2+ and 15 HIV-1+ patients representative of the whole cohorts 
in terms of both CD4+ T-cell counts and viremia). Nevertheless, TNF-α levels were not 
significantly higher in HIV-2+ than in seronegative individuals, in contrast to the HIV-1 
cohort (Figure 5). Moreover, all HIV-2+ patients in early stage disease (>350 CD4+ T 
cells/µl) had serum TNF-α levels within the range found in seronegatives (11.71±3.75 
pg/ml; range: 3.2-28.49; n=7, for HIV-2+ versus 12.33±2.93 pg/ml; range: 5.08-28.16 
pg/ml; n=9, for seronegatives, Supplemental Figure 3).  
Conversely, HIV-2+ individuals featured significantly lower MIP-1β levels than 
seronegatives (Figure 5), though this decrease was not significant in early stage 
disease (Supplemental Figure 3). Notably, serum MIP-1β levels inversely correlated 
with CD4+ T-cell depletion and T-cell activation in the combined cohort (Table 2).  
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No statistically significant differences were found regarding the levels of IL-6, 












Figure 5. Serum cytokines and chemokines in HIV-2-infected patients. Serum levels of TNF-α, MIP-1β, 
IL-6, MCP-1 and IL-10 in subgroups of HIV-1+, HIV-2+ and seronegative (Seroneg) individuals 
representative of the cohorts as a whole in respect to both CD4
+
 T-cell counts and viremia (where 
applicable). Each symbol represents one individual and bars represent median. p values <0.05 were 
considered significant and are shown for all statistical differences observed. 
 
Importantly, there were no significant correlations between plasma LPS levels 
and the serum concentration of the cytokines and chemokines assessed (p>0.05). A 
recent report by Said et al has proposed that, in the context of HIV-1 infection, 
microbial translocation may up-regulate PD-1 levels on monocytes leading to 
increased IL-10 production upon PD-1/PD-L1 interaction [61]. However, no 
associations were found between PD-1 expression on monocytes and plasma LPS 
levels or serum IL-10 (p>0.05).  
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Overall, we showed that, despite the evidence of monocyte activation 
throughout HIV-2 infection, there were no major imbalances in the circulating levels 
of cytokines and chemokines typically produced by monocytes.  
 
Similar alterations in circulating mDC in HIV-2 and HIV-1 infections 
Monocytes differentiate into mDC both in vitro and in vivo [62, 63]. There are 
no data on circulating mDC during HIV-2 infection. It is plausible that the over-
activation of monocytes could impact upon mDC.  
The frequency of circulating mDC was assessed by flow cytometry, as 
illustrated in Figure 6A. HIV-2+ patients featured a statistically significant reduction in 
mDC levels as compared to seronegatives (Figure 6B), in direct correlation with the 
degree of CD4+ T-cell depletion, as well as with the levels of CD4+ and CD8+ T-cell 
activation (Figure 6C). Moreover, the degree of mDC loss in HIV-2+ patients was 
similar to that found in HIV-1 infection (Figure 6B), in spite of the distinct viremia and 
the apparent impact of plasma viral load upon mDC levels. A statistically significant 
negative correlation between viremia and mDC levels was found in both infected 
cohorts (HIV-2: r=-0.5436, p=0.0028; HIV-1: r=-0.7073, p=0.0002). Moreover, as shown 
in Figure 6B, HIV-2+ patients with undetectable viremia, as well as the four HIV-1+ 
elite controllers, showed no decrease in mDC levels. On the other hand, similar levels 
of mDC depletion were found in viremic HIV-1+ and HIV-2+ patients, despite the much 
lower plasma viral load observed in HIV-2 infection, suggesting that even low levels of 
viremia may impact upon the mDC compartment (Figure 6B). Overall, viremia was 
strongly associated with loss of circulating mDC in both infections, contrasting with 
the more limited impact of viremia on the monocyte disturbances discussed above. 
Of note, similar results were obtained when absolute mDC numbers were 
analysed (Supplemental Figure 4), confirming a marked mDC depletion in advanced 
HIV-2 disease, and relatively preserved circulating mDC numbers in early infection 
(>350 CD4+ T cells/µl).   
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Figure 6. Circulating mDC in HIV-2-infected patients. (A) Representative flow cytometric analysis of 
mDC performed after successive gates on lymphocytes and monocytes defined according to forward 
and side scatter characteristics, as well as HLA-DR
+
 cells that do not express lineage markers (left dot-
plot); and CD123CD11c
+
 cells (right dot-plot). Numbers represent the percentage of cells within the 
illustrated gates from an HIV-2+ patient with 523 CD4
+
 T cells/µl and undetectable levels of viremia. The 
proportion of mDC within PBMC was 0.26%, which corresponded to 7 mDC/µl. (B) Circulating mDC 
levels in HIV-1, HIV-2 and seronegative (Seroneg) cohorts expressed as percentage within PBMC (left). 
Each symbol represents one individual and bars represent mean. The infected cohorts were further 
stratified in groups according to CD4
+
 T-cell counts (>350 and <350 cells/µl, centre), or viremic and 
aviremic (below test cut-off, right), and mDC levels compared. Bars represent mean±SEM. Numbers 
under the bars represent the number of individuals analyzed. p values <0.05 were considered 
significant and are shown for all statistical differences observed. (C) Correlation between mDC 
frequency within PBMC and percentages of CD4
+
 T cells (left), of HLA-DR
+
 cells within CD4
+
 T cells 




 cells within CD8
+
 T cells (right). p values <0.05 were considered 
significant and are shown in bold. 
 
We then asked whether mDC maturation status was altered in HIV-2 infection, 
by assessing the expression levels of several maturation-associated molecules that are 
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related to the T-cell priming ability of mDC, namely the co-stimulatory molecules 
CD40, CD80 and CD86, and the inhibitory PD-1 ligands, PD-L1 and PD-L2.  
Circulating mDC expressing CD40 and/or PD-L2 were almost absent in all 
cohorts (data not shown). CD80 expression was significantly higher in both HIV 
cohorts than in seronegatives (Figure 7A), and directly correlated with CD4+ T-cell 
depletion and viremia (Table 3). CD86 expression was also increased in both infections 
but, in contrast to CD80, CD86 was significantly up-regulated even in early disease 
stages (Figure 7B), leading to an absence of significant correlation with CD4+ T-cell 
depletion (Table 3). Of note, significant direct correlations between T-cell activation 
markers and expression of both CD80 and CD86 were seen in the HIV cohorts (Table 
3). PD-L1 expression was also significantly increased throughout both infections 
(Figure 7C), and this up-regulation was also clear in aviremic HIV-2 individuals (Figure 
7C). Interestingly, the PD-L1 MFI/CD86 MFI ratio within mDC was unaltered in the HIV-
2 as compared to the seronegative cohort and was significantly higher in the HIV-2 
than in the HIV-1 cohort (Figure 7D), further supporting a role for the PD-1/PD-L1 
pathway in HIV-2 infection’s relatively “benign” course. Accordingly, this ratio was 
significantly reduced in advanced stage HIV-1+ individuals as compared to 
seronegatives and their HIV-2+ counterparts (Figure 7D). 
 

















 -0.4778;0.0245 0.6029;0.0030 -0.3954;0.0686 0.5784;0.0048 
 HIV-2
c
 -0.5485; 0.003 0.4427;0.0208 0.6014;0.0009 0.5614;0.0023 
 Seroneg
a
 -0.0794;0.770 NA 0.0500;0.8541 -0.0823;0.7617 
%CD86+ (mDC) HIV-1
b
 -0.2874;0.1947 0.4258;0.0482 0.4591;0.0316 0.5144;0.0143 
 HIV-2
c
 -0.2519;0.2049 0.2971;0.1324 0.4198;0.0293 0.4302;0.0251 
 Seroneg
a
 0.0029;0.9914 NA -0.0529;0.8456 -0.1618;0.5495 
%PD-L1+ (mDC) HIV-1
b
 -0.1706;0.4479 0.0045;0.9840 0.2790;0.2086 -0.0056;0.9801 
 HIV-2
c






n=27. Spearman’s correlation coefficient was used to assess the correlation between 
two variables. R;p values are shown. p values <0.05 are highlighted in bold. Seroneg, seronegatives; 
NA, not applicable. 
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Of note, no correlation between plasma LPS levels and mDC levels and 
phenotype was seen in any cohort (p>0.05). However, when the three cohorts were 
analysed as a whole, the degree of mDC depletion was found to negatively correlate 
with serum IL-10 and directly with serum TNF-α levels (Table 2). The latter was also 






















Figure 7. Expression of co-stimulatory and inhibitory molecules in circulating mDC in HIV-2 infection. 




 (B) and PD-L1
+
 (C) cells within mDC, as well as the ratio of 
the PD-L1 MFI and CD86 MFI within mDC (D),  in HIV-1, HIV-2, and seronegative (Seroneg) cohorts (left). 
Each symbol represents one individual and bars represent mean. These analyses are also shown for the 
infected cohorts stratified according to CD4
+
 T-cell counts (>350 and <350 cells/µl, centre) or levels of 
viremia (undetectable/detectable, right). Bars represent mean±SEM. Numbers under the bars 
represent the number of individuals analyzed. p values <0.05 were considered significant and are 
shown for all statistical differences observed.  
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In summary, these initial data regarding circulating mDC imbalances during 
HIV-2 infection revealed a progressive mDC loss associated with a more differentiated 
phenotype markedly similar to that observed during HIV-1 disease. Moreover, in early 
stage HIV-2 disease, the disturbances that we found in monocyte subsets did not 
seem to translate into major mDC alterations. 
 
Discussion 
This first study addressing monocyte and mDC disturbances during HIV-2 
infection, revealed a heightened monocyte activation state and progressive mDC 
depletion in this natural model of attenuated HIV disease. We found that: 1) HIV-2+ 
patients featured a significant expansion of CD14brightCD16+ monocytes accompanied 
by up-regulation of HLA-DR expression and increased levels of serum sCD14; 2) 
monocyte activation occurred even in HIV-2+ individuals with undetectable viremia; 3) 
unlike HIV-1 infection, monocyte alterations were present from early stage HIV-2 
disease; 4) monocyte imbalances were neither associated with increased plasma LPS 
or LBP levels, nor impairments in their ability to respond to LPS upon in vitro 
stimulation; 5) HIV-2+ patients featured an over-expression of the inhibitory 
molecules PD-1/PD-L1 in myeloid cells that may contribute to the lack of significant 
increase in serum levels of pro-inflammatory cytokines and chemokines usually 
produced by activated monocytes; 6) despite the reduced viremia, HIV-2, like HIV-1 
infection, was associated with a progressive decline of circulating mDC levels and 
acquisition of a more differentiated mDC phenotype. 
This heightened state of monocyte activation could be related to the proposed 
better ability of HIV-2 to infect myeloid cells [29]. Myeloid cell restriction of HIV-1 
replication has been recently suggested to be mainly due to the effects of SAMHD1 
[34, 35]. This molecule is targeted by Vpx, a protein only encoded by HIV-2 and some 
SIV strains, but not HIV-1 [64]. Thus, HIV-2 would be expected to circumvent SAMHD1-
imposed restriction to viral replication in monocytes. Additionally, CD16+ monocytes 
(expressing variable levels of CD14), a population that we found to be expanded in 
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HIV-2+ patients, have been shown to have increased susceptibility to HIV-1 infection 
[11, 12]. However, we found no detectable proviral load in monocytes isolated from 
HIV-2+ individuals in early-stage disease. These data indicate that, whilst Vpx can 
facilitate monocyte infection by HIV-2, additional restriction pathways are probably 
activated upon HIV-2 infection of these cells. These results argue against a significant 
amount of productive HIV-2 replication in monocytes. Nevertheless, it is possible that 
viral entry per se impacts on monocyte activation, a possibility that deserves future 
exploration in in vitro studies.  
Increased translocation of microbial products, such as LPS, at the intestinal 
mucosa has been proposed to contribute to monocyte activation and correlate with 
disease severity during HIV infection [21, 22]. In agreement, our data suggest that LPS 
has a significant impact on monocyte activation and differentiation in HIV-1+ 
individuals. However, we found no association between monocyte and mDC 
disturbances with circulating LPS in HIV-2 infection. Higher levels of monocyte 
activation were found in HIV-2+ patients as compared to HIV-1+ counterparts, as 
illustrated by HLA-DR expression levels. These findings argue against a major role of 
microbial translocation in driving immune activation and disease progression in HIV-2 
infection, similar to the situation reported for several African cohorts [25, 26]. Of note, 
even though our HIV-2 cohort was enriched in individuals of African origin, no 
associations were found between ethnicity and LPS levels that could impact on our 
results (data not shown). 
The ability of monocytes to continuously replenish tissue macrophages and 
dendritic cells is thought to be important in the homeostasis of these populations, 
particularly in the context of inflammation [63]. Despite the overall maintenance of 
monocyte numbers observed during HIV-2 and HIV-1 infection, mDC were markedly 
reduced, particularly in more advanced disease stages.  
This is the first report of circulating mDC depletion during HIV-2 infection. The 
underlying mechanisms are likely to be multiple. Our finding of a direct association 
between T-cell activation and mDC disturbances in both HIV-1 and HIV-2 infections, 
support a major contribution of persistent immune activation. Although it has been 
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suggested that disturbances in cell-trafficking may contribute to a preferential loss of 
circulating mDC in HIV-1 infection, the limited data available on lymphoid tissues from 
HIV-2+ individuals precluded the evaluation of this possibility [65, 66]. Additionally, 
mDC could be depleted by direct virus infection, as suggested by recent studies 
addressing the role of Vpx [34, 35]. Although this possibility was not addressed in our 
study, previous data have shown that mDC are less susceptible to HIV-2 than to HIV-1 
infection in vitro [45]. Our data also suggest that factors other than direct viral 
infection are implicated in the mDC decline, as we found a similar decrease in mDC 
levels in HIV-2+ and HIV-1+ individuals, despite their distinct levels of viremia. Another 
explanation that warrants consideration for the documented loss of circulating mDC in 
HIV-2+ patients would be decreased bone-marrow precursor production of mDC, 
particularly given our previous observation of a marked combined leukopenia and 
neutropenia in HIV-2+ patients (AE Sousa, unpublished data). Moreover, it is 
recognized that HIV-1 envelope (Env) protein interferes with the differentiation of 
monocytes into DC in vitro [67]. However, we have shown that HIV-2 envelope 
glycoprotein gp105 does not impact upon this process [47], which argues against this 
as a major contributing factor to the depletion of circulating mDC in HIV-2+ patients.  
The hyper-activated state that characterized both monocytes and mDC was, in 
HIV-2 disease, associated with a marked up-regulation of inhibitory molecules 
involved in limiting exacerbated immune activation (PD-1/PD-L1) [68]. Of note, this 
was not observed in the few HIV-1 “elite controllers” included in this study, although 
this should be investigated in larger cohorts of these particular HIV-1+ individuals that, 
similarly to HIV-2+ patients, have low levels of viremia without antiretroviral drugs. 
HIV-2+ patients featured a significantly higher ratio of inhibitory (PD-L1) and 
co-stimulatory (CD86) molecules on mDC, suggesting that overall balance of signaling 
is tipped towards suppression, which may in turn help limit the rate of increase in 
immune activation. A recent report has suggested that, in the context of HIV-1 
infection, microbial translocation may up-regulate PD-1 levels on monocytes, leading 
to increased IL-10 production upon PD-L1 binding, with consequent attenuation of 
immune responses [61]. This was unlikely to occur in the context of HIV-2 infection 
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since we found no evidence of a significant contribution of microbial translocation to 
the observed monocyte and mDC disturbances. 
Of note, high levels of PD-L1 up-regulation were observed even in the absence 
of detectable viremia and/or significant CD4+ T-cell loss, suggesting that, in HIV-2 
infection, the PD-1/PD-L1 pathway may be limiting immune activation from the 
earliest stages of disease. This was further supported by the lack of any significant 
alterations in monocyte-produced pro-inflammatory cytokine and chemokines in the 
serum of HIV-2+ individuals. Our observations are in agreement with recently 
published data suggesting that, during HIV-2 disease, there is a strict control of PD-
1/PD-L1 expression on T cells, which is disrupted in the context of HIV-1 infection, 
possibly helping limit immunopathology and restrain disease progression [59]. 
Additionally, our previous data on plasmacytoid dendritic cells (pDC) during HIV-2 
disease have also showed significantly increased levels of PD-L1 expression, 
irrespective of disease stage [51]. Taken together, these data suggest that generalized 
PD-L1 over-expression may constitute a specific “HIV-2 signature”. 
In conclusion, we investigated here, for the first time, the monocyte and mDC 
compartments during HIV-2 infection, a naturally-occurring form of attenuated HIV 
disease. We found evidence of monocyte activation since early stage HIV-2 disease, 
and a progressive depletion of circulating mDC with up-regulation of activation 
markers, tightly correlated with markers of T-cell activation. Our data emphasized the 
relationship between generalized immune activation and myeloid cell disturbances in 
HIV-2+ individuals, albeit with no apparent link to microbial translocation. Moreover, 
monocyte and mDC featured marked up-regulation of the inhibitory molecule PD-L1 
from early on in HIV-2 infection, possibly helping limit activation-related immune-
pathology and resulting in a more “benign” disease course. These findings challenge 
current paradigms of the role of monocytes and mDC in HIV/AIDS and have the 
potential to identify novel strategies to modulate inflammatory states. 
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Supplemental Figure 2. Impact of HIV-2 plasma viral load on the imbalances of the CD14
dim
CD16 
monocyte subset. HIV-2 and HIV-1 cohorts were stratified according to presence or absence of 
detectable viremia and compared in terms of: (A) frequency of CD14
dim
CD16 cells within total 
monocytes (CD14
+





subset. Bars represent mean±SEM. Numbers under the bars represent the number of 
individuals analyzed. p values <0.05 were considered significant and are shown for all statistical 
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Supplemental Figure 3. Serum cytokines and chemokines in HIV-2 infected patients according to CD4
+
 
T-cell depletion and viremia status. Graphs show the levels of TNF-α, IL-6, IL-10, MCP-1 and MIP-1β in 
the serum of HIV-1+, HIV-2+ and seronegative (Seroneg) individuals, that were representative of the 
whole cohorts in respect to both CD4
+
 T-cell counts and viremia (where applicable). Each symbol 
represents one individual and bars represent median. The infected cohorts were stratified according to 
CD4
+
 T-cell counts (>350 and <350 cells/µl, left-side graph) or undetectable/detectable levels of viremia 
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Supplemental Figure 4. Circulating mDC in HIV-2-infected patients. (A) Graph on the left shows 
absolute mDC numbers in HIV-1 and HIV-2 cohorts and seronegative (Seroneg) individuals. Each symbol 
represents one individual and bars represent mean. The infected cohorts were stratified, either 
according to CD4
+
 T-cell counts (>350 and <350 cells/µl), or presence or absence of viremia (below test 
cut-off), and mDC counts compared. Bars represent mean±SEM. Numbers under the bars represent the 
number of individuals analyzed. p values <0.05 were considered significant and are shown for all 
statistical differences observed. (B) Correlation between mDC numbers and percentages of CD4
+
 T cells 
(left), of HLA-DR
+
 cells within CD4
+




 cells within CD8
+
 T cells (right). 
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Abstract 
Objective: Hyper-immune activation is a main determinant of HIV disease 
progression, potentially counteracted by T-cell inhibitory pathways. Here we 
investigated, for the first time, inhibitory molecules in HIV-2 infection, a naturally 
occurring attenuated form of HIV disease, associated with reduced viremia and very 
slow rates of CD4+ T-cell decline. 
Design: PD-1/PD-L1, an important pathway in limiting immunopathology, and 
its possible relationship with TIM-3, a recently identified inhibitory molecule, were 
studied in untreated HIV-2 and HIV-1 cohorts, matched for degree of CD4+ T-cell 
depletion, and non-infected individuals.  
Methods: Flow cytometric analysis of T-cell expression of PD-1, PD-L1 and TIM-
3, combined with markers of cell differentiation, activation, cycling and survival. 
Statistical analysis performed using ANOVA, Mann-Whitney/Wilcoxon tests, 
Spearman’s correlations, multiple linear regressions and canonical correlation 
analysis. 
Results: T-cell expression of PD-1 and PD-L1 was tightly associated and directly 
correlated with CD4+ T-cell depletion and immune activation in HIV-2 infection. No 
such correlation was found for PD-L1 expression in HIV-1+ patients. Central-memory 
and intermediate memory cells, rather than terminally-differentiated T cells expressed 
the highest levels of both PD-1 and PD-L1 molecules. Conversely, TIM-3 expression 
was independent of T-cell differentiation and dissociated from cell-cycling, suggesting 
distinct induction mechanisms. Importantly, in contrast with HIV-1, no significant 
increases in TIM-3 expression were found in the HIV-2 cohort. 
Conclusions: Our data suggest that PD-1/PD-L1 molecules, rather than markers 
of T-cell exhaustion, may act as modulators of T-cell immune activation, contributing 
to the slower course of HIV-2 infection. These data have implications for the design of 
ART-complementary immune-based strategies.  
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The hallmark of HIV immunopathogenesis is a hyper-immune activated state 
that directly correlates with progression to AIDS [1, 2]. Since the process of T-cell 
activation is tightly regulated, resulting from a balance between stimulatory and 
inhibitory signaling pathways [3], it is plausible that inhibitory molecules play a major 
role during HIV infection. The Programmed Death-1 (PD-1) receptor/ligand network is 
considered one of the main pathways capable of limiting the deleterious effects of 
inappropriate/exacerbated immune activation [4]. In the context of HIV-1 infection, 
PD-1 was first described as a cellular exhaustion marker for HIV-specific T cells, being 
associated with reduced proliferation and cytokine secretion capacities, and its 
blockade leading to partial recovery of these functional deficits [5-7]. Recently, 
however, several groups have suggested that increased PD-1 levels may instead limit 
tissue damage resulting from chronic immune activation [8, 9] and/or persistent 
antigenemia associated with ongoing viral replication [10-12]. Furthermore, an 
increasing body of evidence indicates that PD-1 expression alone, may not always be 
associated with, nor sufficient to characterize an exhausted phenotype, with the co-
expression of other inhibitory molecules, like the Ig superfamily member T-cell 
immunoglobulin and mucin-domain containing molecule-3 (TIM-3), being essential to 
define T-cell exhaustion [13-18]. 
Here we sought to investigate the contribution of the PD-1/PD-L1 pathway and 
TIM-3 to HIV/AIDS immunopathogenesis through the study of HIV-2 infection, a 
naturally-occurring form of attenuated HIV disease [19]. HIV-2+ individuals typically 
feature lower rates of CD4+ T-cell depletion, reduced amounts of circulating virus and 
slower disease progression as compared to HIV-1+ patients [20]. Nevertheless, when 
matched for the degree of CD4+ T-cell depletion, both infections feature the same 
levels of immune activation [2, 21]. Data regarding the expression of PD-1, PD-L1 and 
TIM-3 in HIV-2+ patients are extremely limited [11]. Investigating the contribution of 
inhibitory pathways to the slower progression to AIDS observed in HIV-2 infection may 
provide a rationale for novel therapeutic interventions in HIV/AIDS. 
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The study included 28 HIV-2+ and 22 HIV-1+ antiretroviral therapy (ART)-naïve, 
asymptomatic individuals and 16 seronegative controls (Supplemental Table 1 for 
clinical and epidemiological data). Written consent for blood sampling and processing 
was provided, and the study approved by the Ethical Board of the Faculty of Medicine 
of the University of Lisbon.  
 
Flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh 
heparinised blood and surface and/or intracellularly stained, as previously described 
[22, 23]. At least 100,000 events were acquired with a FACSCanto. Analysis was 
performed using a “fluorescence minus one” strategy with FlowJo software. 
 
Plasma viral load assessment 
Viremia was quantified by reverse transcriptase PCR (RT-PCR). Detection 
thresholds were: 40 RNA copies/ml for HIV-1 (Roche, Basel, Switzerland), and 200 RNA 
copies/ml for HIV-2, using a previously described in-house assay [24].  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism v5.00, SPSS v15.0 and 
MATLAB v7.3. Data were compared using one-way or repeated measures ANOVA 
(with the Dunns post-test), followed by Mann-Whitney or Wilcoxon tests, as 
appropriate; associations were assessed by Spearman’s correlation coefficient, 
multiple linear regressions and canonical correlation analysis. p-values <0.05 were 
considered significant. 
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PD-1 expression on T cells 
We compared ART-naïve HIV-2 and HIV-1 cohorts matched for CD4+ T-cell 
depletion, with similar levels of T-cell activation, but distinct viremia (Supplemental 
Table 1). PD-1 expression tended to be higher on both CD4+ and CD8+ T cells in HIV 
cohorts as compared to seronegatives, though HIV-2 featured significantly lower 
levels within CD8+ T cells than HIV-1 (Figure 1A). Of note, similarly to seronegatives, 
HIV-2+ individuals exhibited a significant correlation between PD-1 expression on CD8+ 
and CD4+ T cells, which was not found in the HIV-1 cohort (Supplemental Figure 1).  
Next, we investigated whether increased PD-1 expression was related to HIV-
associated T-cell imbalances [25-27]. PD-1 expression varied with CD8+ T-cell 
differentiation in HIV-2+ in a similar way to that previously described for HIV-1+ and 
seronegative individuals [28, 29]. PD-1 levels were lowest on naïve cells, and peaked 
at the CD45RO+CD27+ stage (Supplemental Figure 1), supporting the view that PD-1 
up-regulation, rather than being related to terminal T-cell differentiation and 
exhaustion, may indicate T-cell activation upon antigen encounter. Whilst PD-1 
expression was significantly increased on all CD8+ T-cell subsets in HIV-1+ relative to 
seronegative individuals, this was only observed for CD45RO+CD27+ cells in the HIV-2 
cohort. PD-1 expression on CD4+ T cells was similarly linked to cell differentiation, with 
expression on naïve cells being significantly lower in HIV-1+ and HIV-2+ as compared 
to seronegative individuals; conversely, PD-1 expression on memory subsets was 
increased in both HIV cohorts, although only reaching statistical significance for HIV-1 
(Supplemental Figure 1).  
PD-1 expression on CD4+ T cells was strongly associated with the degree of 
CD4+ T-cell depletion and T-cell activation in both HIV cohorts (Table 1 and 
Supplemental Table 2). Additionally, significantly increased levels of PD-1 on CD4+ and 
CD8+ T cells were found in viremic as compared to both aviremic HIV-2+ and 
seronegative individuals (Supplemental Figure 2).  
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Figure 1. T-cell expression of PD-1, PD-L1 and TIM-3 in HIV-2 infection. (A) PD-1 Mean Fluorescence 




 T cells in seronegative, HIV-1 and HIV-2 cohorts. (B) 




 T cells in the 3 cohorts. (C) 
Illustrative dot-plots of PD-1 and TIM-3 expression within naïve and memory CD8
+
 T-cell subsets, 
defined according to CD45RA and CD27, in an HIV-1+ patient with 650 CD4
+
 T cells/µl and 21731 RNA 




 T cells in seronegative, HIV-1 and HIV-2 cohorts in 
early stage disease as described in Supplementary Digital Content, Table 3. (E) Dot-plots illustrate the 
analysis of TIM-3 and PD-1 in relation to Ki-67 within total CD8
+
 T cells in the same patients as in (C). 








 T cells (Ki-67
+
) 
are shown in the graphs. (F) Correlations between the expression of the pro-survival factor Bcl-2 and 




 T cells in the 3 cohorts. Spearman correlation 
coefficients are shown. Each dot represents one individual. Bars represent mean. 
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Importantly, no statistically significant correlations were found between PD-1 
expression levels on CD8+ T cells and the aforementioned parameters in either HIV 
cohort, except for CD38 MFI within CD8+ T cells (Table 1). 
 
Table 1. Correlations between PD-1 or PD-L1 expression (MFI) on CD4+ and CD8+ T cells 
and surrogate markers of HIV disease progression.a 
 
   PD-1 MFI   
 Seronegatives  HIV-1  HIV-2 
 CD4 CD8  CD4 CD8  CD4 CD8 
% CD4 T cells 0.33;0.21 0.01;0.96  -0.83;<0.0001 -0.20;0.37  -0.62;0.0004 -0.20;0.30 
CD4+ T cells/µl 0.36;0.18 0.13;0.63  -0.85;<0.0001 -0.39;0.07  -0.50;0.007 -0.27;0.17 
%HLA-DR+ in CD4 0.19;0.49 0.32;0.23  0.64;0.001 0.19;0.39  0.68;<0.0001 0.30;0.11 
CD38 MFI in CD8 -0.006;0.98 -0.10;0.72  0.54;0.009 0.59;0.004  0.58;0.001 0.59;0.001 
Viremia (RNA cp/ml)a NA NA  0.43;0.04 0.41;0.05  NA NA 
 PD-L1 MFI 
 Seronegatives  HIV-1  HIV-2 
 CD4 CD8   CD4 CD8  CD4 CD8  
% CD4 T cells 0.04;0.87 0.19;0.47  -0.42;0.05 -0.43;0.04  -0.44;0.02 -0.43;0.02 
CD4+ T cells/µl 0.01;0.98 -0.17;0.52  -0.31;0.16 -0.39;0.07  -0.58;0.001 -0.46;0.01 
%HLA-DR+in CD4 0.16;0.55 0.28;0.30  0.21;0.35 0.25;0.27  0.54:0.003 0.35;0.07 
CD38 MFI in CD8 -0.15;0.57 -0.22;0.41  0.29;0.18 0.26;0.25  0.58;0.001 0.40;0.03 
Viremia (RNA cp/ml)b NA NA  0.18;0.43 0.11;0.64  NA NA 
 
a
 Relationships were tested for significance with Spearman correlations: r;p values are shown. Results 
with p values <0.05 are highlighted in bold. NA, Not Applicable. 
b
 For statistical analyses, half of the cut-off value was considered in the cases in which viremia was below 
the detection limits. 
 
To investigate which of these factors most strongly influenced PD-1 expression 
on T cells, we conducted multiple linear regression (MLR) analyses using combined 
data from all cohorts. Colinearity analysis revealed associations between CD4+ T-cell 
counts and T-cell activation levels (data not shown), in agreement with variable inter-
dependency [21]. MLR analysis revealed a statistically significant association between 
PD-1 and HLA-DR expressions on CD4+ T cells (β=0.444: p=0.030). Moreover, PD-1 
expression levels within CD45RO+CD27+ CD8+ T cells were significantly associated with 
CD38 expression on CD8+ T cells (β=0.542: p=0.025) and nearly significantly associated 
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with viremia (β=0.286: p=0.055). Moreover, a canonical analysis further supported a 
role for immune activation in driving increased PD-1 expression on CD4+ and CD8+ T 
cells, as well as an additional contribution of viremia to PD-1 up-regulation on CD8+ T 
cells (Supplemental Figure 2).  
Overall, our results suggest that immune activation is the main factor 
contributing to the increased PD-1 levels during HIV infection. Additionally, they also 
indicate a role for viremia in PD-1 up-regulation on CD8+ T cells, particularly on the 
CD45RO+CD27+ subpopulation.   
 
PD-L1 expression on T cells  
PD-L1 can also be up-regulated on T cells upon activation [30]. Strong direct 
correlations were observed in HIV-2+ individuals between PD-L1 expression on CD4+ 
and CD8+ T cells and both the degree of CD4+ T-cell depletion and T-cell activation 
(Table 1 and Supplemental Table 2). Such correlations were largely absent in the HIV-1 
cohort and non-existent in seronegative controls (Table 1), suggesting that PD-L1 
expression on T cells increases specifically during HIV-2 disease progression. This was 
observed despite the lack of a significant increase in PD-L1 expression levels on CD8+ 
and CD4+ T cells in HIV-2 infection and of a similar differentiation-associated pattern 
of PD-L1 and PD-1 expression in all cohorts (Supplemental Figure 3). Moreover, the 
expression of PD-L1 and PD-1 expression within CD4+ and CD8+ T cells was apparently 
highly related (Figure 1B). Overall, our data revealed that HIV-2+ individuals showed 
strong correlations between PD-L1 and CD4+ T-cell depletion and T-cell activation, 
suggesting that the strict control of PD-L1 expression may contribute to the slow HIV-2 
disease progression. 
 
TIM-3 expression on T cells 
In order to investigate TIM-3 expression in HIV-2 infection and its relationship 
with PD-1/PD-L1, we studied additional age-matched cohorts of ART-naïve HIV-1+ and 
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HIV-2+ individuals with >300 CD4+ T cells/µl, and seronegative controls (Supplemental 
Table 3 for clinical and epidemiological data). 
The mechanisms regulating TIM-3 expression remain poorly understood [31-
34]. Regarding the CD8+ T-cell subset, the frequency of TIM3+PD1+ cells was very low 
(Figure 1C) and, in contrast to PD-1, TIM-3 expression seemed to be independent of T-
cell differentiation in all cohorts (Supplemental Figure 4). 
TIM-3 expression was higher in HIV-1+ patients as compared to both HIV-2+ 
and seronegative individuals on CD8+ and CD4+ T cells, although only reaching 
significance in comparison with the latter (Figure 1D).  
Of note, the contribution of TIM-3+ cells to cycling T cells was negligible in all 
cohorts in marked contrast to PD-1+ cells (Figure 1E), which represented a significant 
proportion of cycling T cells, particularly in the HIV-1 cohort, further supporting the 
requirement of TCR stimulation for PD-1 up-regulation.  
Conversely, both PD-1 and TIM-3 expression seemed to impact on CD8+ T-cell 
survival, as previously described [35, 36], as indicated by the inverse correlation found 
with Bcl-2 expression levels within CD8+ T cells (Figure 1F). No such correlations were 
found on CD4+ T cells (Figure 1F). 
We also confirmed that the above reported imbalances in the expression of 
inhibitory molecules were unrelated to regulatory CD4+ T cells (Treg), defined by 
FoxP3 expression (Supplemental Figure 5) that have been reported to express high 
levels of PD-1 and TIM-3 [37, 38].  
Overall, our data showed that over-representation of a TIM-3+ population in T 
cells, particularly within the CD8+ subset, was much more marked in HIV-1 than in HIV-
2 infection. Moreover, TIM-3 expression was apparently independent of T-cell 
differentiation and disassociated from cell-cycling. 
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Discussion 
We report here, for the first time, that HIV-2 infection was associated with 
increased PD-1/PDL-1 expression on both CD4+ and CD8+ T cells, in direct correlation 
with the degree of CD4+ T-cell depletion and T-cell activation. PD-1 up-regulation 
occurred despite the low to undetectable viremia found in the majority of untreated 
HIV-2+ patients. We also found strong correlations between the expression of its main 
ligand, PD-L1, within both CD4+ and CD8+ T cells, and the degree of CD4+ T-cell 
depletion and immune activation that were exclusive to the HIV-2 cohort, in 
agreement with our previous data on pDC [23]. The expression of these inhibitory 
markers seemed to be mainly driven by immune activation, the major determinant of 
the rate of CD4+ T-cell loss and AIDS progression, both in HIV-1 and HIV-2 infections [5, 
8, 39, 40]. Our data suggest that PD-1/PD-L1 up-regulation may reflect an attempt to 
limit immunopathology, hence contributing to a more “benign” course of HIV 
infection. 
We showed that HIV-2+ individuals did not feature a significant up-regulation 
of TIM-3, in contrast to the HIV-1 cohort which exhibited an over-expression of TIM-3 
within CD4+ and CD8+ T cells, as previously reported [15, 16], even in early stage 
disease. TIM-3 expression was dissociated from PD-1 expression, and markers of cell 
differentiation and cell-cycling, but inversely correlated with the levels of the anti-
apoptotic molecule Bcl-2 on CD8+ T cells. Thus, PD-1 and TIM-3 may be differentially 
regulated, resulting in their expression by functionally distinct T-cell populations. 
Overall, we found no significant changes in TIM-3 expression in HIV-2+ individuals, in 
contrast to its up-regulation throughout HIV-1 infection, suggesting a role of TIM-3 in 
the protected HIV-2 disease course. 
In conclusion, we showed that, during the relatively “benign” course of HIV-2 
infection, there was a progressive increase in the expression of PD-1 and PD-LI within 
CD4+ and CD8+ T cells but not of TIM-3. Our data suggest that the PD-1/PD-L1 pathway 
may counteract the hyper-immune activation associated with AIDS progression with 
implications for the design of ART-complementary immune-based strategies. 
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Supplemental Table 1. Cohort clinical and epidemiological data.a 
 Seronegatives HIV-1 HIV-2 
Numbers (male/female) 16 (6/10) 22 (17/5) 28 (9/19) 
Age (years) 44 ± 2 (27-57) 40 ± 2 (23-61) 49 ± 3 (19-78) 
Ethnicity (Caucasian/other) 15/1 13/7 14/14 
% CD3
+
 cells 62.6 ± 1.9 (49-76.3) 67.4 ± 2.1 (48.6-82.8) 63.8 ± 2.0 (46.3-87.4) 
CD3
+
 cells/µl 1286 ± 93 (695-1929)  1621 ± 171 (538-3970) 1399 ± 112 (346-2930) 
% CD4
+
 T cells 52.4 ± 2.5 (5.36-67.0) 24.6 ± 3.9 (1.7-70.1)*** 31.6 ± 3.1 (6.8-62)*** 
CD4
+ 
T cells/µl 906 ± 59 (518-1312) 569 ± 105 (18-1848)* 659 ± 81 (52-1511)* 
% HLA-DR
+
 in CD4  4.1 ± 0.4 (1.9-7.6)  17.1 ± 3.0 (1.7-54.5)*** 11.4 ± 1.7 (1.8-36.3)** 
% CD8
+
 T cells 24.0 ± 1.8 (11.7-35.2) 46.7 ± 2.8 (12.4-64.7)*** 38.1 ± 2.3 (21-65.7)***# 
CD8
+
 T cells/µl 503 ± 51 (212-802) 1107 ± 120 (138-2514)*** 816 ± 75 (221-1817)**# 
CD38 MFI in CD8  1237 ± 106 (838-2539) 5128 ± 848 (706-13553)*** 2854 ± 537 (643-13659)* # 
Viremia (RNA cp/ml) NA 778459 ± 334956 (71-4.5x106)b 11266 ± 3,633 (1189-3.6x104)c 
 
a
Data are Mean±SEM with limits in brackets, unless indicated otherwise. NA, Not Applicable. Data 
referring to the early stage cohort are not included in this Table (see Supplemental Table 3). Statistical 
differences between a given HIV cohort and the seronegative controls: *, p < 0.05; **, p < 0.01; ***, 
p<0.001. Statistical differences between HIV-1+ and HIV-2+ individuals: #, p < 0.05. 
b 
HIV-1 viremia was < 40 RNA copies/ml (cutoff) in 3 of the 22 subjects studied. 
c
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Supplemental Table 2. Correlations between PD-1 or PD-L1 MFI on CD4+ and CD8+ T 
cells and additional surrogate markers of HIV disease progression.a 
 
   PD-1 MFI   
 
Seronegatives  HIV-1  HIV-2 
CD4 CD8  CD4 CD8  CD4 CD8 
HLA-DR MFI in CD4 0.36;0.17 0.40;0.13  0.70;0.0003 0.36;0.10  0.67;<0.0001 0.45;0.02 
%HLA-DR+ in CD8 0.16;0.55 0.17;0.52  0.47;0.02 0.43;0.04  0.63;0.0004 0.37;0.05 
HLA-DR MFI in CD8 0.23;0.39 0.21;0.43  0.35;0.12 0.58;0.005  0.60;0.0008 0.47;0.01 
%CD38+ in CD8 -0.11;0.68 -0.11;0.67  0.55;0.009 0.50;0.02  0.46;0.01 0.44;0.02 
β2-microglobulin (mg/l)b ND ND  0.38; 0.18 0.10;0.72  0.57;0.0075 0.35;0.12 
 PD-L1 MFI 
 Seronegatives  HIV-1  HIV-2 
 CD4 CD8   CD4 CD8  CD4 CD8  
HLA-DR MFI in CD4 0.17;0.53 0.41;0.11  0.28;0.21 0.28;0.20  0.53;0.004 0.32;0.09 
%HLA-DR+ in CD8 0.16;0.54 -0.01;0.97  0.56;0.01 0.52;0.01  0.51;0.005 0.39;0.04 
HLA-DR MFI in CD8 0.11;0.68 0.01;0.98  0.41;0.06 0.44;0.04  0.49;0.008 0.34;0.07 
%CD38+ in CD8 -0.31;0.25 -0.37;0.16  0.28;0.20 0.20;0.37  0.53;0.004 0.33;0.08 
β2-microglobulin (mg/l)b ND ND  0.27;0.35 -0.01;0.98  0.66;0.001 0.55;0.01 
 
a
 Relationships were tested for significance with Spearman correlations: r;p values are shown. Results 
with p values <0.05 are highlighted in bold. ND: Not Determined. 
b
β2-microglobulin serum levels were assessed for 21 HIV-2 (3.0±0.4 mg/l) and 14 HIV-1 (3.0±0.4 mg/l) 
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Supplemental Table 3. Clinical and epidemiological data of the early stage cohorts.a 
 Seronegatives HIV-1 HIV-2 
Numbers (male/female) 8 (3/5) 12 (8/4) 7 (1/6) 
Age (years) 42 ± 5 (26-57) 41 ± 3 (25-63) 50 ± 5 (33-66) 
Ethnicity (Caucasian/other) 8/0 9/3 5/2 
% CD3
+
 cells 67.3 ± 3.8 (51.8-88.1) 69.7 ± 2.3 (56.6-86.7) 72.3 ± 2.1 (63.5-78.6) 
CD3
+
 cells/µl 1725 ± 307 (927-3135)  1730 ± 130 (1102-2756) 1547 ± 197 (1126-2517) 
% CD4
+
 T cells 36.3 ± 3.6 (26.2-51.9) 26.9 ± 2.6 (19.4-50.1)* 31.6 ± 3.1 (19.5-45.7) 
CD4
+ 
T cells/µl 905 ± 118 (512-1385) 662 ± 74 (430-1361) 697 ± 143 (335-1464) 
% HLA-DR
+
 in CD4  5.8 ± 0.9 (3.8-10.3)  6.7 ± 1.2 (1.5-13.7) 5.9 ± 1.4 (3.1-11.6) 
% CD8
+
 T cells 30.4 ± 5.4 (13.2-61.1) 42.1 ± 2.9 (26.3-67)* 40.4 ± 2.9 (28.1-47.7) 
CD8
+
 T cells/µl 808 ± 289 (302-2175) 1054 ± 104 (493-1887) 834 ± 76 (526-1130) 
CD38 MFI in CD8  2447 ± 298 (1394-3993) 4895 ± 626 (1865-9787)** 3098 ± 220 (2454-3665) 
Viremia (RNA cp/ml) NA 25,949 ± 8405 (295-73,110) NAb 
 
a
 Data are Mean±SEM with limits in brackets, unless indicated otherwise. NA, Not Applicable. Statistical 
differences between a given HIV cohort and the seronegative controls: *, p < 0.05; **, p < 0.01. 
b
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Supplemental Figure 1. PD-1 expression according to cell-differentiation and viremia in HIV-2+ 
individuals. (A) Gating strategy used to assess PD-1 (clone: MIH-4) expression by flow cytometry: cells 
were first gated according to CD8 or CD4 expression (within a CD3
+
 gate) and PD-1 expression was then 
assessed using as reference a “fluorescence minus one” control (grey histogram). (B) Similarly to 
seronegative controls, HIV-2+ individuals exhibited a significant correlation between PD-1 expression 
on CD8
+
 and on CD4
+





 (D) T-cell subsets defined according to CD45RO and CD27 expression. Bars represent 
mean±SEM and statistically significant differences are shown. (E) PD-1 expression in HIV-2+ individuals 
stratified according to levels of circulating virus: undetectable (aviremic, avir) and viremic (vir). Each dot 
represents one individual. 
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Supplemental Figure 2. Canonical correlation analysis.  
 
As none of the MLR models fully explained the variability in PD-1 expression seen 
among the different T-cell subsets (r2<0.6 for all models), a canonical correlation 
analysis was performed in order to clarify the determinants of PD-1 expression within 
T cells. 
This technique looks for correlations between linear combinations of a set of 
predictive variables and of outcome variables, commonly denominated variates or 
canonical variables. In our analysis, the predictive variate (variate 1) included CD4+ T-
cell counts, viral load and T-cell activation (HLA-DR expression on CD4+ T cells and 
HLA-DR and CD38 expression on CD8+ T cells, measured as MFI), and the outcome 
variate (variate 2) PD-1 expression (MFI) on CD4+ and CD8+ T cells in all the individuals 











































































































































































































































































































































































































































































































































































































The first (A) shows a strong association between a predictive variate dominated by T-
cell activation parameters and a outcome variate with high values for PD-1 expression 
on both total CD4+ and CD8+ T cells, which implicates immune activation as the major 
determinant of PD-1 expression on both T-cell subsets.  
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The second (B) represents an association between low HLA-DR expression on CD4+ T 
cells and high viremia with low PD-1 expression on CD4+ T cells and high PD-1 
expression on CD8+ T cells, thus reinforcing the role of immune activation in driving 
PD-1 over-expression but also indicating a contribution of viremia in the up-regulation 
of PD-1 on CD8+ T cells.  
Colinearity analysis failed to reveal any significant association between PD-1 
expression on the different T-cell subpopulations, which suggests that PD-1 expression 
is regulated in a subset-independent manner. To address the regulation of PD-1 
expression within the different T-cell subpopulations, we performed an additional 
canonical correlation analysis in which disease progression markers (variate 1) were 
correlated to PD-1 expression on memory-effector CD4+ and CD8+ T-cell subsets 
(variate 2 – among memory CD4+ T cells, CD45RO+ cells were considered as a whole as 
no difference in PD-1 expression was observed between CD27+ and CD27 
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The first (C) demonstrates a relationship between a predictive variate combining 
mostly T-cell activation parameters and a outcome variate combining PD-1 expression 











































































































































































































































































































































































































































































































































































































The second (D) represents direct associations between CD4+ T-cell counts, viremia and 
PD-1 expression on CD8+CD45RO+CD27+ T cells and CD4+ T-cell activation (HLA-DR 
expression) and PD-1 expression on memory CD4+ T cells. Overall, this analysis 
supports a major role for T-cell activation in PD-1 up-regulation on both CD4+ and 
CD8+ memory T cells and a contribution of CD4+ T-cell depletion and viremia to PD-1 
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 T cells in seronegative, HIV-1 and HIV-2 cohorts. Bars represent mean and each dot represents 










 (D) T-cell subsets in a group consisting of 14 seronegative, 5 HIV-1+ and 10 HIV-2+ 
individuals. Naïve and memory T-cell subsets were defined according to CD45RO and CD27 expression 
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Supplemental Figure 4. TIM-3 expression on CD8
+
 T-cell subsets. Graph shows TIM-3 MFI (clone: 
344823) within each CD8
+















 T cells. TIM-3 (left), along with PD-1 (middle) and PD-L1 (right) MFI was 
assessed within CD45RA
+




T cells in 
seronegative, HIV-1+ and HIV-2+ individuals. Bars represent mean±SEM. The results obtained with 
naïve and memory FoxP3 subsets were broadly similar to those observed within total CD4
+
 T cells. 
Regarding the Treg population, both HIV-2 and HIV-1 cohorts featured significantly higher levels of PD-1 
expression than the seronegative individuals, but TIM-3 levels were similar in all cohorts. Also, a 
preliminary analysis revealed a strong correlation between PD-L1 MFI on CD4
+
 T cells and the frequency 
of FoxP3-expressing CD4
+
 T cells in the HIV-2 (p=0.007, r=0.881, n=8) but not in the HIV-1 cohort 
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3.3. Preserved CD4+ T-cell telomere length during long-lasting 
HIV-2 infection 
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Abstract 
HIV-2 features a much slower course than HIV-1 infection, often asymptomatic 
for over 20 years without antiretroviral therapy (ART). Nevertheless, CD4+ T cells 
progressively decline, in direct correlation with immune activation and cell-cycling. We 
reported, for the first time, preserved telomere length within naïve and memory CD4+ 
















Chapter 3: Results 
3.3. CD4
+




HIV infection is characterized by progressive CD4+ T-cell depletion, associated 
with persistently high levels of T-cell turnover [1]. HIV-2, as compared to HIV-1 
infection, is associated with a much slower CD4+ T-cell decline and, consequently, 
prolonged disease length [2]. Nevertheless, when matched for the degree of CD4+ T-
cell depletion, HIV-2+ and HIV-1+ individuals show similar levels of T-cell activation 
and cycling [3, 4]. In HIV-1+ patients there is evidence of extensive CD8+ T-cell 
replicative history with telomere shortening [5-7], though data on CD4+ T cells remain 
controversial [8-10]. 
We investigated, for the first time, whether increased CD4+ T-cell turnover and 
prolonged chronic inflammation in HIV-2+ individuals leads to significant telomere 
attrition. CD4+ T-cell telomere length was estimated by three-colour flow-FISH 
(fluorescence in situ hybridization) in thawed peripheral blood mononuclear cells 
(PBMC), as previously described [11]. Blood samples were obtained after written 
consent and study was approval by the Ethical Board of the Faculty of Medicine of the 
University of Lisbon.  
HIV-2 and HIV-1 cohorts featured comparable levels of CD4+ T-cell depletion 
(HIV-2: 647±84 cells/µl, 28.3±2.8%; HIV-1: 530±94 cells/µl, 21.3±2.5%; and 
seronegatives: 950±71 cells/µl; 42.7±1.9%. p<0.01 for both HIV cohorts as compared 
to seronegatives); and hyper-immune activation (HIV-2: 4.4±0.9%, HIV-1: 7.4±1.1%, 
and seronegatives: 1.6±0.2% for frequency of HLA-DR+CD38+ in CD4+ T cells; HIV-2: 
16.1±2.3%, HIV-1: 19.5±2.8%, and seronegatives: 5.4±1.1% for frequency of HLA-
DR+CD38+ in CD8+ T cells. p<0.01 for both HIV cohorts as compared to seronegatives), 
but viremia was strikingly lower in HIV-2+ patients, who included 11 antiretroviral 
therapy (ART)-naïve individuals with undetectable viremia (HIV-2: 5.8x103±1.5x103 
and HIV-1: 6.6x105±6.5x105 RNA copies/ml). 
We found no significant differences in telomere length of circulating CD4+ T 
cells from HIV-2+ and seronegative individuals (Figure 1A). As expected [12], and 
validating the assay, memory CD4+ T cells showed significantly shorter telomeres than 
160 HIV-2 immunopathology: 






































































































































































































naïve in both cohorts (Figure 1A; p<0.0001). Of note, telomere length of naïve and 
memory CD4+ T cells did not differ between HIV-2 and seronegative cohorts. Thus, 
despite the prolonged length of HIV-2 infection [2] and the evidence of increased 













 T-cell telomere length during HIV-2 infection. (A) Telomere length was assessed, using a 
Flow-FISH assay, in terms of Median Fluorescence Intensity (MFI) of whole CD4
+
 T cells (left graph), 
naïve (CD45RO
 
central graph) and memory (CD45RO
+
, right graph) CD4
+
 T cells in HIV-2+ and HIV-1+, 
as well as seronegative (Seroneg) individuals. The HIV cohorts were further stratified, according to the 
degree of CD4
+
 T-cell depletion, into subgroups of patients with > or < 300 CD4
+
 T cells/μl and analysed 
in terms of: (B) Frequency of naïve cells within total CD4
+
 T cells; (C) Telomere length (MFI) of naïve 
CD4
+
 T cells; (D) Proportion of cycling cells within naïve CD4
+
 T cells, assessed by the expression of Ki-
67. Each symbol represents one individual and bars represent mean; closed symbols refer to ART-
treated patients. Data were compared using Mann-Whitney tests. P-values below 0.05 were considered 
significant and are indicated for all statistical differences observed.  
 
Conversely, HIV-1+ individuals featured significantly decreased CD4+ T-cell 
telomere length, as compared to seronegative controls (Figure 1A), in close 
association with the frequency of circulating CD4+ T cells (r=0.4320; p=0.0447). 
HIV-2+ individuals tended to be older (HIV-2: 49±2years; HIV-1: 44±3years; 
seronegatives: 43±3years; not statistically different), a factor known to be associated 
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with shorter telomeres [13], stressing the relevance of our finding of preserved 
telomere length in the HIV-2 cohort. Additionally, and in agreement with 
epidemiological trends [14], our HIV-2 cohort was enriched in non-Caucasians (12/26; 
HIV-1: 1/22; seronegatives: 1/23) and females (13/26; HIV-1: 5/22; seronegatives: 
18/23). As ethnicity and gender have also been described to impact on telomere 
length, although with conflicting results [15-17], linear regression and one-way 
analysis of variance were performed, which indicated a lack of significant effects of 
age, ethnicity and/or gender on the results obtained for telomere length in our HIV-2 
cohort (p>0.05). 
Of note, the overall reduction of CD4+ T-cell telomere length in HIV-1 infection 
seemed to be related to preferential telomere erosion in the naïve subset (Figure 1A), 
with no differences being observed regarding memory CD4+ T cells.  
HIV infection is associated with progressive naïve CD4+ T-cell loss. The ability to 
sustain this subset is thought to affect the size and diversity of the overall CD4+ T-cell 
pool, possibly contributing to slower HIV disease progression. Both HIV cohorts 
exhibited a decline of naïve cells within total CD4+ T cells, which was particularly 
marked in advanced HIV-1 infection (<300 CD4+ T cells/µl) (Figure 1B). Accordingly, in 
HIV-1+ individuals, the proportion of naïve cells was inversely associated with CD4+ T-
cell depletion (CD4+ T-cell counts: r=0.7134, p=0.0002; % of CD4+ T cells: r=0.8080, 
p<0.0001) and T-cell activation (% of HLA-DR+CD38+ in CD4+ T cells: r=-0.8512, 
p<0.0001; and in CD8+ T cells: r=-0.4704, p=0.0272), which did not occur in the HIV-2 
cohort (p>0.05 for all the aforementioned parameters).  
Notably, HIV-1+ individuals in advanced disease stage (<300 CD4+ T cells/µl) 
featured the lowest naïve CD4+ T-cell telomere length (Figure 1C). All but one of these 
patients were on long-term ART (44±8months, n=8), with undetectable viremia 
despite poor immunological recovery, and have been included in a previously 
described ART-discordant cohort [3, 18]. Our findings are in agreement with the 
reported impairment of thymic function that has been linked with discordant 
responses to ART in HIV-1 infection [19, 20]. On the other hand, our data suggest that, 
in advanced HIV-2 infection, there is a better maintenance of naïve CD4+ T-cell 
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telomere length (Figure 1C). The sustainability of the naïve compartment may be 
related to a relatively preserved thymic activity during HIV-2 infection, as we reported 
[21]. Of note, the HIV-2 cohort also included 12 ART-treated patients, that, as 
previously described [22], showed significant CD4+ T-cell depletion (360±69 cells/µl; 
6/12 patients with <300 CD4+ T cells/µl) despite low viremia (undetectable in 9/12 
patients), in agreement with the poor immunological recovery upon ART usually 
observed in HIV-2 infection [2, 22-24].  
Naïve CD4+ T-cell homeostasis also relies on peripheral homeostatic 
proliferation [25]. The frequency of cycling cells within the naïve CD4+ T-cell pool, 
estimated by the cell-cycle marker Ki-67 as previously described [25], was markedly 
increased in both HIV cohorts, in relation to seronegatives (Figure 1D), although 
significantly lower than those observed within memory CD4+ T cells (HIV-2: 18.1±2.1%; 
HIV-1: 18.2±2.8%; seronegatives: 8.9±0.7%; p<0.0001 for the comparison between 
frequency of cycling naïve and memory CD4+ T cells in all cohorts; p<0.001 for the 
comparison of proportion of cycling memory cells between both HIV and seronegative 
cohorts). The proportion of cycling cells within naïve CD4+ T cells was more noticeably 
elevated in patients with advanced HIV-1 infection (<300 CD4+ T cells/µl), reaching 
statistical significance both in comparison with seronegatives and corresponding early 
stage disease group (Figure 1D).  
Thus, in HIV-1+ individuals with advanced disease, maintenance of naïve CD4+ 
T cells seemed to critically depend upon homeostatic peripheral expansion. In 
contrast, no significant increase in the frequency of cycling cells was observed in 
advanced HIV-2 disease with similar levels of immune activation [4].  
Our data further support a contribution of thymopoiesis throughout the course 
of HIV-2 infection that may help limit the degree of telomere attrition in the naïve 
CD4+ T-cell compartment. The latter could also be related to maintained telomerase 
activity in HIV-2 infection. This possibility warrants further investigation in HIV-2+ 
patients, given the evidence indicating their preserved responsiveness to IL-7 [26], an 
important telomerase inducer [27].  
Chapter 3: Results 
3.3. CD4
+
 T-cell telomere length in HIV-2 infection 
163 
 
Overall, this study revealed that prolonged HIV-2 infection is associated with 




1. Grossman, Z., et al., CD4+ T-cell depletion in HIV infection: are we closer to understanding the 
cause? Nat Med, 2002. 8(4): p. 319-23. 
2. Drylewicz, J., et al., Comparison of viro-immunological marker changes between HIV-1 and HIV-
2-infected patients in France. AIDS, 2008. 22(4): p. 457-68. 
3. Foxall, R.B., et al., Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection 
in direct association with CD4+ T-cell depletion irrespectively of viremia. AIDS, 2011. 25(16): p. 
1961-70. 
4. Sousa, A.E., et al., CD4 T cell depletion is linked directly to immune activation in the 
pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol, 2002. 169(6): 
p. 3400-6. 
5. Effros, R.B., et al., Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease 
implicate replicative senescence in HIV pathogenesis. AIDS, 1996. 10(8): p. F17-22. 
6. Pommier, J.P., et al., Immunosenescence in HIV pathogenesis. Virology, 1997. 231(1): p. 148-
54. 
7. Appay, V. and S.L. Rowland-Jones, Premature ageing of the immune system: the cause of AIDS? 
Trends Immunol, 2002. 23(12): p. 580-5. 
8. Nichols, W.S., et al., Increased CD4+ T-lymphocyte senescence fraction in advanced human 
immunodeficiency virus type 1 infection. Scand J Immunol, 1999. 49(3): p. 302-6. 
9. Palmer, L.D., et al., Telomere length, telomerase activity, and replicative potential in HIV 
infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J Exp Med, 
1997. 185(7): p. 1381-6. 
10. Wolthers, K.C., et al., T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T 
cell turnover. Science, 1996. 274(5292): p. 1543-7. 
11. Plunkett, F.J., et al., The flow cytometric analysis of telomere length in antigen-specific CD8+ T 
cells during acute Epstein-Barr virus infection. Blood, 2001. 97(3): p. 700-7. 
12. Wolthers, K.C., et al., Normal telomere lengths in naive and memory CD4+ T cells in HIV type 1 
infection: a mathematical interpretation. AIDS Res Hum Retroviruses, 1999. 15(12): p. 1053-62. 
13. Bekaert, S., T. De Meyer, and P. Van Oostveldt, Telomere attrition as ageing biomarker. 
Anticancer Res, 2005. 25(4): p. 3011-21. 
14. Carvalho, A.C., et al., Population mobility and the changing epidemics of HIV-2 in Portugal. HIV 
Med, 2012. 13(4): p. 219-25. 
15. Barrett, E.L. and D.S. Richardson, Sex differences in telomeres and lifespan. Aging Cell, 2011. 
10(6): p. 913-21. 
16. Diez Roux, A.V., et al., Race/ethnicity and telomere length in the Multi-Ethnic Study of 
Atherosclerosis. Aging Cell, 2009. 8(3): p. 251-7. 
17. Hunt, S.C., et al., Leukocyte telomeres are longer in African Americans than in whites: the 
National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. 
Aging Cell, 2008. 7(4): p. 451-8. 
164 HIV-2 immunopathology: 
how the immune system deals with long-lasting infection 
 
18. Albuquerque, A.S., et al., Low CD4 T-cell counts despite low levels of circulating HIV: insights 
from the comparison of HIV-1 infected patients with a discordant response to antiretroviral 
therapy to patients with untreated advanced HIV-2 disease. Clin Immunol, 2007. 125(1): p. 67-
75. 
19. Li, T., et al., Reduced thymic output is a major mechanism of immune reconstitution failure in 
HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis, 2011. 53(9): p. 944-
51. 
20. Teixeira, L., et al., Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect 
lower thymic function. AIDS, 2001. 15(14): p. 1749-56. 
21. Gautier, D., et al., Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T 
cells during chronic human immunodeficiency virus type 2 infection. J Virol, 2007. 81(22): p. 
12685-8. 
22. Soares, R.S., et al., Cell-associated viral burden provides evidence of ongoing viral replication in 
aviremic HIV-2-infected patients. J Virol, 2011. 85(5): p. 2429-38. 
23. Chiara, M., et al., Characteristics, immunological response & treatment outcomes of HIV-2 
compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. Indian J Med Res, 2010. 132(6): p. 
683-9. 
24. van der Ende, M.E., et al., Clinical, immunological and virological response to different 
antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS, 2003. 17 Suppl 3: p. S55-
61. 
25. Azevedo, R.I., et al., IL-7 sustains CD31 expression in human naive CD4+ T cells and 
preferentially expands the CD31+ subset in a PI3K-dependent manner. Blood, 2009. 113(13): p. 
2999-3007. 
26. Albuquerque, A.S., et al., Rate of increase in circulating IL-7 and loss of IL-7Ralpha expression 
differ in HIV-1 and HIV-2 infections: two lymphopenic diseases with similar hyperimmune 
activation but distinct outcomes. J Immunol, 2007. 178(5): p. 3252-9. 
27. Soares, M.V., et al., IL-7-dependent extrathymic expansion of CD45RA+ T cells enables 
preservation of a naive repertoire. J Immunol, 1998. 161(11): p. 5909-17. 
 
Chapter 3: Results 
3.4. Naïve CD4
+








Manuscript in preparation: 
 
 
Rita Tendeiro, Russell B. Foxall, Rui S. Soares, Emília Valadas, Perpétua Gomes, Rui M. 
M. Victorino, Ana E. Sousa. Preserved naïve CD4+ T-cell ability to proliferate upon IL-7 







This work was supported by grant (PTDC/SAU-MIC/109786/2009) from “Fundação 
para a Ciência e a Tecnologia” (FCT) and by “Programa Operacional Ciência e Inovação 
2010” (POCI2010), as well as by Fundação Calouste Gulbenkian to AES. RT, RBF and 
RSS received scholarships from FCT. 
3.4. Preserved naïve CD4+ T-cell ability to proliferate upon IL-7 
stimulation distinguishes HIV-2 from HIV-1 infection 
 
166 HIV-2 immunopathology: 
how the immune system deals with long-lasting infection 
 
Abstract 
Strategies to preserve and/or recover naïve CD4+ T cells are considered critical 
in helping achieve immune-competence in HIV infection. The maintenance of the 
naïve compartment after thymic export largely relies on IL-7 induced cell proliferation, 
which preferentially expands the CD31+ subset that includes recent thymic emigrants 
(RTE). We investigated here how IL-7 responsiveness disturbances impact upon naïve 
CD4+ T-cell homeostasis in HIV/AIDS.  
Our results revealed that distinct mechanisms contributed to naïve CD4+ T-cell 
maintenance in HIV-2 and HIV-1 infections. HIV-2+ patients, typically characterized by 
a much slower CD4+ T-cell decline and reduced viremia, featured a significant over-
representation of the CD31+ subset within cycling naïve CD4+ T cells, both in relation 
to age-matched HIV-1+ and seronegative individuals. Furthermore, when naïve CD4+ T 
cells from HIV-2+ patients were cultured in the presence of IL-7, their ability to 
proliferate was well-preserved. This was not the case for HIV-1+ patients, whose naïve 
CD4+ T cells, particularly the CD31+ subset, featured impaired IL-7-mediated 
proliferative responses. These differences were neither related to CD127 expression 
nor circulating IL-7 levels. 
Overall, we provide evidence supporting a sustained ability of naïve CD4+ T 
cells to proliferate in response to IL-7 in HIV-2+ individuals. The identification of the 
mechanisms underlying the differences in IL-7 responsiveness in the two HIV 
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HIV infection is characterized by progressive CD4+ T-cell depletion [1], 
eventually leading to immunological failure and, ultimately, death. This depletion 
involves not only memory CD4+ T cells, the main targets of HIV infection, but also 
naïve cells, including recent thymic emigrants (RTE) [2]. 
The maintenance of the peripheral CD4+ T-cell pool is known to depend on a 
continuous replenishment from the thymus that is constrained by the age-related 
decline in thymopoiesis [3]. Moreover, increasing evidence points to an important role 
of naïve T-cell proliferation in the establishment and preservation of the peripheral 
naïve CD4+ T-cell compartment [4, 5]. 
Studies have shown that, during HIV-1 infection, naïve CD4+ T cells are 
preferentially depleted in lymphoid tissues [6-8], indicating a disturbance in naïve T-
cell homeostasis. Hence, elucidation of the processes underlying naïve CD4+ T-cell 
homeostasis during HIV disease is required, in order to better understand HIV/AIDS 
pathogenesis, and for the development of new strategies to enhance the quality of 
immune reconstitution following anti-retroviral therapy (ART). 
When leaving the thymus, mature naïve CD4+ T cells, also known as RTE, 
feature high levels of T-cell receptor excision circles (TREC) and express the surface 
marker platelet endothelial cell adhesion molecule-1 (PECAM-1, or CD31) [9]. 
Maintenance of naïve CD4+ T cells in the periphery relies on a significant degree of 
homeostatic proliferation, which is thought to involve both self-peptide/MHC-TCR 
interactions and IL-7, a member of the common γ chain (γc) cytokine family [10]. We 
have recently reported that IL-7 preferentially expands the CD31+ subset of naïve CD4+ 
T cells in healthy adults [11]. Moreover, although the loss of CD31 expression is 
thought to be linked to cell cycling, we have shown that cells proliferating in response 
to IL-7 preserve CD31 expression [11]. Additionally, IL-7 was observed to maintain, or 
even increase, the levels of CD31 expression on non-proliferating cells [11]. Thus, it is 
likely that IL-7 plays a crucial role in the maintenance of CD31+ naïve CD4+ T cells 
during adulthood, thereby helping to sustain TCR diversity within CD4+ T cells. Of note, 
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HIV-1 infection has been associated with functional defects in naïve T cells, namely 
decreased IL-7Rα chain expression [12, 13] and impaired responsiveness to IL-7 
stimulation [14-16] despite the increased serum IL-7 levels [17]. 
HIV-2 infection, a naturally-occurring form of attenuated HIV disease, is 
characterized by a very slow rate of CD4+ T-cell depletion [18], undetectable to low 
levels of circulating virus [19], and a generally more “benign” disease course [20].  
Here we hypothesize that the slower HIV-2 disease progression is related to a 
better ability of HIV-2+ individuals to replenish their naïve CD4+ T-cell pool from early 
in the infection. Previous data from our group indicated that HIV-2+ individuals may 
feature a better preserved response to γc cytokines [21-23]. Specifically, we have 
shown that, in comparison with their HIV-1+ counterparts, HIV-2+ individuals feature a 
delayed increase in IL-7 levels during disease progression, and a better preservation of 
the IL-7Rα chain expression, particularly in the naïve CD4+ T-cell pool [21], suggesting 
a maximization of available resources in the context of this disease. 
We found that HIV-2+ patients presented a significant over-representation of 
CD31+ cells within the ex vivo pool of cycling naïve CD4+ T cells relative to HIV-1+ and 
seronegative individuals. Furthermore, when naïve CD4+ T cells from HIV-2+ patients 
were cultured in the presence of IL-7, their ability to proliferate in response to 




Studied cohorts were specifically designed in order to include age-matched, 
untreated HIV-1+ and HIV-2+ individuals, in early stage disease (more than 300 CD4+ T 
cells/µl), with no ongoing opportunistic infections or tumors. Table 1 depicts the 
epidemiological and clinical characteristics of the 11 HIV-2+ and 9 HIV-1+ individuals 
studied, as well as of the 9 age-matched seronegative controls. Written consent was 
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obtained for blood sampling and processing. The study was approved by the Ethical 
Board of the Faculty of Medicine of Lisbon. 
 
Table 1. Clinical and epidemiological data of the studied cohorts. 
 Seronegatives HIV-1 HIV-2 
Numbers (male/female) 9 (4/5) 9 (6/3) 11 (2/9) 
Age (years) 43±3 (32-57) 46±4 (25-63) 52±3 (33-66) 
Ethnicity 
(caucasian/other) 
9/0 6/3 7/4 
% CD4
+
 T cells 45.6±3.1 (26.2-58.2) 25.4±3.3 (18.0-50.1)** 30.5±2.4 (16.8-45.7)** 
CD4
+















 in CD8 5.5±1.5 (1.5-12.9) 31.1±5.1 (13.5-54)*** 15.8±2.7 (6.3-35.9)**/# 








Data are Mean±SEM with limits in brackets, unless indicated otherwise. NA, Not applicable. Statistical 
differences between a given HIV infected cohort and seronegative controls: *, p < 0.05; **, p < 0.01; 
***, p < 0.001. Statistical differences between HIV-1 and HIV-2 infected individuals: #, p < 0.05.
 
a




 cells, in a lymphocyte gate of whole PBMC, according to 
forward and side scatter characteristics, which were confirmed to be CD27
+
 in all individuals. 
 
PBMC isolation and naïve CD4+ T-cell purification 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh 
heparinised venous blood by density gradient centrifugation on Ficoll-Paque PLUS (GE 
Healthcare, Sweden), as previously described [24]. Immunomagnetic separation of 
untouched naïve CD4+ T cells from PBMC was performed, according to the 
manufacturer’s instructions (Human Naïve CD4+ T-cell Enrichment Kit, StemCell 
Technologies, France). Sorted naïve CD4+ T-cell purity was assessed by flow cytometry 
within a lymphocyte gate, defined by forward and side scatter characteristics (mean 
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frequency  of CD4+CD45RA+ cells was 95±1% for seronegatives, 92±1% for HIV-1+ 
individuals, and 94±1% for HIV-2+ patients). 
 
Cell cultures 
Purified naïve CD4+ T cells were cultured at 1x106 cell/ml in round-bottom 96-
well plates in RPMI1640 supplemented with 100 U/ml penicillin/100 µg/ml 
streptomycin, 2 mM glutamine (all from Gibco-Invitrogen, U.K.) and 10% human AB 
serum (Sigma-Aldrich), in the presence of either IL-7 (10 ng/ml) or IL-2 (20 U/ml), at 
37ºC with 5% CO2, for seven days. Cells were re-fed with medium supplemented with 
the appropriate cytokine at the indicated concentration after three days of culture, 
and harvested on day 7 for subsequent flow cytometric analysis. 
 
Flow cytometry 
Surface and intracellular staining were performed as previously described [11, 
24], using combinations of the following monoclonal antibodies (clone and 
manufacturer specified in brackets): FITC-conjugated CD4 (RPA-T4, eBiosciences, USA), 
CD45RA (HI100, eBiosciences, USA), HLA-DR (L243, BD Biosciences, USA), and Bcl-2 
(124, Dako, Denmark); PE-conjugated CD38 (HB7, eBiosciences, USA), CD95 (DX2, 
eBiosciences, USA), CD127 (40131, R&D systems, USA) and Ki-67 (B56, BD Biosciences, 
USA); PerCP-conjugated CD3 (OKT3, eBiosciences, USA), CD4 (SK3, eBiosciences, USA), 
and CD45RA (HI100, eBiosciences, USA); PE-Cy7 CD27 (O323, eBiosciences, USA); APC-
conjugated CD8 (RPA-T8, eBiosciences, USA) and CD31 (WM59, eBiosciences, USA); 
APC.Cy7-conjugated CD3 (SK7, BD Biosciences, USA), CD4 (RPA-T4, BD Biosciences, 
USA) and CD8 (SK1, BD Biosciences, USA). Briefly, for surface staining, cells were 
suspended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin 
(BSA; Sigma-Aldrich) and 0.1% sodium azide (Sigma-Aldrich), stained with monoclonal 
antibodies (mAb) for 20 minutes in the dark at room temperature, extensively washed 
and fixed with 1% formaldehyde (Sigma-Aldrich). Intracellular staining for Bcl-2 and Ki-
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67 was performed using fixation and permeabilization reagents from eBiosciences. 
Annexin V staining was performed using the Annexin V-FITC Apoptosis Detection Kit I 
(BD Biosciences), according to the manufacturer’s instructions, and acquisition was 
performed within one hour of the protocol’s completion. Samples were acquired with 
a FACSCanto or a FACSCAlibur flow cytometer (both from BD Biosciences), and 
analyzed using FlowJo software (Tree Star, Ashland, OR). At least 50,000 or 100,000 
events were acquired for each sample (on FACSCalibur or FACSCanto, respectively). 
 
Serum IL-7 levels quantitation 
IL-7 levels were assessed in serum samples, collected after centrifugation of 
freshly drawn blood and stored at -80ºC until use, with the commercially available 
Quantikine HS ELISA kit, according to the manufacturer’s instructions (R&D systems). 
All samples were assayed in duplicate. 
 
sjTREC quantification by real-time PCR 
Isolated naïve CD4+ T cells were lysed with proteinase K (Qiagen, Valencia, CA), 
in a proportion of 20 µl of proteinase K to 5x106 cells, in order to obtain genomic DNA. 
Signal-joint TREC (sjTREC) were quantified by nested real-time PCR using Power SYBR 
Green PCR Master Mix (Applied Biosystems) and ABI PRISM 7500 FAST Sequence 
Detection System (Applied Biosystems). Specific primers and probes were used for 
sjTREC and CD3γ, used as a housekeeping gene for absolute quantification of sjTREC 
levels, as follows: sj-out5 5’-CTC TCC TAT CTC TGC TCT GAA-3’; sj-out3 5’-ACT CAC TTT 
TCC GAG GCT GA-3’; sj-in5 5’-CCT CTG TCA ACA AAG GTG AT-3’; sj-in3 5’-GTG CTG GCA 
TCA GAG TGT GT-3’; CD3-out5 5’-ACT GAC ATG GAA CAG GGG AAG-3’; CD3-out3 5’-
CCA GCT CTG AAG TAG GGA ACA TAT-3’; CD3-in5 5’-GGC TAT CAT TCT TCT TCA AGG T-
3’; CD3-in3 5’-CCT CTC TTC AGC CAT TTA AGT A-3’; sj-Probe1 5’-AAT AAG TTC AGC CCT 
CCA TGT CAC ACTf-3’; sj-Probe2 5’-XTG TTT TCC ATC CTG GGG AGT GTT TCAp-3’; CD3-
Probe1 5’-GGC TGA AGG TTA GGG ATA CCA ATA TTC CTG TCT Cf-3’; CD3-Probe2 5’-XCT 
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AGT GAT GGG CTC TTC CCT TGA GCC CTT Cp-3’. The pCD3-TREC plasmid was kindly 
provided by Rémy Cheynier (Institute Cochin, Paris). 
 
Plasma viral load and proviral DNA assessment 
HIV-1 plasma viral load (viremia) was quantified by a reverse transcriptase PCR 
(RT-PCR) assay with a detection threshold of 40 RNA copies/ml (Roche, Basel, 
Switzerland). HIV-2 viremia was quantified using a previously described in-house-
developed assay [25] with a detection threshold of 40 RNA copies/ml. The cut-off 
values of these tests were considered for statistical analysis, in cases where values 
were below these detection levels. Cell-associated HIV-1 and HIV-2 total viral DNA 
(integrated and nonintegrated viral DNA species) was quantified using real-time PCR 
assays that amplify highly conserved regions in HIV-1 and HIV-2 gag, with a detection 




Statistical analysis was performed using GraphPad Prism v5.00 (GraphPad 
Software Inc., San Diego, CA). Results are presented as arithmetic mean±SEM. Data 
were compared using Mann-Whitney or Wilcoxon tests, as appropriate. Spearman’s 
correlation coefficient was used to determine association between two parameters. P-
values <0.05 were considered significant. 
 
Results 
Ex-vivo analysis of naïve CD4+ T cells in HIV-1+ and HIV-2+ individuals 
In order to investigate naïve CD4+ T-cell homeostasis, we studied HIV+ 
individuals in early stage disease as a means to avoid potentially confounding 
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immunopathologic factors associated with advanced HIV infection and to identify 
mechanisms that may help slow the rate of CD4+ T-cell decline. In agreement with this 
strategy, recent data suggested that measuring peripheral naïve CD4+ T cells from 
HIV+ individuals at earlier stages of disease may identify those at higher risk for poor 
CD4+ T-cell reconstitution [27], supporting that even early disturbances in the naïve 
CD4+ T-cell pool may impact on the rate of disease progression. Additionally, only the 
study of early stage HIV+ individuals would allow the isolation of sufficient naïve CD4+ 
T cells from peripheral blood required to perform this type of study. Therefore, all HIV 
infected subjects had more than 300 CD4+ T cells/μl and were therapy-naïve. Age-
matched HIV-2 (n=11), HIV-1 (n=9), and seronegative (n=9) cohorts (Table 1) were 
studied to elucidate whether slower HIV-2 disease progression could be related to a 
better ability of HIV-2+ individuals to preserve their naïve CD4+ T-cell pool. 
Notwithstanding the distinct levels of viral load in HIV-2+ and HIV-1+ 
individuals (all undetectable viremia vs. all viremic, respectively), the two cohorts 
featured similarly increased levels of T-cell activation (Table 1). This is in agreement 
with our previous data showing that CD4+ T-cell depletion is more directly associated 
with T-cell activation than viral load both in HIV-2 and HIV-1 infections [28]. Moreover, 
although HIV-2+ individuals were expected to have been infected for a much longer 
period of time than their HIV-1+ counterparts [18], the frequencies of total and naïve 
CD4+ T cells were similar in both HIV cohorts (Table 1). However, HIV-1+ patients had 
significantly higher ex vivo frequencies of cycling naïve CD4+ T cells (assessed by Ki-67 
expression, Figures 1A and 1B), as compared to both age-matched HIV-2+ individuals 
and seronegative controls. Importantly, the specific contribution of the CD31+ subset, 
which is enriched in RTE, to this pool of cycling naïve CD4+ T cells was significantly 
lower in HIV-1+ than HIV-2+ individuals, the latter also presenting an increased 
proportion of cycling CD31+ naïve CD4+ T cells in relation to seronegative controls 
(Figure 1C). Of note, no significant differences were observed in circulating IL-7 levels 
in the two infected cohorts (HIV-1+, n=9: 16.61±1.65 pg/ml; HIV-2+, n=10: 13.62±1.60 
pg/ml). 
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Figure 1. Ex vivo frequency of cycling naïve CD4
+
 T cells in early HIV-2 and HIV-1 infection. (A) 
Illustrative dot-plots of the expression of the cell cycling marker Ki-67 and of CD31 expression on gated 
naïve CD4
+
 T cells analysed ex vivo. Representative HIV+ individuals presented similar CD4
+
 T-cell counts 
(HIV-1: 546 CD4
+
 T cells/μl; HIV-2: 635 CD4
+
 T cells/μl), but distinct viremia (HIV-1: 49 918 RNA 
copies/ml; HIV-2: undetectable). (B) Frequency of Ki-67
+
 cells within total naïve CD4
+
 T cells in HIV-2, 
HIV-1 and seronegative cohorts. (C) Frequency of CD31
+




 T cells in the 
same cohorts. Each dot represents one individual, bars represent mean. Data were compared using 
Mann-Whitney tests. P-values <0.05 were considered significant and are indicated. 
 
Overall, these results suggest that, despite a similar frequency of naïve CD4+ T 
cells in early stage HIV-1 and HIV-2 infection, the mechanisms underlying the 
maintenance of the naïve CD4+ T-cell pool appear distinct. Whilst HIV-1+ patients 
apparently relied on extensive cell cycling, including that of the CD31 subset, in HIV-2 
disease a preferential proliferation of RTE-enriched CD31+ cells, likely mediated by IL-
7, in association with the expected better preserved thymic output [29], contributed 
to naïve CD4+ T-cell preservation.  
 
Naïve CD4+ T cells from HIV-2+ individuals featured a better preserved 
proliferative response to IL-7 upon in vitro stimulation 
To elucidate the role of IL-7-induced proliferation in the maintenance of naïve 
CD4+ T cells during HIV infection, these cells were isolated from early stage HIV-1+ and 
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HIV-2+ patients, and seronegative controls, and cultured for seven days in the 
presence of IL-7. In parallel, cells were cultured with IL-2 as a control, given the high 
rates of purified naïve CD4+ T-cell death in culture without cytokines. Cells were 
harvested on day 7, and flow cytometry analysis confirmed the maintenance of a 
naïve phenotype throughout culture both with IL-7 and IL-2. Cell recovery of live cells, 
assessed by direct cell count via trypan blue dye exclusion, was higher for cells 
cultured in the presence of IL-7 in all cohorts (data not shown), in agreement with 








Figure 2. Ability of naïve CD4
+
 T cells to proliferate in vitro in response to IL-7 stimulation in early HIV-
2 and HIV-1 infection. (A) Illustrative dot-plots of the expression of the cell cycling marker Ki-67 and of 
CD31 expression on cultured naïve CD4
+
 T cells. Representative HIV+ individuals presented similar CD4
+
 
T-cell counts (HIV-1: 546 CD4
+
 T cells/μl; HIV-2: 635 CD4
+
 T cells/μl), but distinct viremia (HIV-1: 49 918 
RNA copies/ml; HIV-2: undetectable), at the time of sampling. (B) Frequency of Ki-67
+
 cells within total 
naïve CD4
+
 T cells upon 7 days of culture in the presence of IL-7 (black dots) or IL-2 (grey) in HIV-2, HIV-1 
and seronegative cohorts. Each pair of connected grey and black dots corresponds to one individual. 
Inter- and intra-cohort data were compared using Mann-Whitney or Wilcoxon tests, respectively. P-
values <0.05 were considered significant and are indicated. 
 
As illustrated in Figure 2, naïve CD4+ T cells from HIV-2+ individuals featured a 
preserved IL-7 responsiveness in terms of cycling, which was similar to that of age-
matched seronegatives. In contrast, naïve CD4+ T cells from HIV-1+ individuals 
featured an overall decreased ability to expand in response to IL-7 in comparison to 
seronegative controls (p=0.0503). Notably, the distinct ability to respond upon in vitro 
IL-7 stimulation was not apparently related to the basal levels of IL-7Rα (CD127) 
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expression on naïve CD4+ T cells, since these were not significantly different in the two 
infected cohorts with early stage disease (MFI of CD127: 78.62±1.26, n=9 HIV-1+ 
subjects; 75.32±4.02, n=10 HIV-2+ subjects). 
These findings suggest a better preserved response to γc cytokines in the 
context of HIV-2 infection, which may be related to the slower CD4+ T-cell depletion 
and more “benign” disease course that characterize this infection. 
 
Similar impact of IL-7 stimulation on anti- and pro- apoptotic molecules in 
naïve CD4+ T cells from HIV-2+ and HIV-1+ individuals 
One of the main functions of IL-7 is the promotion of cell survival through the 
up-regulation of the anti-apoptotic molecule Bcl-2 [30]. Nevertheless, IL-7 has also 
been shown to up-regulate Fas (CD95) expression and, in this way, promote cell death 
[31, 32]. In order to further investigate these processes in the context of early stage 
HIV disease, the expression of Bcl-2 and CD95 was assessed. 
As shown in Figure 3A (left and middle graphs, respectively), although no 
significant inter-cohort differences were observed in the ex vivo expression of Bcl-2, 
the frequency of CD95-expressing naïve CD4+ T cells tended to be increased in both 
HIV cohorts, although only reaching significance relative to age-matched 
seronegatives for HIV-1+ individuals. Of note, the ex vivo balance of anti- vs. pro-
apoptotic factors resulted in only a borderline increase in the overall frequency of 
early apoptotic and dead naïve CD4+ cells, evaluated as the percentage of Annexin V+ 
cells, in the HIV-1 cohort (Figure 3A, right-hand graph), which did not reach statistical 
significance. 
All cohorts showed a preserved ability to up-regulate Bcl-2 and CD95 
expression on naïve CD4+ T cells upon IL-7 stimulation (Figure 3B, left and middle 
graphs, respectively). Moreover, there were no differences in the overall frequency of 
Annexin V expression (Figure 3B, graph on the right) which was, as expected, 
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Figure 3. Ex vivo expression of anti- and pro-apoptotic molecules by naïve CD4
+
 T cells and up-
regulation upon IL-7 stimulation in early HIV-2 and HIV-1 infection. Purified naïve CD4
+
 T cells were 
analysed by flow cytometry, both ex vivo (A), and after 7-day culture with either IL-7 or IL-2, as a 
control (B). Naïve cells were characterized in terms of Bcl-2 (graphs on the left) and CD95 expression 
(graphs in the middle). Cell death and commitment to undergo apoptosis was estimated by the total 
percentage of Annexin V
+
 cells (graphs on the right). Each open dot represents one individual; bars 
represent mean. Closed dots represent individuals whose cells were cultured in the presence of IL-7 
(black) or IL-2 (grey). Each pair of connected grey and black dots corresponds to one individual. Inter- 
and intra-cohort data were compared using Mann-Whitney or Wilcoxon tests, respectively. P-values 
<0.05 were considered significant and are indicated. 
 
Taken together, our results suggest that discrepancies in IL-7 responsiveness of 
naïve CD4+ T cells from HIV-2 and HIV-1 cohorts were mainly related to proliferation. 
Our data further support that distinct intracellular signaling pathways are involved in 
IL-7-induced proliferation and up-regulation of anti- and pro-apoptotic factors, which 
are differently affected in HIV-2- and HIV-1-infected individuals. 
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Naïve CD4+ T cells from HIV-2+ individuals showed preserved levels of CD31 
expression and were able to up-regulate CD31 upon IL-7 stimulation 
We have previously shown that CD31+ naïve CD4+ T cells from adults 
preferentially expand in response to IL-7 without a concomitant loss of CD31 
expression, potentially contributing to the maintenance of the naïve CD4+ T-cell 
compartment size and diversity [11]. 
As mentioned above, the contribution of the CD31+ subset to the overall pool 
of cycling naïve CD4+ T cells was found to be significantly increased in the context of 
HIV-2 infection, both in relation to age-matched HIV-1+ and seronegative individuals 
(Figure 1C). This was despite the lack of statistically significant differences observed in 
terms of the ex vivo frequencies of CD31+ cells within total naïve CD4+ T cells in both 
cohorts (Figure 4A). Nevertheless, when the density of CD31 molecules per cell 
(assessed as Mean Fluorescence Intensity, MFI) was evaluated within the CD31+ naïve 
CD4+ T-cell population, significantly lower levels were found in HIV-1+ patients, as 
compared to both HIV-2+ and seronegative individuals (Figure 4B). This may in part be 
related to the significant reduction in CD31bright cell frequency within the naïve CD4+ T-
cell pool observed in HIV-1+ (22.4±2.3%; p=0.040), but not HIV-2+ individuals 
(30.9±2.5%; p=0.790), in comparison to age-matched seronegative controls 
(31.1±3.3%). As it has been demonstrated that the CD31bright naïve CD4+ T-cell subset 
includes the majority of RTE [33], our observations may indicate impaired thymic 
output even in early HIV-1 disease. RTE are known to express high levels of sjTRECS 
[29]. We quantified sjTREC levels in purified naïve CD4+ T cells, and found  no 
significant inter-cohort differences (seronegatives: 2261±741; HIV-1+: 1463±353; HIV-
2+: 1508±475 sjTREC/105 naïve CD4+ T cells). Of note, no correlations were found 
between sjTREC levels and CD31bright frequency in naïve CD4+ T cells in any cohort 
(data not shown). However, we observed significant positive correlations between 
sjTREC levels in naïve CD4+ T cells and both the percentage of circulating naïve CD4+ T 
cells and the frequency of CD31+ cells within naïve CD4+ T cells in HIV-1+ patients 
(r=0.7167, p=0.0298; and r=0.8000, p=0.0096, respectively), suggesting a possible 
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preferential incorporation of RTE in the peripheral naïve CD4+ T-cell pool in the 
context of HIV-1 infection. 
Thus, despite the evidence of an apparent incorporation of RTE in the naïve 
CD4+ T-cell pool in HIV-1+ individuals, their levels of CD31 were significantly reduced, 












Figure 4. The CD31
+
 subset of naïve CD4
+
 T cells in early HIV-2 and HIV-1 infection. Purified naïve CD4
+
 
T cells characterized in terms of the relative frequency of CD31
+
 cells (A) and the amount of CD31 
expression per CD31
+
 cell (assessed as mean fluorescence intensity, MFI) (B). Graphs on the left refer to 
the assessment of these parameters ex vivo, with those on the right indicating their variation from the 
basal values (white bars) upon 7-day stimulation with either IL-7 (black bars), or IL-2 (grey bars). Each 
dot represents one individual; bars represent mean. Inter- and intra-cohort data were compared using 
Mann-Whitney or Wilcoxon tests, respectively. P-values <0.05 were considered significant and are 
indicated. 
 
Our group has previously reported that IL-7 increases the levels of CD31 
expression on CD31+ naïve CD4+ T cells from healthy subjects, without inducing its 
expression on their CD31 counterparts [11]. We found a statistically significant 
increase in the levels of CD31 expression within CD31+ cells upon IL-7 stimulation in 
HIV-2+ patients (Figures 4A and 4B). 
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Overall, our data supported a maintained response to IL-7 in vivo and in vitro in 
HIV-2 infection. 
 
Limited contribution of IL-7 to the extensive cycling of naïve CD4+ T cells 
observed in early HIV-1 infection 
We have previously shown that HIV-2+, as compared to HIV-1+ individuals, 
have better preserved thymic function [29], despite the fact that they have, most-
likely, been infected for a longer period of time [18]. Thus, it is possible that these 
individuals preferentially compensate for naïve CD4+ T-cell loss through increased 
CD4+ T-cell production and/or maintenance of RTE cells within the naïve CD4+ T-cell 
pool; whereas naïve CD4+ T-cell homeostasis in HIV-1+ patients may be more reliant 
on extensive peripheral expansion. A concomitant and pronounced loss of the 
CD31bright subset would suggest this extensive proliferation to be mainly IL-7-
indpendant. 
In agreement with this hypothesis, HIV-1+ patients had significantly higher ex 
vivo frequencies of cycling CD31+ and CD31 naïve CD4+ T cells, as compared to HIV-2+ 
individuals (Figures 5A and 5B, respectively). Furthermore, direct correlations were 
found between the cycling of CD31 naïve CD4+ T cells and both viremia (r=0.7500, 
p=0.0199) and T-cell activation (CD4: r=0.8000, p=0.0096; CD8: r=0.7833; p=0.0125) in 
HIV-1 infection. 
These data suggest a marked loss of CD31 expression during extensive 
proliferation of naïve CD4+ T cells, as well as additionally increased 
proliferation/differentiation of the CD31 subset, probably via self-peptides-MHC 
stimulation, in the context of HIV-1, but not HIV-2 infection. Of note, proviral DNA in 
purified naïve CD4+ T cells was only detectable in HIV-1+ individuals (270±51 
copies/106 naïve CD4+ T cells, n=3 out of 9 patients). 
On the other hand, only HIV-2+ individuals featured a direct correlation 
between naïve CD4+ T-cell cycling and CD31 MFI within the CD31+ population 
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(r=0.7545, p=0.0073), suggesting that this particular, RTE-enriched, subset is relevant 
for the maintenance of naïve CD4+ T cells in this infection, probably through IL-7-












Figure 5. Cell cycling of naïve CD4
+
 T-cell subsets defined according to CD31 expression in early HIV-2 
and HIV-1 infection. Purified naïve CD4
+
 T cells characterized in terms of the relative frequency of 
cycling cells (assessed as those expressing Ki-67
+
) within the CD31
+
 (A) and CD31 (B) subsets. Graphs 
on the left refer to this characterization ex vivo, with those on the right indicating their variation from 
the basal values (white bars) upon 7-day stimulation with either IL-7 (black bars), or IL-2 (grey bars). 
Each dot represents one individual; bars represent mean. Inter- and intra-cohort data were compared 
using Mann-Whitney or Wilcoxon tests, respectively. P-values <0.05 were considered significant and are 
indicated. 
 
Importantly, although some degree of proliferation was observed in CD31 
cells in response to IL-7, the CD31+ subset was the one found to preferentially cycle in 
response to this cytokine in all cohorts. However, this capacity was significantly 
reduced in HIV-1+ patients in relation to seronegative controls, whilst being 
maintained in the HIV-2 cohort (Figures 5A and 5B). Of note, both CD31+ and CD31 
naïve CD4+ T-cell subsets featured similar up-regulation of Bcl-2 and CD95 in all 
cohorts (Figure 6), supporting the impact of IL-7 on survival/apoptotic pathways in 
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Figure 6. Expression of anti- and pro-apoptotic molecules in naïve CD4
+
 T cell subsets defined 
according to CD31 expression in early HIV-2 and HIV-1 infection. Purified naïve CD4
+
 T cells were gated 
according to CD31 expression: CD31
+
 (A) and CD31
 
(B); and characterized in terms of Bcl-2 (graphs on 
the left) and CD95 expression (graphs in the middle). Cell death and commitment to undergo apoptosis 
was estimated by the total percentage of Annexin V
+
 cells (graphs on the right). Graphs refer to the 
evaluation of these parameters both ex vivo (white bars), and after 7-day stimulation with either IL-7 
(black bars), or IL-2 (grey bars). Due to cell availability, CD95 expression and Annexin V
+
 cell frequency 
were only assessed in sub-groups of age-matched individuals (7/9 seronegatives; 9/9 HIV-1+ and 10/11 
HIV-2+ for the ex vivo characterization; 7/9 seronegatives; 8/9 HIV-1+ and 7/11 HIV-2+ for the analysis 
upon culture in the presence of cytokines). Bars represent mean±SEM. Inter- and intra-cohort data 
were compared using Mann-Whitney or Wilcoxon tests, respectively. P-values <0.05 were considered 
significant and are indicated. 
 
Our results suggest that, in HIV-2 infection, naïve CD4+ T-cell homeostasis was 
maintained by a combination of preserved thymic output [29] and the preferential IL-
7-mediated homeostatic proliferation of CD31+ naïve CD4+ T-cell subset. Conversely, in 
HIV-1 infection, the maintenance of the naïve CD4+ T-cell compartment appeared to 
rely on extensive peripheral proliferation, with a significant contribution of the CD31 
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subset, probably via self-peptides-MHC stimulation, although a direct contribution of 
HIV-1 antigenemia cannot be excluded. 
 
Discussion 
We found that distinct mechanisms underpinned the maintenance of naïve 
CD4+ T cells in early stage HIV-1 and HIV-2 infections. HIV-2+ patients featured a 
significant over-representation of RTE-enriched CD31+ cells within the ex vivo pool of 
cycling naïve CD4+ T cells, both relative to seronegative and HIV-1+ individuals. Of 
note, as this occured in the presence of sustained CD31 expression levels, it suggested 
a role for IL-7, given its ability to induce the proliferation of the CD31+ subset and to 
sustain/increase CD31 expression [11]. The HIV-1 cohort featured a significantly higher 
frequency of cycling naïve CD4+ T cells, with a significant involvement of the CD31 
subset. These ex-vivo data support distinct abilities to respond to IL-7 in the two 
infections, which were confirmed in vitro in cultures of purified naïve CD4+ T cells with 
IL-7 or IL-2. Naïve CD4+ T cells from HIV-2+ individuals were better able to proliferate 
and to up-regulate CD31 upon in vitro stimulation with IL-7. Of note, a similar impact 
of IL-7 stimulation on anti- and pro- apoptotic molecules were observed in naïve CD4+ 
T cells from HIV-2+ and HIV-1+ individuals. 
We have previously shown that IL-7 preferentially expands the CD31+ naïve 
CD4+ T-cell subset, without concomitant loss of CD31 expression [11], thus helping 
maintain the size and diversity of the naïve CD4+ T-cell pool during adulthood. 
Moreover, our previous report of a delayed increase in IL-7 levels, and a better 
sustained IL-7Rα chain expression, particularly in the naïve CD4+ T-cell pool, during 
HIV-2 disease progression [21], suggested that HIV-2+ individuals may have a 
sustained ability to respond upon IL-7 stimulation. In agreement with this possibility, 
only HIV-2+, and not HIV-1+ patients, featured preserved proliferative responses of 
naïve CD4+ T cells, and in particular of the CD31+ subset, to IL-7 stimulation in relation 
to age-matched seronegative controls. 
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Of note, the studied cohorts showed no differences in naïve CD4+ T-cell ability 
to up-regulate anti- and pro-apoptotic factor expression upon IL-7 stimulation.  
After binding to its receptor, IL-7 signals via both Jak/STAT5 and PI3K/Akt 
pathways, with STAT5 acting both directly as a transcription factor, and indirectly by 
triggering additional PI3K pathway-dependent signaling [34]. The two pathways 
interact to promote T-cell survival and proliferation [30, 35]. Nevertheless, a number 
of studies have provided evidence that IL-7-induced proliferation is critically 
dependent on PI3K activity [11, 35, 36]. Defects in IL-7 responsiveness due to 
disturbances in the Jak/STAT5 signaling pathway have been extensively reported in 
HIV-1 infection [14-16, 37, 38]. As the survival and proliferation effects of IL-7 on 
human RTEs have been shown to be distinguished on the basis of dose [35], it is 
possible that STAT5 signaling impairment, and consequent PI3K under-stimulation, in 
HIV-1 disease, translate into lower levels of IL-7-mediated signaling. This may help 
explain our data indicating that discrepancies in naïve CD4+ T cell IL-7 responsiveness 
in the HIV-2 and HIV-1 cohorts were mainly related to proliferation. Hence, the study 
of how distinct intracellular pathways involved in IL-7 responsiveness are affected 
during HIV-2 and HIV-1 disease is a subject warranting further investigation. Taken 
together, our results suggest that, in early HIV-2 infection, preservation of the naïve 
CD4+ T-cell pool largely relies on the maintenance of an RTE-enriched population in 
the periphery via preferential IL-7-mediated homeostatic proliferation. 
On the other hand, in early HIV-1 infection, the high levels of viremia, and thus 
large amounts of circulating antigen, potentially cause increased pressure on the naïve 
CD4+ T-cell compartment, forcing naïve cells to enter the memory pool at a higher 
rate. 
Nevertheless, as previously mentioned, comparable frequencies of naïve CD4+ 
T cells were documented for HIV-1 and HIV-2 infections. Moreover, we found no 
significant differences in the naïve CD4+ T cell sjTREC levels between cohorts, despite 
the higher levels of cycling reported in HIV-1 infection. As the measurement of sjTREC 
levels is known to be affected by their progressive dilution during peripheral cell 
proliferation [39], our observations may indicate a preferential incorporation of RTE 
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(with high sjTREC content) in the peripheral naïve CD4+ T-cell pool in the context of 
HIV-1 infection, which will then help sustain the naïve CD4+ T-cell pool via extensive 
proliferation. In agreement, significant positive correlations between sjTREC levels in 
naïve CD4+ T cells and both the percentage of circulating naïve CD4+ T cells and the 
frequency of CD31+ cells within naïve CD4+ T cells were exclusive to the HIV-1 cohort. 
The dynamics of human RTE incorporation into the peripheral naïve T-cell pool 
remains unclear [5]. However, it is possible that, in agreement with recently published 
data [40], new CD4+ T cells are preferentially incorporated into the depleted 
peripheral naïve CD4+ T-cell pool in HIV-1+ infection increasing the average sjTREC 
content even in the presence of a reduction in thymic output [41, 42]. In the future it 
will be relevant to investigate possible reasons for a putative lower rate of 
incorporation of RTE in HIV-2+ individuals. Data from our group showed that, HIV-2+ 
but not HIV-1+ individuals were able to maintain thymic production, as assessed by 
the ratio of sj/βTREC, for prolonged periods of time, even after 45 years of age 
comparable levels of sjTREC were found in the two infections [29]. Importantly, 
although thymic output was not formally evaluated in our HIV-1 cohort, the 
significantly reduced frequencies of CD31bright naïve CD4+ T cells that were observed in 
these individuals, argue against it playing a major role in naïve CD4+ T-cell 
maintenance. 
In contrast to HIV-2 infection, naïve CD4+ T-cell homeostasis in early HIV-1 
infection seemed to be highly dependent on the extensive proliferation of CD31, and 
not CD31+, cells. It is likely that this increased cell cycling results from low-affinity self-
peptide-MHC interactions, a process that can result in the loss of CD31 expression 
and, thus, the preferential expansion of the CD31 naïve T-cell subset. Of note, this 
observation is in agreement with previous data showing that, in the context of thymic 
impairment, CD31+ cells decreased, whilst the CD31 subset was maintained via 
extensive proliferation [43]. Additionally, the increased self-peptide/MHC-induced 
proliferation may be a consequence of the impaired ability to proliferate in response 
to IL-7. These results are particularly relevant given the recently proposed use of IL-7 
therapy in HIV-1 infection [44-46]. 
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Overall, we found a better preserved proliferative response of naïve CD4+ T 
cells to IL-7 stimulation in HIV-2 infection, which could contribute to its 
characteristically slow disease progression. Further investigation of the mechanisms 
underlying the distinct response to IL-7 in the two HIV infections may help in the 
development of new therapeutic strategies aimed at achieving immunological 
competence in HIV-1 infection.   
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Abstract 
Objective: Memory B-cell loss has long been recognized as an important 
contributor to HIV immunodeficiency. HIV-2 infection, which is characterized by a 
slow rate of progression to AIDS and reduced to undetectable viremia, provides a 
unique model to investigate B-cell disturbances. 
Design and Methods: B-cell subsets were evaluated in 38 HIV-2-infected 
individuals, along with markers of T-cell activation and serum levels of 
Immunoglobulins and a major B-cell homeostatic cytokine, B-cell Activating Factor 
(BAFF). Untreated HIV-1-infected and non-infected control subjects were studied in 
parallel. Statistical analysis was performed using Mann-Whitney tests and Spearman’s 
correlations. 
Results: We found that HIV-2 was associated with significant depletion of both 
unswitched (CD27+IgD+) and switched (CD27+IgD) memory B cells that directly 
correlated with T-cell activation, even in individuals with undetectable plasma viral 
load. Nevertheless, the presence of detectable viremia, even at low levels, was 
associated with significant memory B-cell loss and higher BAFF levels. Moreover, these 
alterations were not recovered by antiretroviral-therapy, as treated HIV-2+ patients 
featured more pronounced B-cell disturbances, possibly related to their extended 
length of infection.  
Conclusions: These first data regarding B-cell imbalances during HIV-2 infection 
show that, irrespective of viremia, prolonged HIV infection leads to irreversible 
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HIV-1 infection is associated with progressive impairment of specific humoral 
responses and loss of memory B cells that are only partly recovered by antiretroviral 
therapy (ART) [1-4]. These B-cell disturbances have been linked to the persistent 
heightened state of immune activation associated with HIV-1 infection [3-5]. In fact, 
polyclonal B-cell activation with marked hypergammaglobulinemia is usually observed 
in acute HIV-1 infection [6], persisting throughout the chronic phase of the disease [3, 
5]. HIV-1 proteins, particularly gp120 [7, 8] and Nef [9, 10], have also been shown to 
induce intrinsic B-cell functional defects.  
HIV-2 infection is characterized by a much slower rate of disease progression, 
with low to undetectable viremia, providing a unique naturally-occurring model of 
attenuated disease to investigate B-cell disturbances in HIV pathogenesis. HIV-2 
plasma viral load is usually low to undetectable throughout the entire disease course 
[11, 12]. This low viremia is thought to account for the low transmission rates [13, 14], 
contributing to the confinement of HIV-2 infection to West Africa and connected 
countries, such as Portugal [15, 16]. Additionally, HIV-2 has limited impact on the 
mortality of infected adults, even in rural West African areas, where its prevalence has 
reached 8-10% [17-19]. In agreement, a prospective study of a French HIV-2 cohort 
has revealed that the rate of CD4+ T-cell decline is, on average, 10 times lower than in 
HIV-1+ individuals, leading to a median time of progression to AIDS of more than 20 
years [20]. 
We have previously shown that, as for HIV-1, CD4+ T-cell depletion is directly 
linked to increased immune activation in HIV-2+ individuals [12, 21]. Moreover, HIV-2 
infection also induces polyclonal B-cell activation, as demonstrated by the frequently 
observed hypergammaglobulinemia [22, 23] and hyperplastic lymph nodes [24]. Of 
note, several studies have suggested a better ability of HIV-2+, in comparison with 
HIV-1+ individuals, to generate and preserve significant levels of circulating HIV-
neutralizing antibodies during the chronic phase of the disease [23, 25-28].  This 
finding is thought to be mainly related to particular conformations of the HIV-2 
envelope proteins that favour triggering of potent neutralizing antibody responses 
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[23, 25-30], although the possibility of a superior function of the B-cell compartment 
in HIV-2+ patients has not been formally evaluated. 
Here we report the first data on memory B-cell imbalances during HIV-2 
infection. We found an unexpected major depletion of both switched and unswitched 
memory B cells not recovered by ART in HIV-2+ individuals, suggesting that, 
irrespective of viremia, prolonged HIV infection leads to irreversible damage of 




The study involved 38 HIV-2+, 20 HIV-1+, and 16 non-infected (Seronegatives) 
individuals. Table 1 details the cohort clinical and epidemiological data. HIV+ patients 
were followed at the Hospital de Santa Maria, Lisbon, and had no ongoing 
opportunistic infections or tumours. All patients gave written informed consent for 
blood sample collection and processing. The study was approved by the Ethical Board 
of the Faculty of Medicine, University of Lisbon. All HIV-1+ individuals were therapy-
naive. The HIV-2 cohort included 10 patients on ART that did not differ significantly 
from the untreated HIV-2+ subjects in respect to viremia and proviral DNA levels 
(Supplemental Table 1). HIV-2+ individuals on ART showed significantly reduced CD4+ 
T cells, both in relation to seronegatives and untreated HIV-2+ patients (Supplemental 
Table 1), in agreement with previous reports on weak virologic and immunological 
responses to ART in HIV-2+ individuals [20, 31].   
 
Plasma viral load and proviral DNA assessment 
HIV viremia was quantified by RT-PCR for both HIV-1+ (detection threshold: 40 
RNA copies/ml, Roche, Basel, Switzerland) and HIV-2+ (detection threshold: 200 RNA 
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copies/ml, as described [31]) individuals. Viremia was, as expected [12, 20, 32], 
significantly lower in HIV-2+ than in untreated HIV-1+ patients (Table 1). 
HIV-1 and HIV-2 total viral DNA (integrated and non-integrated DNA species) 
were quantified, as previously described [33]. Briefly, DNA was extracted from 5x106 
PBMC and total viral DNA was quantified using real-time PCR assays amplifying highly 
conserved regions in HIV-1 and HIV-2 gag (detection range:  7 orders of magnitude; 
sensitivity: 5 copies). Cut-off values of the tests were considered for statistical analysis 
in cases where detection was below these levels. 
 
Table 1. Clinical and epidemiological characteristics of the studied cohorts. 
 
Data are expressed as median, with limits in brackets. Statistical analysis was performed 










P< 0.01 for comparisons between infected cohorts.  
a
A distinct cohort was used for serum BAFF quantification, as described in Figure 3. 
 
Flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated immediately after 
venopuncture by Ficoll-Hypaque density gradient centrifugation (Sigma, St. Louis, MO, 
USA), and surface stained as previously described [34]. Briefly, after isolation, PBMC 
 Seronegativesa HIV-2a HIV-1 a 
    
Number [male/female] 16 [6/10] 38 [14/24] 20 [15/5] 
Age, years 44 (27-57) 56 (19-78)
*/#
 38 (23-61) 
Caucasian/black 15/1 21/17 15/5 
CD4
+












Viremia, HIV RNA cp/ml - 200 (200-34x103)
##
 15x103 (40-45x105) 
Proviral DNA, cp/10
6
 PBMC - 78 (5-1033) 66 (5-975) 
B cells,  % 6 (3-13) 7 (3-20) 6 (2-16) 
B cells/μl 120 (63-369) 133 (30-369) 118 (33-406) 
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were washed and surface-stained for 20 minutes at room temperature with the 
following monoclonal antibodies (mAb) (clone specified in brackets): FITC-conjugated 
CD10 (CB-CALLA), PE-Cy7-conjugated CD19 (HIB19), and APC-conjugated CD27 (O323) 
from eBioscience (San Diego, CA), as well as with PE-conjugated IgD (IA6-2) and APC-
Cy7-conjugated CD3 (SK7) from BD Biosciences (San Jose, CA). At least 150,000 events 
were acquired using a CANTO flow cytometer (BD Biosciences) and analysed using 
FlowJo software (version 8.5.3, TreeStar, Inc., Ashland, OR). Cells were successively 
gated on lymphocytes, according to forward/side scatter characteristics, and B cells 
(CD19+CD3), which were then analysed in terms of CD27 and IgD expression, as 
illustrated in Figure 1. T-cell activation was assessed as previously described [34], 
using the following mAbs (clone specified in brackets): FITC-conjugated HLA-DR (L243), 
PerCP-conjugated CD4 (SK3) and APC-Cy7- conjugated CD3 (SK7) from BD Biosciences; 
and PE-conjugated CD38 (HIT2) and APC-conjugated CD8 (RPA-T8), both from 
eBioscience. 
 
IL-7, BAFF, total serum immunoglobulin, β2-microglobulin, and specific 
antibodies quantifications 
Serum IL-7 and BAFF were quantified by ELISA (R&D Systems, Minneapolis, 
MN), according to the manufacturer’s specifications. Samples were assayed in 
duplicate. 
Total IgG, IgA and IgM were quantified by immunonephelometry (Beckman-
Coulter, Brea, CA), and β2-microglobulin by immunoturbidimetry (Roche Diagnostics, 
Indianapolis, IN), at the clinical laboratory of the Hospital de Santa Maria. 
Quantification of specific antibodies against HIV-2 env glycoproteins gp36 and 
gp125 (C2-C3 region) was performed using a dual-antigen ELISA, as previously 
described [29]. The results of the assay were expressed quantitatively as ODclinical 
sample/ODcut-off (S/CO) ratios. For ratio values of >1, the samples were considered 
seroreactive. 
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Statistical analysis was performed with Mann-Whitney tests and Spearman’s 
correlations using GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA). 
Results were expressed as median and P values <0.05 were considered significant. 
 
Results 
HIV-2 disease was associated with a marked depletion of memory B cells  
We investigated here, for the first time, memory B-cell disturbances during 
HIV-2 infection. HIV-2+ patients showed no significant alterations in either the total 
numbers of peripheral blood B cells or the proportion of B cells within total PBMC as 
compared with seronegative individuals (Table 1). Memory B-cell populations were 






Figure 1. Flow-cytometric analysis of B-cell subsets. Representative dot-plots of the flow cytometric 
analysis of circulating B cells (CD19
+
CD3), according to the surface expression of IgD and CD27. Age-
matched individuals are shown. Data refer to one seronegative (31 years old, 778 CD4
+
 T cells/µl), one 
untreated HIV-2+ (34 years old, 321 CD4
+
 T cells/µl, undetectable viremia), one treated (ART) HIV-2+ 
(34 years old, 326 CD4
+
 T cells/µl, undetectable viremia) and one untreated HIV-1+ (30 years old, 306 
CD4
+
 T cells/µl, 1814256 HIV-1 RNA copies/ml) individuals. Numbers inside quadrants represent the 
proportion of B cells expressing the respective markers.  
 
A marked reduction in the proportion of memory B cells (CD27+) was found in 
HIV-2+ individuals (Figure 1 and 2A), both in comparison with seronegative and HIV-1+ 
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individuals with similar degrees of CD4+ T-cell depletion (Table 1). Of note, numbers of 
circulating memory B cells were significantly lower in HIV-2 individuals than in 

















Figure 2. Memory B-cell subset frequency in HIV-2 infection. (A) Relative proportions of total memory 
cells (CD27
+
, top graph), switched memory cells (CD27
+





, bottom graph), within total B cells, in the HIV-2 cohort, as well as seronegative (Seroneg) and 
HIV-1+ individuals. (B) HIV-2+ patients were further subdivided according to disease stage (early: >350 
CD4
+
 T cells/µl; late: <350 CD4
+
 T cells/µl) and levels of plasma viral load (aviremic: undetectable plasma 
viral load; viremic: detectable). The frequencies of the B-cell subsets described in (A) were compared 
between seronegatives and all sub-groups of HIV-2+ individuals. Each dot represents one individual and 
bars indicate median. Filled circles refer to ART-treated individuals. Statistical analysis was performed 
using the Mann-Whitney test and the significant P values are shown. 
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Memory B-cell loss was strongly correlated with CD4+ T-cell depletion and 
immune activation, assessed both in terms of T-cell activation and serum β2-
microglobulin, in HIV-2+ individuals (Table 2 and Supplemental Table 2 for absolute B-
cell counts). In agreement, this loss was significantly more marked in advanced as 
compared to early stage HIV-2 disease (less or more than 350 CD4+ T cells; Figure 2B 
and Supplemental Figure 1B for absolute B-cell counts). 
 
Table 2. Relationship between B-cell subsets and markers of disease progression. 
  Analysis within B cells 












HIV-2 (n=38)           
CD4+ T cells/µl -0.0222;0.8947 -0.5551;0.0003 0.6001;<0.0001 0.7591;<0.0001 0.5717;0.0002 
Viremia, HIV RNA cp/ml 0.0167;0.9209 0.3697;0.0223 -0.4214;0.0084 -0.4250;0.0078 -0.3981;0.0133 
%HLA-DR+CD38+  within CD4a 0.2132;0.1988 0.4842;0.0021 -0.5541;0.0003 -0.7152;<0.0001 -0.5036;0.0013 
%HLA-DR+CD38+ within CD8a 0.1664;0.3180 0.4323;0.0067 -0.4641;0.0033 -0.6157;<0.0001 -0.4224;0.0082 
β2-microglobulin (mg/l)b -0.0327;0.8638 0.5894;0.0006 -0.6416;0.0001 -0.7961;<0.0001 -0.5877;0.0006 
                      
HIV-1 (n=20)           
CD4+ T cells/µl -0.0911;0.7026 -0.2295;0.3304 0.2528;0.2822 0.6566;0.0017 0.0391;0.8700 
Viremia, HIV RNA cp/ml 0.0866;0.7165 -0.0934;0.6953 0.1574;0.5074 -0.5467;0.0126 0.3614;0.1174 
%HLA-DR+CD38+  within CD4a -0.0730;0.7598 0.1068;0.6539 -0.0760;0.7501 -0.5709;0.0086 0.1873;0.4291 
%HLA-DR+CD38+ within CD8a 0.0008;0.9975 -0.2685;0.2523 0.2941;0.2082 -0.3820;0.0965 0.5759;0.0079 
β2-microglobulin (mg/l)b -0.4180;0.1369 -0.0550;0.8518 0.1342;0.6474 -0.3934;0.1640 0.2396;0.4094 
 
Spearman’s correlation coefficient was used and results are expressed as r;P, with significant 
correlations in bold.  
a





cells (median, range) – HIV-2:  3.4%, 0.4-23.5% (CD4), and 15.1%, 0.6-69.5% (CD8); untreated HIV-1: 
5.5%, 0.3-34.8% (CD4), and 23.7%, 1.4-62.2% (CD8). No significant differences were found between 
infected cohorts, which exhibited significantly higher levels than seronegative controls (CD4: 1.1%, 0.7-
2.0%; CD8: 2.7%, 1.3-22.7%). 
b
β2-microglobulin serum levels were assessed for 30 HIV-2- (median: 2.6 mg/l, range: 1.1-7.8 mg/l) 
and 14 HIV-1- (median: 2.4 mg/l, range: 1.3-6.0 mg/l) infected individuals, with no statistically 
significant differences being observed between cohorts. 
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Additionally, an association was found between memory B-cell loss and 
viremia (Table 2 and Supplemental Table 2 for absolute B-cell counts). Accordingly, 
HIV-2+ patients with measurable viremia featured significantly less memory B cells 
than those with undetectable viremia (Figure 2B and Supplemental Figure 1B), despite 
the highest measured level being only 34314 RNA copies/ml (Table 1). 
No such correlations were found in the untreated HIV-1 cohort (Table 2 and 
Supplemental Table 2 for absolute B-cell counts), despite the viremia being, on 
average, two-log higher than in the HIV-2 cohort (Table 1). The differences in memory 
B-cell loss between the two infections were particularly marked when groups of 
infected individuals in advanced disease stage or with detectable viremia were 
compared (Supplemental Figure 2A, and Supplemental Tables 3 and 4).  
In spite of the distinct viremia, comparable amounts of cell-associated viral 
load (proviral DNA) were observed in the two infections (Table 1; Supplemental Tables 
3 and 4), as previously reported [31-33]. Notably, no significant correlations were 
found between levels of proviral DNA and frequency of memory B cells in either 
infection (P>0.05). 
HIV-1 has also been associated with an expansion of peripheral blood 
immature (CD27CD10+) B cells that was shown to be directly correlated with 
circulating IL-7 levels, and been suggested to arise from lymphopenia-induced IL-7-
mediated homeostasis [35]. We have previously shown that serum IL-7 is significantly 
increased in HIV-2 infection in strong association with CD4+ T-cell levels [36]. In fact, 
we also observed a significant expansion of CD27CD10+ B cells in HIV-2+ patients 
(median: 1.09%, range: 0.09-7.95; P=0.0007), as compared to seronegatives (median: 
0.39%, range: 0.10-1.41). Nevertheless, we found no significant correlations between 
the frequency of CD27CD10+ B cells with serum IL-7 levels in the HIV-2 cohort (n=35; 
serum IL-7 levels median: 12.21 pg/ml, range: 2.26-28.70; r=0.1859, P=0.2850), 
suggesting that other mechanisms are modulating the expansion of immature B cells 
during HIV-2 infection.  
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Although, the HIV-2 cohort included 10 individuals under ART (Supplemental 
Table 1), the B-cell imbalances were also found when only untreated subjects were 
compared to seronegatives (Supplemental Figure 3A). 
Moreover, ART-treated patients showed a significantly lower frequency of 
memory B cells than their untreated counterparts (Supplemental Figure 3A), which 
may reflect their prolonged infection, as estimated below, and the poor 
immunological recovery under ART typically observed in HIV-2 infection 
(Supplemental Table 1).  
Overall, HIV-2 infection was associated with progressive loss of memory B cells. 
 
Both switched and unswitched memory B cells were lost during HIV-2 disease  
The CD27+ B-cell subset can be further subdivided in terms of class-switched 
and unswitched immunoglobulin production, assessed here by IgD surface expression 
[37]. Class-switched memory B cells (CD27+IgD) are mainly generated in germinal 
centres and play a key role in adaptive immune responses, whilst unswitched 
CD27+IgD+ B cells are thought to include largely marginal zone B cells, and are known 
to play a role in protection against encapsulated bacteria [37]. 
Memory B-cell loss observed during HIV-2 disease was related to a pronounced 
depletion of cells with a class-switched phenotype (Figure 1 and 2A; Supplemental 
Figure 1 for absolute counts), which showed strong positive correlations with markers 
of disease progression (Table 2 and Supplemental Table 2 for absolute B-cell counts). 
No such correlations were observed in the HIV-1 cohort (Table 2 and Supplemental 
Table 2), and the switched memory B-cell depletion was much lower in HIV-1 than in 
HIV-2 infection (Figure 1 and 2A; Supplemental Figure 1 for absolute counts). 
Moreover, in the HIV-2 cohort, switched memory B-cell frequency was significantly 
lower in patients with less than 350 CD4+ T cells/µl, as compared to early stage 
disease, as well as in patients with detectable viremia versus their aviremic 
counterparts (Figure 2B; Supplemental Figure 1B for absolute counts). This was also 
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observed for untreated and ART-treated HIV-2+ individuals, when analysed separately 
(Supplemental Figure 3B), but was not documented for HIV-1 infection (Supplemental 
Figure 2B). Notably, despite both infections exhibiting similar levels of immune 
activation (Table 2), as previously reported [12], the impairment in switched memory 
B-cell preservation seemed to be more strongly linked to the persistent immune 
activation in HIV-2 than in HIV-1 infection (Table 2 and Supplemental Table 2 for 
absolute B-cell counts). 
Conversely, the loss of unswitched (IgD+) memory B cells in HIV-2 infection was 
comparable to that observed in HIV-1 infection (Figure 2A and Supplemental Figure 1A 
for absolute counts). This loss was positively correlated with markers of disease 
progression in both HIV-1 and HIV-2 cohorts (Table 2 and Supplemental Table 2 for 
absolute B-cell counts), being significantly more pronounced in patients with CD4+ T-
cell counts below 350 cells/µl or detectable viremia (Figure 2B; Supplemental Figures 
1B and 2C).  
Of note, both switched and unswitched memory B cells were markedly 
decreased in HIV-2+ patients under ART (Supplemental Figure 3B and 3C, 
respectively), which may be, at least in part, related to the more prolonged length of 
disease. Given the slow rate of CD4+ T-cell decline, it is expected that HIV-2+ patients 
have been infected for much longer than untreated HIV-1+ individuals. Our estimation 
of the length of follow-up, for those patients for whom these data were available, was 
in agreement with this possibility (median months for treated HIV-2: 97, range: 8-242, 
n=10; untreated HIV-2: 71, range: 24-235, n=16; untreated HIV-1: 75, range: 13-184, 
n=9). 
Notably, B-cell imbalances did not correlate with age in all the cohorts 
(p>0.05). 
Altogether, progressive memory B-cell loss during HIV-2 infection was due to a 
depletion of both switched and unswitched memory B cells.  
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Memory B-cell imbalances did not translate into decreased immunoglobulin 
levels 
Notwithstanding the generalized memory B-cell loss, most HIV-2+ patients 
showed increased levels of IgG, as previously reported [22, 23], whilst maintaining IgM 
and IgA titers within the normal range (Supplemental Figure 4A). 
Additionally, we quantified serum levels of antibodies against HIV-2 env 
glycoproteins gp36 and gp125 (C2-C3 region) as previously described [29]. No 
significant differences were observed in specific antibody levels when HIV-2+ patients 
were sub-divided, either according to CD4+ T-cell counts, or viremia (P>0.05). 
Nevertheless, whilst IgG, IgM and IgA levels did not significantly differ between 
untreated and treated HIV-2 infection, HIV-2+ individuals under ART had significantly 
lower levels of specific antibodies against the C2-C3 region of gp125 (Supplemental 
Figure 4B). 
Overall, HIV-2+ patients did not feature major impairments in total 
immunoglobulin levels or HIV-2-specific antibody production, despite the observed 
memory B-cell imbalances. 
 
BAFF levels increased during HIV-2 disease, particularly in the presence of 
detectable viremia, in direct association with memory B-cell disturbances 
B-cell survival and differentiation rely on BAFF, a cytokine mainly produced by 
stromal cells, monocytes and T cells, detectable in the serum of healthy subjects [38-
40]. BAFF levels were significantly higher in the HIV-2 cohort, as compared with 
seronegatives (Figure 3A). Notably, a direct correlation was found between serum 
BAFF levels and viremia in the HIV-2 cohort (r=0.4939, P=0.0195, n=12), and in 
agreement, significantly higher BAFF titres were observed in HIV-2+ patients with 
detectable viremia, both in relation to aviremic individuals and seronegatives (Figure 
3B, Supplemental Figure 5A); this was observed in untreated as well as in ART-treated 
HIV-2 groups (Supplemental Figure 5B). A similar relationship between serum BAFF 
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levels and viremia was observed in the HIV-1 cohort (r=0.5916, P=0.0428, n=12; and 














Figure 3. Serum BAFF levels in HIV-2 infection. (A) Serum BAFF levels in HIV-2+, HIV-1+, and 
seronegative (Seroneg) individuals. Due to sample availability, a distinct seronegative cohort was used 
(11 females/6 males; 39 (26-61) median years of age; 63.85 (40.10-76.90) median CD4
+
 T-cell 
frequency; 908 (537-1312) median CD4
+
 T cells/µl; 8.15 (2.56-18.19) median B-cell frequency; 163 (63-
383) median B cells/µl), as well as representative subgroups of the infected cohorts (HIV-2, including 
the 10 treated subjects: 13 females/9 males; 56 (19-72) median years of age; 28.02 (4.51-63.20) median 
CD4
+
 T-cell frequency; 337 (52-1336) median CD4
+
 T cells/µl; 200 (200-34314) median RNA copies/ml; 
108 (5-1002) median proviral DNA copies/10
6
 PBMC; 7.41 (2.89-19.70) median B-cell frequency; 132 
(30-369) median B cells/µl; and untreated HIV-1: 3 females/9 males; 42 (23-61) median years of age; 
32.85 (7.71-74.4) median CD4
+
 T-cell frequency; 431 (77-1425) median CD4
+





) RNA copies/ml; 88 (5-573) median proviral DNA copies/10
6
 PBMC; 6.64 (2.08-15.60) median B-
cell frequency; 112 (56-324) median B cells/µl). (B) The HIV-2 cohort was further stratified according to 
disease stage (early: >350 CD4
+
 T cells/µl; late: <350 CD4
+
 T cells/µl) and levels of plasma viral load 
(aviremic: undetectable; viremic: detectable), and the BAFF levels were compared between 
seronegatives and all groups of HIV-2+ individuals. Each dot represents one individual and bars indicate 
median. Filled circles refer to ART-treated individuals. Statistical analysis was performed using the 
Mann-Whitney test and the significant P values are shown. 
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Although no significant correlations were found between serum BAFF levels 
and the degree of CD4+ T-cell depletion, advanced HIV-2 disease (less than 350 CD4+ T 
cells/µl) was associated with higher BAFF levels (Figure 3B). Moreover, HIV-2+ 
individuals under ART showed a significant increase in BAFF as compared to 
seronegatives irrespective of viremia possibly related to their reduced CD4+ T-cell 
counts (Supplemental Figure 5B). 
Of note, HIV-2+ patients showed significant inverse correlations between 
serum BAFF levels and frequency of total (r=-0.5456, P=0.0086, n=22) and switched 
memory B cells (r=-0.5247, P=0.0122, n=22). Such correlations were not found in the 
HIV-1 cohort (P>0.05). 
In conclusion, HIV-2 infection was associated with an increase in serum BAFF 
levels that correlated with memory B-cell loss. 
 
Discussion  
We report here, for the first time, that despite its relatively “benign” course 
and low viremia, HIV-2 disease progression was associated with major losses of both 
switched and unswitched memory B cells and elevated serum BAFF levels. 
Additionally, we found that these disturbances were not recovered by ART.  
We showed that memory B-cell levels negatively correlated with T-cell 
activation in HIV-2+ individuals, suggesting a close association between B-cell 
disturbances and hyper-immune activation, even in the context of low viremia. This is 
in agreement with previous reports associating B-cell dysregulation during HIV-1 
disease with hyper-immune activation [3, 4].  
In order to account for the possible impact of CD4+ T-cell lymphopenia on B-
cell disturbances, we compared HIV-1+ and HIV-2+ individuals with similar degrees of 
CD4+ T-cell depletion, despite differences in length of disease and viremia. 
Importantly, memory B-cell loss, particularly of the switched memory pool, was much 
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more marked in HIV-2 than HIV-1 infection, despite the clearly better prognosis and 
the much lower amounts of circulating virus in HIV-2 infection.  
A recent report associated the loss of switched memory B cells in HIV-1 
infection with impairment in the ability of B cells to respond to IL-2 or other γc 
cytokines, leading to an increase in their susceptibility to apoptosis [4]. Although this 
possibility was not excluded in the current study of HIV-2+ patients, our previous data 
support a relatively better preserved ability to produce and respond to γc cytokines in 
HIV-2, as compared to HIV-1 infection [36, 41, 42].  
The marked levels of switched memory B-cell depletion in HIV-2 infection were 
unlikely to be solely attributable to loss of the small subset of IgM-only 
(CD27+IgDIgM+) memory B cells [43, 44]. Nevertheless, it would be of interest to 
address in future studies the detailed phenotype of memory B cells, including levels of 
expression of IgM and CD21, whose loss has been associated with ongoing HIV 
replication and disease progression in HIV-1+  individuals [37]. 
It is also possible that cell redistribution contributed, at least in part, to the 
reduction of circulating memory B cells, emphasizing the relevance of tissue studies. 
Moreover, given the expected prolonged length of HIV-2 disease, it is plausible that 
the marked loss of switched memory B cells may be related to cumulative lymphoid 
tissue damage, and consequent disruption of the generation of germinal centres 
where these cells are produced, and/or of the microenvironment required for their 
survival, ultimately reaching an irreversible level. Accordingly, a more marked 
switched memory B-cell loss was found in HIV-2+ patients under long-term 
antiretroviral treatment, who were estimated to have been infected for a longer 
period of time.  
To our knowledge, there are no data on HIV-2-infected secondary lymphoid 
organs (SLO). The persistent immune activation observed during HIV-2 infection [12] 
may be associated with SLO inflammation and collagen deposition with progressive 
disruption of their architecture, as has been described during HIV-1 infection [45]. 
HIV-1 has been shown to mainly reside in lymphoid tissues, trapped in the follicular 
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dendritic cell (FDC) network, potentially contributing to progressive disruption of 
germinal centre responses and limiting the survival signals required for memory B-cell 
maintenance [46, 47]. It is also possible that low levels of HIV-2 replication occur in 
SLO, contributing to the hyper-activated immune state and the putative progressive 
tissue damage. In fact, the cytopathicity documented upon HIV-2 infection of human 
lymphoid tissue explant cultures was shown to be comparable to that observed for 
HIV-1 [48].  
Importantly, we and others have reported similar levels of cell-associated viral 
burden in HIV-1+ and HIV-2+ patients, as assessed by the levels of proviral DNA within 
PBMC [31-33]. Thus, the ability to disseminate and establish a reservoir of infected 
cells is apparently similar in both infections. Furthermore, we have recently provided 
evidence of a significant degree of ongoing viral replication in HIV-2+ individuals based 
on the levels of viral gag and tat gene transcripts within PBMC [31]. These data raised 
questions about the control of HIV-2 latency. It is plausible that HIV-2 continuously 
replicates in SLO at low levels, possibly by cell-to-cell mediated transmission. In spite 
of this putative HIV-2 replication being locally contained, given the reduced viremia, it 
may have a long-term impact, contributing to accelerated immune-senescence. 
Additionally, it may contribute to the poor immunological recovery that is usually 
observed in HIV-2+ patients receiving ART [20, 31, 49, 50], highlighting the importance 
of rethinking the guidelines on when to start ART in HIV-infected patients [51].  
Our findings are particularly relevant in view of the cumulative data suggesting 
that HIV-1+ patients under apparently effective ART have significant degrees of 
replication in SLO [52, 53]. These low levels of viral replication were suggested to 
contribute to a pro-inflammatory state and to the related complications found in long-
term treated HIV-1+ patients [53].  
Notably, in spite of the reduced amounts of plasma HIV-2 load, irrespective of 
disease stage, we found that the presence of detectable viremia was associated with 
significantly lower levels of memory B cells. These results suggest a direct role of the 
free virions in B-cell disturbances. Alternatively, the presence of detectable virus may 
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itself represent indirect evidence for the disruption of the FDC network, which 
eventually becomes unable to contain the produced virions.  
BAFF has been shown to be critical for B-cell maturation and survival upon 
bone-marrow egress [38]. Of note, we found that serum BAFF levels were increased in 
HIV-2-infected patients, particularly in association with viremia, in agreement with 
previous reports in HIV-1 infection [39, 40]. Moreover, HIV-2+ individuals under ART, 
who had longer follow-up, featured significant increases in BAFF levels irrespective of 
viremia, which may contribute to their heightened inflammatory state and B-cell 
imbalances, as has been suggested in HIV-1 infection [8, 39, 40, 54].  
Overall, we showed, for the first time, that despite the reduced amount of 
circulating virus, HIV-2 infection is associated with a marked depletion of both 
switched and unswitched memory B cells, in association with an increase in serum 
BAFF levels. Our data provide evidence that prolonged HIV disease, even in the 
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Supplemental Table 1. Clinical and epidemiological characteristics of the therapy 
naïve and treated HIV-2-infected individuals. 
 
 Seronegatives Untreated HIV-2 ART-HIV-2
a
 
    
Number [male/female] 16 [6/10] 28 [9/19] 10 [5/5] 
Age, years 44 (27-57) 54 (19-78) 57 (34-62)** 
Caucasian/black 15/1 15/13 6/4 
CD4
+












Viremia, HIV RNA cp/ml - 200 (200-26263) 200 (200-34314) 
Proviral DNA, cp/10
6
 PBMC - 5 (5-1033) 130 (5-726) 
B cells,  % 6 (3-13) 6 (3-20) 10 (4-17)
*
 
B cells/μl 120 (63-369) 131 (30-369) 135 (63-313) 
 







P< 0.001 in comparison with seronegatives. 
##
P< 0.01 for comparisons between infected cohorts. 
a
ART regimens were as follows (number of ART-HIV-2 patients): 3TC+AZT+LPV/r (3); 
3TC+d4T+SQV/r (2); 3TC/AZT+IDV/r (1); 3TC+AZT+IDV (1); ABC+3TC+AZT (3). Nucleoside 
analog reverse transcriptase inhibitors (NRTIs): AZT – Zidovudine, 3TC- Lamivudine, ABC- 
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Supplemental Table 2. Relationship between absolute counts of circulating B-cell 
populations and markers of disease progression in the HIV-2 and HIV-1 cohorts. 
 
 
 B cells/μl 
 











HIV-2 (n=38)           
CD4+ T cells/µl 0.3522;0.0301 0.1322;0.4288 0.7561;<0.0001 0.7830;<0.0001 0.7137;<0.0001 
Viremia, HIV RNA cp/ml -0.0754;0.6526 0.0557;0.7396 -0.4280;0.0074 -0.3842;0.0172 -0.4273;0.0074 
%HLA-DR+CD38+  within CD4a 0.0153;0.9275 0.1899;0.2535 -0.5002;0.0014 -0.5512;0.0003 -0.4611;0.0036 
%HLA-DR+CD38+ within CD8a -0.0390;0.8164 0.1324;0.4281 -0.4466;0.0049 -0.4964;0.0015 -0.4166;0.0093 
β2-microglobulin (mg/l)b -0.2110;0.2631 -0.0039;0.9837 -0.6758;<0.0001 -0.7367;<0.0001 -0.6326;0.0002 
           
           
HIV-1 (n=20)           
CD4+ T cells/µl 0.2144;0.3639 0.2023;0.3923 0.2866;0.2206 0.5957;0.0056 0.2153;0.3620 
Viremia, HIV RNA cp/ml 0.0098;0.9673 -0.1340;0.5732 0.0919;0.7001 -0.4339;0.0559 0.2027;0.3914 
%HLA-DR+CD38+  within CD4a -0.2506;0.2866 -0.3106;0.1825 -0.1971;0.4050 -0.5794;0.0074 -0.0941;0.6932 
%HLA-DR+CD38+ within CD8a -0.0669;0.7792 -0.2857;0.2220 0.1985;0.4015 -0.3350;0.1488 0.3168;0.1736 
β2-microglobulin (mg/l)b -0.3740;0.1877 -0.4462;0.1098 -0.1209;0.6806 -0.5433;0.0447 -0.0264;0.9286 
 
Spearman’s correlation coefficient was used and results are expressed as R;P, with significant 
correlations in bold. 
a




 T cells 
(median, range) – HIV-2:  3.4%, 0.4-23.5% (CD4), and 15.1%, 0.6-69.5% (CD8); untreated HIV-1: 5.5%, 
0.3-34.8% (CD4), and 23.7%, 1.4-62.2% (CD8). No significant differences were found between infected 
cohorts, which exhibited significantly higher levels than seronegative controls (CD4: 1.1%, 0.7-2.0%; 
CD8: 2.7%, 1.3-22.7%). 
b
β2-microglobulin serum levels were assessed for 30 HIV-2 (median: 2.6 mg/l, range: 1.1-7.8 mg/l) and 
14 HIV-1 (median: 2.4 mg/l, range: 1.3-6.0 mg/l) infected individuals, with no statistically significant 
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Supplemental Table 3. Clinical and epidemiological characteristics of the HIV-2 and 




 HIV-2  HIV-1 
  >350 CD4
+
/µl <350  CD4
+
/µl  >350  CD4
+
/µl <350  CD4
+
/µl 
        
Number [male/female] 16 [6/10]  22 [7/15] 16 [7/9]  10 [7/3] 10 [8/2] 
Age, years 44 (27-57)  56 (28-78)
*
 51 (19-63)  41 (27-61) 35 (23-49)
#
 
Caucasian/black 15/1  13/9 8/8  10/0 5/5 
CD4
+ 














































-  78 (5-1033) 57 (5-1002)  81 (5-573) 41 (5-975) 
B cells,  % 6 (3-13)  7 (3-17) 6 (3-20)  5 (2-11) 6 (2-16) 
B cells/μl 120 (63-369)  141 (52-357) 100 (30-369)  118 (56-406) 117 (33-267) 
 
Data are expressed as median, with limits in brackets. Statistical analysis was performed with Mann-
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Supplemental Table 4. Clinical and epidemiological characteristics of the HIV-2 and 
HIV-1 cohorts stratified according to viremia status. 
 
Data are expressed as median, with limits in brackets. Statistical analysis was performed with Mann-










P< 0.01 in comparison 
with the reciprocal subgroup (Aviremic versus Viremic). 
#


























 HIV-2  HIV-1 
  Aviremic Viremic  Aviremic Viremic 
        
Number 
[male/female] 
16 [6/10]  28 [9/19] 10 [5/5]  3 [2/1] 17 [13/4] 
Age, years 44 (27-57)  56 (28-78) 52 (19-62)  47 (30-61) 38 (23-59) 
Caucasian/black 15/1  17/11 4/6  3/0 12/5 
CD4
+ 































(HIV RNA cp/ml) 










-  5 (5-1033)+ 187 (5-1002)  104 (5-324) 53 (5-975) 
B cells,  % 6 (3-13)  7 (3-17) 7 (3-20)  10 (4-11) 6 (2-16) 
B cells/μl 120 (63-369)  135 (37-357) 131 (30-369)  125 (92-324) 111 (33-406) 
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Supplemental Figure 1. Absolute numbers of memory B-cell subsets in HIV-2-infected individuals. (A) 
Circulating numbers of total memory cells (CD27
+









) in HIV-2 infected, as well as seronegative (Seroneg) and HIV-1+ 
individuals. (B) HIV-2+ patients were further subdivided according to disease stage (early: >350 CD4
+
 T 
cells/µl; late: <350 CD4
+
 T cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral 
load; viremic: detectable) and the absolute counts of memory B-cell populations are shown. Each dot 
represents one individual and bars indicate median. Statistical analysis was performed using the 
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Supplemental Figure 2. B-cell disturbances in HIV-2 as compared to HIV-1 groups of infected patients 
stratified to disease stage and viremia status. Patients were divided according to disease stage (early: 
>350 CD4
+
 T cells/µl; late: <350 CD4
+
 T cells/µl) and levels of plasma viral load (aviremic: undetectable 
plasma viral load; viremic: detectable). Relative frequencies of (A) total memory cells (CD27
+
), (B) 








) within total B cells. 
Comparisons were made between seronegatives and all groups of infected individuals. Each dot 
represents one individual and bars indicate median. Statistical analysis was performed using the 
Mann-Whitney test and significant P values are shown. 
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Supplemental Figure 3. B-cell disturbances in treated as compared to untreated HIV-2-infected 
patients stratified to disease stage and viremia status. Patients were divided according to disease 
stage (early: >350 CD4
+
 T cells/µl; late: <350 CD4
+
 T cells/µl) and levels of plasma viral load (aviremic: 
undetectable plasma viral load; viremic: detectable). Relative frequencies of (A) total memory cells 
(CD27
+









total B cells. Comparisons were made between seronegatives and all groups of infected individuals. 
Each dot represents one individual and bars indicate median. Statistical analysis was performed using 
the Mann-Whitney test and significant P values are shown. 
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Supplemental Figure 4. Serum levels of immunoglobulin and of specific antibodies against HIV-2 
envelope glycoproteins gp125 and gp36. (A) Serum levels of total IgG, total IgM, and total IgA in 
untreated HIV+ and in ART-treated HIV-2+ patients. (B) Serum levels of specific antibodies against gp36 
and gp125 expressed as ODclinical sample/ODcut-off (S/CO) ratios in HIV-2+ individuals. Each dot represents 
one individual. Patients with viremia below cut-off are shown as open dots and viremic patients as filled 
dots. Normal range of immunoglobulin values is represented by grey shading. Statistical analysis was 
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Supplemental Figure 5. Serum BAFF levels in HIV-infected individuals stratified according to disease 
stage and viremia status. Patients were divided according to disease stage (early: >350 CD4
+
 T cells/µl; 
late: <350 CD4
+
 T cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral load; 
viremic: detectable). Comparisons were made between seronegatives and (A) groups of HIV-2 and HIV-1 
infected individuals; (B) groups of untreated and treated HIV-2 infected individuals. Each dot represents 
one individual and bars indicate median. Statistical analysis was performed using the Mann-Whitney test 
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Clarification of the immune responses underlying the more “benign” disease 
course that characterizes HIV-2 infection is of utmost importance for the general 
understanding of HIV/AIDS immunopathology. Furthermore, it may contribute to the 
identification of new potential targets to be used in ART-complementary immune-
based therapy. 
Chronic immune activation has long been recognized as a hallmark of HIV 
infection, constituting a stronger predictor of disease progression and concomitant 
CD4+ T-cell depletion than viremia [1, 2]. Hence, strategies aimed at limiting immune 
activation may be beneficial to control the infection, possibly contributing to slow 
down disease progression. 
 
Cells of the innate immune system constitute the primary line of defense 
against infection [3]. In acute HIV disease, innate immunity plays a major role in 
limiting viral replication and promoting the development of adaptive immune 
responses, whilst during chronic infection it may act as a modulator of immune 
activation [3]. 
We have previously shown that, despite the undetectable to low viremia found 
in HIV-2+ individuals, a comparable marked reduction in circulating pDC levels, 
associated with both CD4+ T-cell depletion and T-cell activation, was observed in 
untreated HIV-1 and HIV-2 infections [4]. Moreover, the same over-expression of 
CD86 and PD-L1 molecules on circulating pDC was found in both infections, 
irrespective of disease stage and viremia [4]. Nevertheless, although, on a per cell 
basis, IFN-α production upon in vitro stimulation was observed to be equally impaired 
in viremic HIV-1+ and HIV-2+ patients, aviremic HIV-2+ individuals showed in vitro 
levels of IFN-α production similar to seronegatives [4]. 
These results suggested that mechanisms other than the direct infection of 
pDC could determine their depletion and activation during HIV-2 disease. Additionally, 
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these findings were in agreement with a lower in vivo IFN-α activity throughout the 
course of HIV-2 disease [4], possibly contributing to the slower heightening of immune 
activation and consequent lower rate of CD4+ T-cell depletion observed in this 
infection [5]. 
In chapter 3.1., we sought to further address the role of innate immunity 
during HIV disease. An increased activation of both monocytes and mDC, with 
concomitant particularly marked PD-L1 up-regulation, also constituted a hallmark of 
HIV-2 infection. A pronounced loss of circulating mDC was observed in HIV infection, 
with no alterations in total monocyte numbers being found, despite the substantial 
expansion of a specific subset featuring the highest expression of co-stimulatory and 
inhibitory molecules (HLA-DR and PD-L1, respectively). Nevertheless, both monocytes 
and mDC from HIV-infected patients displayed a hyper-activated state that, in the 
context of HIV-2 infection, was accompanied by a more marked and significant up-
regulation of PD-L1 expression. It is important to note that this occurred even in the 
absence of viremia and, more importantly, in early disease stages. These findings 
suggest that, in HIV-2+ individuals, the PD-1/PD-L1 inhibitory pathway could play a 
role in limiting immune activation from the early stages of infection. In agreement 
with this hypothesis, no major disturbances in the circulating levels of monocyte-
produced cytokines and chemokines were found in the HIV-2 cohort, which typically 
displayed similar or lower titers of circulating TNF-α, IL-6, IL-10, MIP-1β and MCP-1 
than those observed in HIV-1 infection. Moreover, monocyte activation and cytokine 
production ability, as well as mDC disturbances, appeared to be dissociated from 
plasma LPS levels in the context of HIV-2 disease, arguing against a major role for 
microbial translocation in HIV-2 immunopathology, as reported for several African 
populations [6, 7]. 
Taken together, our data suggest that the marked PD-L1 up-regulation 
observed on pDC, mDC and monocytes during HIV-2 disease may contribute to its 
slow disease course. The process underlying the up-regulation of this molecule is 
apparently independent, to a large degree, of both IFN-α and TLR-4-mediated 
stimulation. Hence, other mechanisms, possibly involving T-cell-dependent monocyte 
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activation and/or response to γc cytokines, may contribute to a better maintained 
balance between activating and inhibiting pathways in the context of HIV-2 infection, 
and warrants further investigation. 
 
T-cell hyper-activation is strongly associated with HIV immunopathogenesis 
and progression to AIDS [1]. Nevertheless, as well as the expected increase in the 
surface expression of markers associated with stimulation, activated T cells have also 
been shown to up-regulate the expression of both PD-1 and PD-L1 expression [8], 
further supporting the possibility that inhibitory signaling pathways play a major role 
during HIV infection. Although PD-1 expression on HIV-1-specific T cells was first 
described as a cellular exhaustion marker [9-11], more recent data have emerged 
indicating that PD-1 expression may instead constitute an attempt to limit immune 
activation-related immunopathology [12, 13], or simply indicate viral exposure [14, 
15]. Furthermore, an increasing body of evidence indicates that PD-1 expression alone 
may neither be associated with, nor sufficient to characterize an exhausted 
phenotype, with the co-expression of other inhibitory molecules, such as TIM-3, being 
essential to define T-cell exhaustion [16, 17]. 
In chapter 3.2., we investigated the contribution of the PD-1/PD-L1 pathway 
and TIM-3 expression on T cells to HIV/AIDS immunopathogenesis. Both HIV-1- and 
HIV-2-infected individuals presented similar patterns of increased PD-1 expression on 
T cells, with the early and intermediate memory subsets featuring the highest levels of 
the inhibitory molecule. These data argue against PD-1 expression as an indicator of 
terminal T-cell differentiation and exhaustion, supporting instead the view that PD-1 
up-regulation may indicate T-cell activation upon antigen encounter. In agreement, 
PD-1+ T cells were shown to constitute a sizeable proportion of all cycling T cells. This 
was in marked contrast to TIM-3 expression, which was found to be dissociated from 
both T-cell cycling and differentiation, identifying a population that was significantly 
increased in early HIV-1, but not HIV-2, infection. Moreover, the frequency of double-
positive PD-1- and TIM-3-expressing T cells was very low in all cohorts, suggesting a 
differential regulation of PD-1 and TIM-3, and indicating that they are likely expressed 
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by distinct T-cell subpopulations. Conversely, PD-1 and PD-L1 molecules featured a 
similar and tightly associated pattern of T-cell expression in all cohorts. Nevertheless, 
only in the context of HIV-2 infection did the expression of PD-1 and PD-L1 molecules 
strongly correlate with both the degree of CD4+ T-cell depletion and immune 
activation. This was despite the undetectable to low levels of viremia found in HIV-2+ 
patients, and in contrast to what was documented for HIV-1+ individuals, who 
featured no significant associations between PD-L1 expression and surrogate markers 
of disease progression. 
Overall, these data support a model in which, during HIV-2 infection, a strict 
and sustained control of PD-L1 expression by T cells takes place, that is somewhat 
disrupted in the course of HIV-1 disease [18]. In this scenario, a better maintenance of 
the PD-1/PD-L1 pathway during HIV-2 infection, in the absence of significant TIM-3 
expression, could, instead of indicating T-cell exhaustion, help limit immunopathology, 
thus resulting in slower CD4+ T-cell depletion and, consequently, a more “benign” 
disease course. These observations have implications for the design of new 
therapeutic approaches and should be further clarified, namely by the study of PD-1 
and PD-L1 expression in lymphoid tissues and the mechanisms underlying their 
regulation (TCR- and/or γc cytokine-mediated). 
 
The ability to replenish the CD4+ T-cell pool is a main determinant of the 
course of HIV infection [19]. In chapters 3.3. and 3.4., we aimed to investigate 
whether the preservation of naïve CD4+ T cells, in particular, could contribute to the 
characteristically slower rate of HIV-2 disease progression. 
As described in chapter 3.3., naïve CD4+ T-cell telomere length was similar in 
HIV-2-infected individuals and age-matched seronegative controls. This was despite 
significantly higher levels of cycling naïve CD4+ T cells in HIV-2+ in comparison to 
seronegative individuals. More importantly, this finding was in marked contrast to 
what we found in age-matched HIV-1+ individuals, who showed significantly reduced 
naïve CD4+ T-cell telomere length, relative to age-matched seronegatives, also in the 
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context of increased cycling. Importantly, our HIV-1 cohort included ART-treated 
patients who, despite having achieved successful virological suppression, had failed to 
recover their CD4+ T-cell counts [20]. We found that these so-called HIV-1+ ART-
discordants showed the highest frequency of naïve CD4+ T-cell cycling and the most 
marked reduction in telomere length in comparison to age-matched seronegatives. 
Interestingly, HIV-1+ ART-discordants have been described to feature impaired thymic 
function [21, 22]. This is in contrast with previous data from our group supporting a 
preserved thymic output in the context of HIV-2 infection [23], which possibly 
contributes to the continuous refill of the CD4+ T-cell pool with cells with long 
telomeres. Telomere preservation during HIV-2 infection could contribute to a better 
maintenance of the replicative potential of CD4+ T cells, thereby facilitating CD4+ T-cell 
compartment homeostasis during chronic disease and promoting slower disease 
progression. 
Together with thymic output, peripheral homeostatic proliferation is 
considered to play a major role in maintaining the naïve CD4+ T-cell pool [24, 25]. In 
this respect, we had previously reported that the homeostatic cytokine IL-7 induces a 
preferential expansion of CD31+ naïve CD4+ T cells, a subset highly enriched in RTE, 
with no concomitant loss of CD31 expression [26], thereby contributing to maintain 
the size and diversity of the naïve CD4+ T-cell pool. Furthermore, previous results from 
our group had also shown that HIV-2+ individuals, who are characterized by a slow 
rate of CD4+ T-cell depletion and disease progression, presented delayed increases in 
IL-7 serum levels, coupled with sustained T-cell expression of the IL-7Rα chain, 
suggesting a maximization of available resources during HIV-2 disease [27]. In order to 
further explore whether the observed differences in the ability to replenish the CD4+ 
T-cell pool in HIV-1 and HIV-2 disease could relate to differential responsiveness of 
naïve CD4+ T cells to IL-7 in the two infections, naïve CD4+ T cells, isolated from 
individuals in early stage HIV-1 or HIV-2 infection, were stimulated, in vitro, with IL-7, 
as described in sub-chapter 3.4. 
Although, at this early stage disease, HIV-1+ individuals featured the highest 
levels of ex vivo naïve CD4+ T-cell proliferation, a significantly higher contribution of 
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CD31+ cells to the overall pool of cycling naïve CD4+ T cells was observed in the HIV-2 
cohort, both in relation to age-matched seronegative and HIV-1+ individuals. 
Furthermore, naïve CD4+ T cells from HIV-2+ patients were found to have a better 
sustained proliferative response to IL-7 stimulation, behaving very similarly to those of 
age-matched seronegative controls. Importantly, this was despite the estimated 
length of infection being longer in HIV-2+ individuals [5]. 
Altogether, our data suggest that both preserved telomere length, and 
enhanced cycling of the RTE-containing CD31+ subset, likely achieved via better 
preserved IL-7 responsiveness, may account for the slow rate of CD4+ T-cell decline 
during HIV-2 disease. The identification of the mechanisms underlying the 
maintenance of naïve CD4+ T-cell responsiveness to IL-7 and the differences on IL-7-
mediated signaling pathways during HIV-1 and HIV-2 infection, will be of utmost 
importance, since IL-7 has been proposed to be used as an ART-complementary 
therapeutic approach [28]. 
 
Despite CD4+ T-cell loss constituting the major hallmark of HIV disease 
progression, several other immune disturbances that occur during chronic infection 
are important contributors to HIV-related immunodeficiency [29]. Of note, HIV-1 
infection has been extensively reported to be associated with a progressive 
impairment of specific humoral responses and generalized loss of memory B cells, 
perturbations that are only partially recovered by ART [30]. In chapter 3.5., we sought 
to address if the memory B-cell compartment was better preserved during HIV-2 
infection. 
Of note, we found that HIV-2 disease was associated with an overall and 
irreversible disruption of memory B-cell homeostasis [31], with significant depletion of 
both unswitched and switched memory B cells being observed, in direct correlation 
with T-cell activation. This was found even in the absence of circulating viral load, and 
was not recovered by ART, with treated HIV-2+ patients featuring even more 
pronounced B-cell imbalances, possibly related to their longer time of infection [5]. 
                                                 Chapter 4: 
Conclusions and Future Perspectives 
227 
 
It is likely that, despite the low to undectable viremia, significant levels of HIV-2 
replication occur in secondary lymphoid organs. Over time, it may result in 
cumulative, and eventually irreversible, damage to lymphoid tissues, and consequent 
disruption of germinal centre formation and function, with direct impact on B-cell 
homeostasis. As data concerning secondary lymphoid organs during HIV-2 infection 
are still very limited [32, 33], studies regarding the evaluation of lymphoid tissue 
structure maintenance are key to validating this model.  
 
Of note, it is worth to emphasise that all the aforementioned parameters are 
inter-related and, thus, their contribution to HIV-2 disease progression in particular, 
and HIV/AIDS immunopathogenesis in general, cannot be considered individually. A 
better sustained response to IL-7 stimulation could contribute to an increase in 
telomere length, due to telomerase induction, and also to PD-1 and PD-L1 up-
regulation. On the other hand, it could also possibly facilitate enhanced viral 
replication in secondary lymphoid tissues, thereby mediating collagen deposition and 
a progressive slow structural effacement [34, 35]. Further investigation is, therefore, 
needed, to determine if it is possible to reach an equilibrium point between these 
inter-connected pathways, such that any benefits are not outweighed by potentially 
harmful outcomes.   
 
The aim of this project was to address strategies underlying the host’s immune 
response to persistent HIV infection, taking advantage of HIV-2 as a model of 
naturally-occurring attenuated HIV disease. 
Overall, the data presented here support that the slow and more “benign” 
course that characterizes HIV-2 infection is, in part, related to two main factors. 
Firstly, a tight regulation of T-cell activation-inhibition pathways, with over-
expression of PD-L1 on both APC and T cells constituting a specific “HIV-2 signature”. 
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Secondly, a better preservation of CD4+ T-cell telomere length and a sustained 
ability of naïve CD4+ T cells to respond to IL-7 stimulation, which likely impact on the 
ability to replenish the CD4+ T-cell compartment in HIV-2-infected individuals.   
Nevertheless, it is important to note that over the increased time frame of the 
asymptomatic/chronic phase of HIV-2 infection, exhaustion of immune resources 
ultimately takes place, as evidenced by the irreversible loss of memory B cells that we 
documented, even in aviremic HIV-2 disease. 
 
HIV-2 infection is a naturally-occurring attenuated model of HIV disease that 
remains underrated and not fully explored. This natural model provides an invaluable 
tool to explore the mechanisms underlying HIV/AIDS immunopathology, with the 
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